[VERSION]
 18.0
[PREFERENCES]
 132,120,25,64,1,2,3,4,6,13,5,7,6,2,3,4,5,1,8,720,720,720,720,12,8,9,1,0,120,3,7,99,10,720,720,0,0,Courier New,11,14,15,16
 NB,PC,CT,BC,SC,SH,^-,%-,SN,CB,RU,T3,QA,LA,BL,BH,FS,MH,TF,SOO
 Mean,Median,Standard Deviation,Standard Error,N,Grouped Median
 Sample Size for Statistic Base,Mode,1st Quartile,3rd Quartile,Chi-Square | Significance,Minimum,Maximum,Effective Sample Size for Statistic Base
 Total,Total Answering,No Answer,Sigma,Unweighted Total,Effective Sample Size,#c Percentile,Mean Confidence Interval (Lower),Mean Confidence Interval (Upper),Mean Number of Mentions
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 Total^TN^1
 
 
 
 
[GLOSSARY]
[TABLES]
TS1_NEW^1
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 S1 - What is your primary medical specialty?
 Total^TN^1
 Dermatologist^          S1_NEW (1)
 Allergist[Show only for US]^ S1_NEW (2)
 Nurse Practitioner[Show only for US]^S1_NEW (3)
 Physician Assistant^    S1_NEW (4)
 Family Practice (FP)^   S1_NEW (5)
 Internal Medicine (IM)^ S1_NEW (6)
 Other ^                 S1_NEW (7)

TS2_NEW^2
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 S2 - Are you board certified in your specialty?
S|Only ask S2 to Dermatologists (All Countries) and Allergists (US only)] 
 Total^TN^1
 Yes^ S2_NEW (1)
 No^  S2_NEW (2)

TS3_NEW^3
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 S3 - What is the primary medical specialty of the physician(s) in the office in which you practice?
S|Only ask S3 to respondents NP / PAs 
 Total^TN^1
 Dermatology^             S3_NEW (1)
 Allergy^                 S3_NEW (2)
 Internal Medicine^       S3_NEW (3)
 Family Medicine^         S3_NEW (4)
 Pediatrics^              S3_NEW (5)
 Obstetrics / Gynecology^ S3_NEW (6)
 Other ^                  S3_NEW (7)

TS4_NEW^4
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 S4 - Which of the following best describes your primary practice setting?
 Total^TN^1
 Academic Hospital^             S4_NEW (1)
 Community Hospital^            S4_NEW (2)
 Private Office-Based Practice^ S4_NEW (3)
 Government / VA Hospital^      S4_NEW (4)

TS5_NEW^5
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 S5 - Are you currently affiliated with any pharmaceutical company or other health care manufacturer, serving as a clinical investigator, consultant, researcher, medical / promotional speaker or in any other capacity?
 Total^TN^1
 Yes^ S5_NEW (1)
 No^  S5_NEW (2)

TS6_NEW^6
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 S6 - How many years have you been in active clinical practice since completing your education?
 Total^TN^1
 Mean^S6_NEW(0-99)^SM
 STDDEV^S6_NEW(0-99)^SV

 Categories:^ ^BLD
 2 to 5 years^    S6_NEW (2-5)
 6 to 10 years^   S6_NEW (6-10)
 11 to 20 years^  S6_NEW (11-20)
 21 to 30 years^  S6_NEW (21-30)
 31 to 35 years^  S6_NEW (31-35)
 
TS7_NEW^7
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 S7 -What percent of your professional time do you spend in direct patient care, as opposed to clinical trials, non-clinical research, teaching, or administration?
 Total^TN^1
 Mean^S7_NEW(0-100)^SM
 STDDEV^S7_NEW(0-100)^SV

TS8_1_1^8
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 S8 - Thinking of all your patient visits, what percentage has a cosmetic focus as opposed to a medical dermatology focus? 
S|Only ask S8 to Derms and Derm NP/PAs (US only)] 
 Total^TN^1
 Mean Summary:^ ^BLD
 Cosmetic^S8_1_1(0-100)^SM
 Medical Dermatology^S8_2_1(0-100)^SM

 STDDEV Summary:^ ^BLD
 Cosmetic^S8_1_1(0-100)^SV
 Medical Dermatology^S8_2_1(0-100)^SV
 
TS9_1_1^9
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 S9 - Please think of your patients you have treated for any dermatological condition (e.g., Atopic Dermatitis, Psoriasis, etc.) in the past 6 months. How many patients are on each of the following types of treatments? 
 Total^TN^1
 Mean Summary:^ ^BLD
 Biologics^S9_1_1_NEW(0-9999)^SM
 Oral systemics^S9_2_1_NEW(0-9999)^SM
 Topical therapies^S9_3_1_NEW(0-9999)^SM
 Phototherapy^S9_4_1_NEW(0-9999)^SM

 STDDEV Summary:^ ^BLD
 Biologics^S9_1_1_NEW(0-9999)^SV
 Oral systemics^S9_2_1_NEW(0-9999)^SV
 Topical therapies^S9_3_1_NEW(0-9999)^SV
 Phototherapy^S9_4_1_NEW(0-9999)^SV

TS10_NEW^10
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 S10 - Within your role, do you personally treat, manage, and write prescriptions for patients with Atopic Dermatitis?
 Total^TN^1
 Yes^ S10_NEW (1)
 No^  S10_NEW (2)

TQS11^11
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 S11 - In the past 6 months, how many patients have you personally managed with Atopic Dermatitis?Please include all your patients regardless of whether untreated, on treatment, or in remission.
 Total^TN^1
 Mean^S11_NEW(0-9999)^SM
 STD DEV^S11_NEW(0-9999)^SV
 Median^S11_NEW(0-9999)^SD 

TS12^12
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 S12 - Thinking of the [S11] Atopic Dermatitis patients you have personally managed in the past 6 months, how many would you describe as mild, moderate, and severe?
S|Skip S12 if S11 = 0 
 Total^TN^1
 Mean Summary:^ ^BLD
 Mild^S12_1_1_NEW(0-9999)^SM
 Moderate^S12_2_1_NEW(0-9999)^SM
 Severe^S12_3_1_NEW(0-9999)^SM

 STDDEV Summary:^ ^BLD
 Mild^S12_1_1_NEW(0-9999)^SV
 Moderate^S12_2_1_NEW(0-9999)^SV
 Severe^S12_3_1_NEW(0-9999)^SV

TS13^13
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 S13 - Among the [S12] moderate and severe Atopic Dermatitis patients you have treated with prescription therapies in the past 6 months, how many are biologic candidates? 
S|Show S13 if S12_b + S12_c > 0 and S9_a>0 /Skip S13 if S11 = 0 
 Total^TN^1
 Mean Summary:
 Number of Moderate Atopic Dermatitis Patients^S13_1_1_NEW(0-9999)^SM
 Number of Severe Atopic Dermatitis Patients ^S13_1_1_NEW(0-9999)^SM

 STD DEV Summary:
 Number of Moderate Atopic Dermatitis Patients^S13_1_1_NEW(0-9999)^SV
 Number of Severe Atopic Dermatitis Patients ^S13_1_1_NEW(0-9999)^SV

TS14^14
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 S14 - In the past 6 months, how many of your moderate-to-severe Atopic Dermatitis patients have you treated with Dupixent® (dupilumab) [PN: In France show “biologic systemics”]?
S|Skip S14, if S9_a = 0 
 Total^TN^1
 Mean^S14_NEW(0-9999)^SM
 STDDEV^S14_NEW(0-9999)^SV
 Median^S14_NEW(0-9999)^SD

TS16_NEW^15
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 S16 - Are you or your practice affiliated with any of the following?
 Total^TN^1
 An advertising agency in the healthcare area^                   S16_NEW (1)
 A market research company in the healthcare area^               S16_NEW (2)
 A pharmaceutical or healthcare company or medical manufacturer^ S16_NEW (3)
 A government drug approval and/or reimbursement authority^      S16_NEW (4)
 Kaiser or Kaiser Permanente or the Permanente Group^            S16_NEW (5)
 None of the above^                                              S16_NEW (6)

TA1_1_1^16
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 A1 - [Moderate] Among your [S13] Atopic Dermatitis patients who are biologic candidates and you have treated in the past 6 months, how many are biologic-naïve and are biologic-experienced? 
S|Show only columns with severities >0 in S13 
 Total^TN^1
 Mean Summary:
 Biologic-naïve^A1_1_1_NEW(0-9999)^SM
 Biologic-experienced^A1_2_1_NEW(0-9999)^SM

 STD DEV Summary:
 Biologic-naïve^A1_1_1_NEW(0-9999)^SV
 Biologic-experienced^A1_2_1_NEW(0-9999)^SV

 Median Summary:
 Biologic-naïve^A1_1_1_NEW(0-9999)^SD
 Biologic-experienced^A1_2_1_NEW(0-9999)^SD

TA1_1_1^17
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 A1 - [Severe] Among your [S13] Atopic Dermatitis patients who are biologic candidates and you have treated in the past 6 months, how many are biologic-naïve and are biologic-experienced? 
S|Show only columns with severities >0 in S13  
 Total^TN^1
 Mean Summary:
 Biologic-naïve^A1_1_2_NEW(0-9999)^SM
 Biologic-experienced^A1_2_2_NEW(0-9999)^SM

 STD DEV Summary:
 Biologic-naïve^A1_1_2_NEW(0-9999)^SV
 Biologic-experienced^A1_2_2_NEW(0-9999)^SV

 Median Summary:
 Biologic-naïve^A1_1_2_NEW(0-9999)^SD
 Biologic-experienced^A1_2_2_NEW(0-9999)^SD

TA2_Naive^18
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 A2 - [Percent of Biologic-Naïve Patients] Among your moderate-to-severe Atopic Dermatitis patients who are biologic candidates and you have treated in the past 6 months, what percent have moderate-to-severe asthma? 
S|Show if A1_a >0 in any of the columns
 Total^TN^1
 Mean Summary:
 Patients with moderate-to-severe Atopic Dermatitis with moderate-to-severe [Show “severe” for France]  asthma^A2_1_1(0-9999)^SM
 Patients with moderate-to-severe Atopic Dermatitis without moderate-to-severe [Show “severe” for France]  asthma^A2_2_1(0-9999)^SM

 STD DEV Summary:
 Patients with moderate-to-severe Atopic Dermatitis with moderate-to-severe [Show “severe” for France]  asthma^A2_1_1(0-9999)^SV
 Patients with moderate-to-severe Atopic Dermatitis without moderate-to-severe [Show “severe” for France]  asthma^A2_2_1(0-9999)^SV

TA2_Naive^19
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 A2 - [Percent of Biologic-Experienced Patients] Among your moderate-to-severe Atopic Dermatitis patients who are biologic candidates and you have treated in the past 6 months, what percent have moderate-to-severe asthma? 
S|Show if A1_b >0 in any of the columns 
 Total^TN^1
 Mean Summary:
 Patients with moderate-to-severe Atopic Dermatitis with moderate-to-severe [Show “severe” for France]  asthma^A2_1_2(0-9999)^SM
 Patients with moderate-to-severe Atopic Dermatitis without moderate-to-severe [Show “severe” for France]  asthma^A2_2_2(0-9999)^SM

 STD DEV Summary:
 Patients with moderate-to-severe Atopic Dermatitis with moderate-to-severe [Show “severe” for France]  asthma^A2_1_2(0-9999)^SV
 Patients with moderate-to-severe Atopic Dermatitis without moderate-to-severe [Show “severe” for France]  asthma^A2_2_2(0-9999)^SV

TA3_1^20
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 A3 - [Moderate Atopic Dermatitis Patients] Thinking of your [Show moderate based on A1_b>0] Atopic Dermatitis patients you have treated in the past 6 months with Dupixent® (dupilumab), what percent fall into each of the below categories? 
S|Show if A1_b>0
 Total^TN^1
 Mean Summary:
 Currently on Dupixent® (dupilumab) ^ A3_1_1 (0-100)^SM
 Discontinued Dupixent® (dupilumab) ^ A3_2_1 (0-100)^SM

 STD DEV Summary:
 Currently on Dupixent® (dupilumab) ^ A3_1_1 (0-100)^SV
 Discontinued Dupixent® (dupilumab) ^ A3_2_1 (0-100)^SV

TA3_2^21
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 A3 - [Percent of Severe Atopic Dermatitis] Thinking of your [Show severe based on A1_b>0] Atopic Dermatitis patients you have treated in the past 6 months with Dupixent® (dupilumab), what percent fall into each of the below categories? 
S|Show if A1_b>0
 Total^TN^1
 Mean Summary:
 Currently on Dupixent® (dupilumab) ^ A3_1_2 (0-100)^SM
 Discontinued Dupixent® (dupilumab) ^ A3_2_2 (0-100)^SM

 STD DEV Summary:
 Currently on Dupixent® (dupilumab) ^ A3_1_2 (0-100)^SV
 Discontinued Dupixent® (dupilumab) ^ A3_2_2 (0-100)^SV

TA4_1^22
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 A4 - [Percent of Moderate Atopic Dermatitis Patients]Please think of your [Show moderate based on A3_a > 0%] Atopic Dermatitis patients you have treated in the past 6 months who are currently on Dupixent® (dupilumab). What percent fall into each of the below categories?
S|Show if A3_a > 0% 
 Total^TN^1
 Mean Summary:
 Patient is controlled on Dupixent® (dupilumab) ^ A4_1_1 (0-100)^SM
 Patient had a partial response to Dupixent® (dupilumab) and is currently uncontrolled ^ A4_2_1 (0-100)^SM
 Patient had initial response to Dupixent® (dupilumab) but is currently uncontrolled  ^ A4_3_1 (0-100)^SM
 Patient never responded to Dupixent® (dupilumab) and is currently uncontrolled ^ A4_4_1 (0-100)^SM

 STD DEV Summary:
 Patient is controlled on Dupixent® (dupilumab) ^ A4_1_1 (0-100)^SV
 Patient had a partial response to Dupixent® (dupilumab) and is currently uncontrolled ^ A4_2_1 (0-100)^SV
 Patient had initial response to Dupixent® (dupilumab) but is currently uncontrolled  ^ A4_3_1 (0-100)^SV
 Patient never responded to Dupixent® (dupilumab) and is currently uncontrolled ^ A4_4_1 (0-100)^SV

TA4_2^23
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 A4 - [Percent of Severe Atopic Dermatitis Patients]Please think of your [Show  severe based on A3_a > 0%] Atopic Dermatitis patients you have treated in the past 6 months who are currently on Dupixent® (dupilumab). What percent fall into each of the below categories?
S|Show if A3_a > 0% 
 Total^TN^1
 Mean Summary:
 Patient is controlled on Dupixent® (dupilumab) ^ A4_1_2 (0-100)^SM
 Patient had a partial response to Dupixent® (dupilumab) and is currently uncontrolled ^ A4_2_2 (0-100)^SM
 Patient had initial response to Dupixent® (dupilumab) but is currently uncontrolled  ^ A4_3_2 (0-100)^SM
 Patient never responded to Dupixent® (dupilumab) and is currently uncontrolled ^ A4_4_2 (0-100)^SM

 STD DEV Summary:
 Patient is controlled on Dupixent® (dupilumab) ^ A4_1_2 (0-100)^SV
 Patient had a partial response to Dupixent® (dupilumab) and is currently uncontrolled ^ A4_2_2 (0-100)^SV
 Patient had initial response to Dupixent® (dupilumab) but is currently uncontrolled  ^ A4_3_2 (0-100)^SV
 Patient never responded to Dupixent® (dupilumab) and is currently uncontrolled ^ A4_4_2 (0-100)^SV

TA5_1^24
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 A5 - [Percent of Moderate Atopic Dermatitis Patients]Please think of your [Show moderate based on A3_b > 0%] Atopic Dermatitis patients you have treated in the past 6 months that have discontinued Dupixent® (dupilumab). What percent fall into each of the below categories?
S|Show if A3_b > 0% 
 Total^TN^1
 Mean Summary:
 Patient was controlled on Dupixent® (dupilumab), but discontinued for other reasons ^ A5_1_1 (0-100)^SM
 Patient had a partial response to Dupixent® (dupilumab) and discontinued ^ A5_2_1 (0-100)^SM
 Patient had initial response to Dupixent® (dupilumab) but was later uncontrolled and hence discontinued ^ A5_3_1 (0-100)^SM
 Patient never responded to Dupixent® (dupilumab) and discontinued ^ A5_4_1 (0-100)^SM

 STD DEV Summary:
 Patient was controlled on Dupixent® (dupilumab), but discontinued for other reasons ^ A5_1_1 (0-100)^SV
 Patient had a partial response to Dupixent® (dupilumab) and discontinued ^ A5_2_1 (0-100)^SV
 Patient had initial response to Dupixent® (dupilumab) but was later uncontrolled and hence discontinued ^ A5_3_1 (0-100)^SV
 Patient never responded to Dupixent® (dupilumab) and discontinued ^ A5_4_1 (0-100)^SV

TA5_1^25
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 A5 - [Percent of Severe Atopic Dermatitis Patients]Please think of your [Show severe based on A3_b > 0%] Atopic Dermatitis patients you have treated in the past 6 months that have discontinued Dupixent® (dupilumab). What percent fall into each of the below categories?
S|Show if A3_b > 0% 
 Total^TN^1
 Mean Summary:
 Patient was controlled on Dupixent® (dupilumab), but discontinued for other reasons ^ A5_1_2 (0-100)^SM
 Patient had a partial response to Dupixent® (dupilumab) and discontinued ^ A5_2_2 (0-100)^SM
 Patient had initial response to Dupixent® (dupilumab) but was later uncontrolled and hence discontinued ^ A5_3_2 (0-100)^SM
 Patient never responded to Dupixent® (dupilumab) and discontinued ^ A5_4_2 (0-100)^SM

 STD DEV Summary:
 Patient was controlled on Dupixent® (dupilumab), but discontinued for other reasons ^ A5_1_2 (0-100)^SV
 Patient had a partial response to Dupixent® (dupilumab) and discontinued ^ A5_2_2 (0-100)^SV
 Patient had initial response to Dupixent® (dupilumab) but was later uncontrolled and hence discontinued ^ A5_3_2 (0-100)^SV
 Patient never responded to Dupixent® (dupilumab) and discontinued ^ A5_4_2 (0-100)^SV

TA6_1^26
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 A6 - [Percent of Moderate Atopic Dermatitis Patients]Among the [Show moderate based on A3_b] biologic-experienced Atopic Dermatitis patients who failed on Dupixent® (dupilumab) in the past 6 months, what percent failed for the following reasons? 
S|Show if A3_b >0% 
 Total^TN^1
 Mean Summary:
 Conjunctivitis / Ocular issues ^ A6_1_1 (0-100)^SM
 Other safety / side effects ^ A6_2_1 (0-100)^SM
 Lack of efficacy ^ A6_3_1 (0-100)^SM
 Other ^ A6_4_1 (0-100)^SM

 STD DEV Summary:
 Conjunctivitis / Ocular issues ^ A6_1_1 (0-100)^SV
 Other safety / side effects ^ A6_2_1 (0-100)^SV
 Lack of efficacy ^ A6_3_1 (0-100)^SV
 Other ^ A6_4_1 (0-100)^SV

TA6_1^27
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 A6 - [Percent of Severe Atopic Dermatitis Patients]Among the [Show severe based on A3_b] biologic-experienced Atopic Dermatitis patients who failed on Dupixent® (dupilumab) in the past 6 months, what percent failed for the following reasons? 
S|Show if A3_b >0% 
 Total^TN^1
 Mean Summary:
 Conjunctivitis / Ocular issues ^ A6_1_1 (0-100)^SM
 Other safety / side effects ^ A6_2_1 (0-100)^SM
 Lack of efficacy ^ A6_3_1 (0-100)^SM
 Other ^ A6_4_1 (0-100)^SM

 STD DEV Summary:
 Conjunctivitis / Ocular issues ^ A6_1_1 (0-100)^SV
 Other safety / side effects ^ A6_2_1 (0-100)^SV
 Lack of efficacy ^ A6_3_1 (0-100)^SV
 Other ^ A6_4_1 (0-100)^SV

TC1_1^28
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 C1 - [Percent of Moderate Patients]Please think of your [PN: Show moderate and severe dynamically based on A1_a >0] Atopic Dermatitis patients who you have seen in the past 6 months. Thinking of those who were biologic-naive when they arrived at their last visit, what therapies did these patients receive?
S|Show if A1_a >0
 Total^TN^1
 Mean Summary:
 Dupixent® (dupilumab) ^ C1_5_1 (0-100)^SM
 Oral Systemics (e.g., cyclosporine, methotrexate) ^ C1_6_1 (0-100)^SM
 Prescription Topical Corticosteroids (TCS) ^ C1_7_1 (0-100)^SM
 Prescription Topical Calcineurin Inhibitors (TCI) ^ C1_8_1 (0-100)^SM
 Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole)) ^ C1_9_1 (0-100)^SM
 [Shown in US only]Oral Corticosteroids  ^ C1_10_1 (0-100)^SM
 Other Prescription Therapies ^ C1_11_1 (0-100)^SM

 STD DEV Summary:
 Dupixent® (dupilumab) ^ C1_5_1 (0-100)^SV
 Oral Systemics (e.g., cyclosporine, methotrexate) ^ C1_6_1 (0-100)^SV
 Prescription Topical Corticosteroids (TCS) ^ C1_7_1 (0-100)^SV
 Prescription Topical Calcineurin Inhibitors (TCI) ^ C1_8_1 (0-100)^SV
 Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole)) ^ C1_9_1 (0-100)^SV
 [Shown in US only]Oral Corticosteroids  ^ C1_10_1 (0-100)^SV
 Other Prescription Therapies ^ C1_11_1 (0-100)^SV

TC1_2^29
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 C1 - [Percent of Severe Patients]Please think of your [PN: Show moderate and severe dynamically based on A1_a >0] Atopic Dermatitis patients who you have seen in the past 6 months. Thinking of those who were biologic-naive when they arrived at their last visit, what therapies did these patients receive?
S|Show if A1_a >0
 Total^TN^1
 Mean Summary:
 Dupixent® (dupilumab) ^ C1_5_3 (0-100)^SM
 Oral Systemics (e.g., cyclosporine, methotrexate) ^ C1_6_3 (0-100)^SM
 Prescription Topical Corticosteroids (TCS) ^ C1_7_3 (0-100)^SM
 Prescription Topical Calcineurin Inhibitors (TCI) ^ C1_8_3 (0-100)^SM
 Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole)) ^ C1_9_3 (0-100)^SM
 [Shown in US only]Oral Corticosteroids  ^ C1_10_3 (0-100)^SM
 Other Prescription Therapies ^ C1_11_3 (0-100)^SM

 STD DEV Summary:
 Dupixent® (dupilumab) ^ C1_5_3 (0-100)^SV
 Oral Systemics (e.g., cyclosporine, methotrexate) ^ C1_6_3 (0-100)^SV
 Prescription Topical Corticosteroids (TCS) ^ C1_7_3 (0-100)^SV
 Prescription Topical Calcineurin Inhibitors (TCI) ^ C1_8_3 (0-100)^SV
 Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole)) ^ C1_9_3 (0-100)^SV
 [Shown in US only]Oral Corticosteroids  ^ C1_10_3 (0-100)^SV
 Other Prescription Therapies ^ C1_11_3 (0-100)^SV

TC2_5_2^30
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 C2 - [Percent of Moderate Patients]Please think of your [PN: Show moderate and severe dynamically based on A1_b >0] Atopic Dermatitis patients who you have seen in the past 6 months. Thinking of those who were biologic-experienced when they arrived at their last visit, what therapies did these patients receive?
S|Show if A1_a >0
 Total^TN^1 
 Mean Summary:
 Dupixent® (dupilumab) ^ C2_5_2 (0-100)^SM
 Oral Systemics (e.g., cyclosporine, methotrexate) ^ C2_6_2 (0-100)^SM
 Prescription Topical Corticosteroids (TCS) ^ C2_7_2 (0-100)^SM
 Prescription Topical Calcineurin Inhibitors (TCI) ^ C2_8_2 (0-100)^SM
 Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole)) ^ C2_9_2 (0-100)^SM
 [Shown in US only]Oral Corticosteroids  ^ C2_10_2 (0-100)^SM
 Other Prescription Therapies ^ C2_11_2 (0-100)^SM

 STD DEV Summary:
 Dupixent® (dupilumab) ^ C2_5_2 (0-100)^SV
 Oral Systemics (e.g., cyclosporine, methotrexate) ^ C2_6_2 (0-100)^SV
 Prescription Topical Corticosteroids (TCS) ^ C2_7_2 (0-100)^SV
 Prescription Topical Calcineurin Inhibitors (TCI) ^ C2_8_2 (0-100)^SV
 Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole)) ^ C2_9_2 (0-100)^SV
 [Shown in US only]Oral Corticosteroids  ^ C2_10_2 (0-100)^SV
 Other Prescription Therapies ^ C2_11_2 (0-100)^SV

TC2_5_2^31
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 C2 - [Percent of Severe Patients]Please think of your [PN: Show moderate and severe dynamically based on A1_b >0] Atopic Dermatitis patients who you have seen in the past 6 months. Thinking of those who were biologic-experienced when they arrived at their last visit, what therapies did these patients receive?
S|Show if A1_a >0
 Total^TN^1 
 Mean Summary:
 Dupixent® (dupilumab) ^ C2_5_4 (0-100)^SM
 Oral Systemics (e.g., cyclosporine, methotrexate) ^ C2_6_4 (0-100)^SM
 Prescription Topical Corticosteroids (TCS) ^ C2_7_4 (0-100)^SM
 Prescription Topical Calcineurin Inhibitors (TCI) ^ C2_8_4 (0-100)^SM
 Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole)) ^ C2_9_4 (0-100)^SM
 [Shown in US only]Oral Corticosteroids  ^ C2_10_4 (0-100)^SM
 Other Prescription Therapies ^ C2_11_4 (0-100)^SM

 STD DEV Summary:
 Dupixent® (dupilumab) ^ C2_5_4 (0-100)^SV
 Oral Systemics (e.g., cyclosporine, methotrexate) ^ C2_6_4 (0-100)^SV
 Prescription Topical Corticosteroids (TCS) ^ C2_7_4 (0-100)^SV
 Prescription Topical Calcineurin Inhibitors (TCI) ^ C2_8_4 (0-100)^SV
 Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole)) ^ C2_9_4 (0-100)^SV
 [Shown in US only]Oral Corticosteroids  ^ C2_10_4 (0-100)^SV
 Other Prescription Therapies ^ C2_11_4 (0-100)^SV

TC3_1^32
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 C3 - [Naïve-Moderate Atopic Dermatitis Patients] Please consider your [Show moderate and severe dynamically based on C1_a/C2_a] Atopic Dermatitis patients whom you have treated with Dupixent® (dupilumab) in the past 6 months. To what percent of patients did you prescribe Dupixent® (dupilumab) as a monotherapy versus in combination with another prescription therapy?
S|C1_a OR C2_a > 0%
 Total^TN^1
 Mean Summary:
 Monotherapy ^ C3_1_1 (0-100)^SM
 Treated in combination with another prescription therapy ^ C3_2_1 (0-100)^SM

 STD DEV Summary:
 Monotherapy ^ C3_1_1 (0-100)^SV
 Treated in combination with another prescription therapy ^ C3_2_1 (0-100)^SV

TC3_2^33
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 C3 - [Experienced-Moderate Atopic Dermatitis Patients] Please consider your [Show moderate and severe dynamically based on C1_a/C2_a] Atopic Dermatitis patients whom you have treated with Dupixent® (dupilumab) in the past 6 months. To what percent of patients did you prescribe Dupixent® (dupilumab) as a monotherapy versus in combination with another prescription therapy?
S|C1_a OR C2_a > 0%
 Total^TN^1
 Mean Summary:
 Monotherapy ^ C3_1_2 (0-100)^SM
 Treated in combination with another prescription therapy ^ C3_2_2 (0-100)^SM

 STD DEV Summary:
 Monotherapy ^ C3_1_2 (0-100)^SV
 Treated in combination with another prescription therapy ^ C3_2_2 (0-100)^SV

TC3_3^34
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 C3 - [Naïve-Severe Atopic Dermatitis Patients] Please consider your [Show moderate and severe dynamically based on C1_a/C2_a] Atopic Dermatitis patients whom you have treated with Dupixent® (dupilumab) in the past 6 months. To what percent of patients did you prescribe Dupixent® (dupilumab) as a monotherapy versus in combination with another prescription therapy?
S|C1_a OR C2_a > 0%
 Total^TN^1
 Mean Summary:
 Monotherapy ^ C3_1_3 (0-100)^SM
 Treated in combination with another prescription therapy ^ C3_2_3 (0-100)^SM

 STD DEV Summary:
 Monotherapy ^ C3_1_3 (0-100)^SV
 Treated in combination with another prescription therapy ^ C3_2_3 (0-100)^SV

TC3_4^35
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 C3 - [Experienced-Severe Atopic Dermatitis Patients] Please consider your [Show moderate and severe dynamically based on C1_a/C2_a] Atopic Dermatitis patients whom you have treated with Dupixent® (dupilumab) in the past 6 months. To what percent of patients did you prescribe Dupixent® (dupilumab) as a monotherapy versus in combination with another prescription therapy?
S|C1_a OR C2_a > 0%
 Total^TN^1
 Mean Summary:
 Monotherapy ^ C3_1_4 (0-100)^SM
 Treated in combination with another prescription therapy ^ C3_2_4 (0-100)^SM

 STD DEV Summary:
 Monotherapy ^ C3_1_4 (0-100)^SV
 Treated in combination with another prescription therapy ^ C3_2_4 (0-100)^SV

TC4_1^36
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 C4 - Please consider your [PN: Show moderate and severe dynamically based on C1_a/C2_a] Atopic Dermatitis patients whom you have treated with Dupixent® (dupilumab) in the past 6 months. How have you prescribed Dupixent® (dupilumab) to manage your patients’ symptoms? 
 Total^TN^1
 Treatment of flares-ups^  C4_1 (1)
 As a maintenance therapy^ C4_1 (2)

TC4_2^37
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 C4 - Use of Dupixent® (dupilumab) / dupilumab / biologic systemics in PAST 6 Months Moderate Atopic Dermatitis Patients Percent of Biologic-Experienced Patients
 Total^TN^1
 Treatment of flares-ups^  C4_2 (1)
 As a maintenance therapy^ C4_2 (2)

TC4_3^38
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 C4 - Use of Dupixent® (dupilumab) / dupilumab / biologic systemics in PAST 6 Months Severe Atopic Dermatitis Patients Percent of Biologic-Naïve Patients
 Total^TN^1
 Treatment of flares-ups^  C4_3 (1)
 As a maintenance therapy^ C4_3 (2)

TC4_4^39
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 C4 - Use of Dupixent® (dupilumab) / dupilumab / biologic systemics in PAST 6 Months Severe Atopic Dermatitis Patients Percent of Biologic-Experienced Patients
 Total^TN^1
 Treatment of flares-ups^  C4_4 (1)
 As a maintenance therapy^ C4_4 (2)

TC5_1^40
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 C5 - What are the reason(s) you do not use Dupixent® (dupilumab) for more of your patients who are biologic candidates?
 Total^TN^1 
 Lack of efficacy ^ C5_1 (1)
 Patient has concerns about safety / side effects ^ C5_2 (1)
 I am concerned about the long-term safety of product ^ C5_3 (1)
 I am concerned about the side effects of product ^ C5_4 (1)
 Product is not covered on formulary  ^ C5_5 (1)
 Product is covered by insurance, but too high out-of-pocket cost for patient [PN: Do not show in France, Germany, UK]  ^ C5_6 (1)
 Product not covered by insurance ^ C5_7 (1)
 Patients do not want injection / would prefer oral treatment ^ C5_8 (1)
 Lack of familiarity with product ^ C5_9 (1)
 Other reasons ^ C5_OTHER (1)

TD1_COMB_2^41
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST,FU
 D1 - [Moderate Atopic Dermatitis Patients] Please think of all your moderate and severe Atopic Dermatitis patients who are biologic candidates and you will treat in the next 6 months.what percent of these patients with Atopic Dermatitis will receive the following prescription therapies?Please consider both your controlled and uncontrolled patients whom you will treat with any of the below therapies alone or in combination with another therapy.
S|Percent of Biologic-Naïve Patients
 Weighted Total^TN^1
 Sample Size Summary:
 Sample Size for Oral Corticosteroids^D1_10_2(0-100)^HR
 Sample Size for "Product Z"^D1_4_2(0-100)^HR
 Sample Size for Rest of Products^D1_1_2(0-100)^HR
 Sample Size for Oral Corticosteroids^D1_10_2(0-100)^SB,DW
 Sample Size for "Product Z"^D1_4_2(0-100)^SB,DW
 Sample Size for Rest of Products^D1_1_2(0-100)^SB,DW

 Mean Summary:
 JAK-ls:
 Product P^                                        D1_1_2(0-100)^SM
 Product Q^                                        D1_2_2(0-100)^SM
 Product R^                                        D1_3_2(0-100)^SM
 Product Z^                                        D1_4_2(0-100)^SM
 Biologics:
 Dupixent(dupilumab) ^                             D1_5_2(0-100)^SM
 Oral Systemics:                                   
 Oral Systemics (e.g., cyclosporine, methotrexate)^D1_6_2(0-100)^SM
 Prescription Topical Medications:
 Prescription Topical Corticosteroids (TCS)^       D1_7_2(0-100)^SM
 Prescription Topical Calcineurin Inhibitors (TCI)^D1_8_2(0-100)^SM
 Other Prescription Topical Medications (e.g., Eucrisa (crisaborole)) ^D1_9_2(0-100)^SM
 Other Prescription Therapies:
 Oral Corticosteroids [Show in US only]^           D1_10_2(0-100)^SM
 Other Prescription Therapies^                     D1_OTHER_2(0-100)^SM

 STD DEV Summary:
 JAK-ls:
 Product P^                                        D1_1_2(0-100)^SV
 Product Q^                                        D1_2_2(0-100)^SV
 Product R^                                        D1_3_2(0-100)^SV
 Product Z^                                        D1_4_2(0-100)^SV
 Biologics:
 Dupixent(dupilumab) ^                             D1_5_2(0-100)^SV
 Oral Systemics:                                   
 Oral Systemics (e.g., cyclosporine, methotrexate)^D1_6_2(0-100)^SV
 Prescription Topical Medications:
 Prescription Topical Corticosteroids (TCS)^       D1_7_2(0-100)^SV
 Prescription Topical Calcineurin Inhibitors (TCI)^D1_8_2(0-100)^SV
 Other Prescription Topical Medications (e.g., Eucrisa (crisaborole)) ^D1_9_2(0-100)^SV
 Other Prescription Therapies:
 Oral Corticosteroids [Show in US only]^           D1_10_2(0-100)^SV
 Other Prescription Therapies^                     D1_OTHER_2(0-100)^SV

TD1_COMB_4^42
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST,FU
 D1 - [Moderate Atopic Dermatitis Patients] Please think of all your moderate and severe Atopic Dermatitis patients who are biologic candidates and you will treat in the next 6 months.what percent of these patients with Atopic Dermatitis will receive the following prescription therapies?Please consider both your controlled and uncontrolled patients whom you will treat with any of the below therapies alone or in combination with another therapy.
S|Percent of Biologic-Experienced Patients
 Weighted Total^TN^1
 Sample Size Summary:
 Sample Size for Oral Corticosteroids^D1_10_4(0-100)^HR
 Sample Size for "Product Z"^D1_4_4(0-100)^HR
 Sample Size for Rest of Products^D1_1_4(0-100)^HR
 Sample Size for Oral Corticosteroids^D1_10_4(0-100)^SB,DW
 Sample Size for "Product Z"^D1_4_4(0-100)^SB,DW
 Sample Size for Rest of Products^D1_1_4(0-100)^SB,DW

 Mean Summary:
 JAK-ls:
 Product P^                                        D1_1_4(0-100)^SM
 Product Q^                                        D1_2_4(0-100)^SM
 Product R^                                        D1_3_4(0-100)^SM
 Product Z^                                        D1_4_4(0-100)^SM
 Biologics:
 Dupixent(dupilumab) ^                             D1_5_4(0-100)^SM
 Oral Systemics:                                   
 Oral Systemics (e.g., cyclosporine, methotrexate)^D1_6_4(0-100)^SM
 Prescription Topical Medications:
 Prescription Topical Corticosteroids (TCS)^       D1_7_4(0-100)^SM
 Prescription Topical Calcineurin Inhibitors (TCI)^D1_8_4(0-100)^SM
 Other Prescription Topical Medications (e.g., Eucrisa (crisaborole)) [Show in France and Germany as "Other Prescription Topical Medications"]^D1_9_4(0-100)^SM
 Other Prescription Therapies:
 Oral Corticosteroids [Show in US only]^           D1_10_4(0-100)^SM
 Other Prescription Therapies^                     D1_OTHER_4(0-100)^SM

 STD DEV Summary:
 JAK-ls:
 Product P^                                        D1_1_4(0-100)^SV
 Product Q^                                        D1_2_4(0-100)^SV
 Product R^                                        D1_3_4(0-100)^SV
 Product Z^                                        D1_4_4(0-100)^SV
 Biologics:
 Dupixent(dupilumab) ^                             D1_5_4(0-100)^SV
 Oral Systemics:                                   
 Oral Systemics (e.g., cyclosporine, methotrexate)^D1_6_4(0-100)^SV
 Prescription Topical Medications:
 Prescription Topical Corticosteroids (TCS)^       D1_7_4(0-100)^SV
 Prescription Topical Calcineurin Inhibitors (TCI)^D1_8_4(0-100)^SV
 Other Prescription Topical Medications (e.g., Eucrisa (crisaborole)) [Show in France and Germany as "Other Prescription Topical Medications"]^D1_9_4(0-100)^SV
 Other Prescription Therapies:
 Oral Corticosteroids [Show in US only]^           D1_10_4(0-100)^SV
 Other Prescription Therapies^                     D1_OTHER_4(0-100)^SV

TD1_COMB_6^43
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST,FU
 D1 - [Severe Atopic Dermatitis Patients] Please think of all your moderate and severe Atopic Dermatitis patients who are biologic candidates and you will treat in the next 6 months.what percent of these patients with Atopic Dermatitis will receive the following prescription therapies?Please consider both your controlled and uncontrolled patients whom you will treat with any of the below therapies alone or in combination with another therapy.
S|Percent of Biologic-Naïve Patients
 Weighted Total^TN^1
 Sample Size Summary:
 Sample Size for Oral Corticosteroids^D1_10_6(0-100)^HR
 Sample Size for "Product Z"^D1_4_6(0-100)^HR
 Sample Size for Rest of Products^D1_1_6(0-100)^HR
 Sample Size for Oral Corticosteroids^D1_10_6(0-100)^SB,DW
 Sample Size for "Product Z"^D1_4_6(0-100)^SB,DW
 Sample Size for Rest of Products^D1_1_6(0-100)^SB,DW

 Mean Summary:
 JAK-ls:
 Product P^                                        D1_1_6(0-100)^SM
 Product Q^                                        D1_2_6(0-100)^SM
 Product R^                                        D1_3_6(0-100)^SM
 Product Z^                                        D1_4_6(0-100)^SM
 Biologics:
 Dupixent(dupilumab) ^                             D1_5_6(0-100)^SM
 Oral Systemics:                                   
 Oral Systemics (e.g., cyclosporine, methotrexate)^D1_6_6(0-100)^SM
 Prescription Topical Medications:
 Prescription Topical Corticosteroids (TCS)^       D1_7_6(0-100)^SM
 Prescription Topical Calcineurin Inhibitors (TCI)^D1_8_6(0-100)^SM
 Other Prescription Topical Medications (e.g., Eucrisa (crisaborole)) [Show in France and Germany as "Other Prescription Topical Medications"]^D1_9_6(0-100)^SM
 Other Prescription Therapies:
 Oral Corticosteroids [Show in US only]^           D1_10_6(0-100)^SM
 Other Prescription Therapies^                     D1_OTHER_6(0-100)^SM

 STD DEV Summary:
 JAK-ls:
 Product P^                                        D1_1_6(0-100)^SV
 Product Q^                                        D1_2_6(0-100)^SV
 Product R^                                        D1_3_6(0-100)^SV
 Product Z^                                        D1_4_6(0-100)^SV
 Biologics:
 Dupixent(dupilumab) ^                             D1_5_6(0-100)^SV
 Oral Systemics:                                   
 Oral Systemics (e.g., cyclosporine, methotrexate)^D1_6_6(0-100)^SV
 Prescription Topical Medications:
 Prescription Topical Corticosteroids (TCS)^       D1_7_6(0-100)^SV
 Prescription Topical Calcineurin Inhibitors (TCI)^D1_8_6(0-100)^SV
 Other Prescription Topical Medications (e.g., Eucrisa (crisaborole)) [Show in France and Germany as "Other Prescription Topical Medications"]^D1_9_6(0-100)^SV
 Other Prescription Therapies:
 Oral Corticosteroids [Show in US only]^           D1_10_6(0-100)^SV
 Other Prescription Therapies^                     D1_OTHER_6(0-100)^SV

TD1_COMB_8^44
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST,FU
 D1 - [Severe Atopic Dermatitis Patients] Please think of all your moderate and severe Atopic Dermatitis patients who are biologic candidates and you will treat in the next 6 months.what percent of these patients with Atopic Dermatitis will receive the following prescription therapies?Please consider both your controlled and uncontrolled patients whom you will treat with any of the below therapies alone or in combination with another therapy.
S|Percent of Biologic-Experienced Patients
 Weighted Total^TN^1
 Sample Size Summary:
 Sample Size for Oral Corticosteroids^D1_10_8(0-100)^HR
 Sample Size for "Product Z"^D1_4_8(0-100)^HR
 Sample Size for Rest of Products^D1_1_8(0-100)^HR
 Sample Size for Oral Corticosteroids^D1_10_8(0-100)^SB,DW
 Sample Size for "Product Z"^D1_4_8(0-100)^SB,DW
 Sample Size for Rest of Products^D1_1_8(0-100)^SB,DW

 Mean Summary:
 JAK-ls:
 Product P^                                        D1_1_8(0-100)^SM
 Product Q^                                        D1_2_8(0-100)^SM
 Product R^                                        D1_3_8(0-100)^SM
 Product Z^                                        D1_4_8(0-100)^SM
 Biologics:
 Dupixent(dupilumab) ^                             D1_5_8(0-100)^SM
 Oral Systemics:                                   
 Oral Systemics (e.g., cyclosporine, methotrexate)^D1_6_8(0-100)^SM
 Prescription Topical Medications:
 Prescription Topical Corticosteroids (TCS)^       D1_7_8(0-100)^SM
 Prescription Topical Calcineurin Inhibitors (TCI)^D1_8_8(0-100)^SM
 Other Prescription Topical Medications (e.g., Eucrisa (crisaborole)) [Show in France and Germany as "Other Prescription Topical Medications"]^D1_9_8(0-100)^SM
 Other Prescription Therapies:
 Oral Corticosteroids [Show in US only]^           D1_10_8(0-100)^SM
 Other Prescription Therapies^                     D1_OTHER_8(0-100)^SM

 STD DEV Summary:
 JAK-ls:
 Product P^                                        D1_1_8(0-100)^SV
 Product Q^                                        D1_2_8(0-100)^SV
 Product R^                                        D1_3_8(0-100)^SV
 Product Z^                                        D1_4_8(0-100)^SV
 Biologics:
 Dupixent(dupilumab) ^                             D1_5_8(0-100)^SV
 Oral Systemics:                                   
 Oral Systemics (e.g., cyclosporine, methotrexate)^D1_6_8(0-100)^SV
 Prescription Topical Medications:
 Prescription Topical Corticosteroids (TCS)^       D1_7_8(0-100)^SV
 Prescription Topical Calcineurin Inhibitors (TCI)^D1_8_8(0-100)^SV
 Other Prescription Topical Medications (e.g., Eucrisa (crisaborole)) [Show in France and Germany as "Other Prescription Topical Medications"]^D1_9_8(0-100)^SV
 Other Prescription Therapies:
 Oral Corticosteroids [Show in US only]^           D1_10_8(0-100)^SV
 Other Prescription Therapies^                     D1_OTHER_8(0-100)^SV

TD2_COMB_1^45
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 D2 - [Moderate Atopic Dermatitis Patients in NEXT 6 Months] Please think of your [“Moderate”] Atopic Dermatitis patients whom you will treat in the next 6 months with [“Product P, Product Q, and Product R”]. What percent of patients do you envision prescribing [“Product P, Product Q, and Product R”] as a monotherapy versus in combination with another prescription therapy?
S|Biologic-Naïve Patients 
 Weighted Total^TN^1
 Mean Summary:
 Monotherapy^                                   D2_1_1(0-100)^SM
 Combination with another prescription therapy^ D2_2_1(0-100)^SM

 STD DEV Summary:
 Monotherapy^                                   D2_1_1(0-100)^SV
 Combination with another prescription therapy^ D2_2_1(0-100)^SV

TD2_COMB_2^46
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 D2 - [Moderate Atopic Dermatitis Patients in NEXT 6 Months] Please think of your [“Moderate”] Atopic Dermatitis patients whom you will treat in the next 6 months with [“Product P, Product Q, and Product R”]. What percent of patients do you envision prescribing [“Product P, Product Q, and Product R”] as a monotherapy versus in combination with another prescription therapy?
S|Biologic-Experienced Patients 
 Weighted Total^TN^1
 Mean Summary:
 Monotherapy^                                   D2_1_2(0-100)^SM
 Combination with another prescription therapy^ D2_2_2(0-100)^SM

 STD DEV Summary:
 Monotherapy^                                   D2_1_2(0-100)^SV
 Combination with another prescription therapy^ D2_2_2(0-100)^SV

TD2_COMB_3^47
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 D2 - [Severe Atopic Dermatitis Patients in NEXT 6 Months] Please think of your [“Severe”] Atopic Dermatitis patients whom you will treat in the next 6 months with [“Product P, Product Q, and Product R”]. What percent of patients do you envision prescribing [“Product P, Product Q, and Product R”] as a monotherapy versus in combination with another prescription therapy?
S|Biologic-Naïve Patients 
 Weighted Total^TN^1
 Mean Summary:
 Monotherapy^                                   D2_1_3(0-100)^SM
 Combination with another prescription therapy^ D2_2_3(0-100)^SM

 STD DEV Summary:
 Monotherapy^                                   D2_1_3(0-100)^SV
 Combination with another prescription therapy^ D2_2_3(0-100)^SV

TD2_COMB_3^48
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 D2 - [Severe Atopic Dermatitis Patients in NEXT 6 Months] Please think of your [“Severe”] Atopic Dermatitis patients whom you will treat in the next 6 months with [“Product P, Product Q, and Product R”]. What percent of patients do you envision prescribing [“Product P, Product Q, and Product R”] as a monotherapy versus in combination with another prescription therapy?
S|Biologic-Experienced Patients 
 Weighted Total^TN^1
 Mean Summary:
 Monotherapy^                                   D2_1_4(0-100)^SM
 Combination with another prescription therapy^ D2_2_4(0-100)^SM

 STD DEV Summary:
 Monotherapy^                                   D2_1_4(0-100)^SV
 Combination with another prescription therapy^ D2_2_4(0-100)^SV

TD4_a1^49
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,FU,ST
 D4_a1 - Now, please review the same profile again using our “click and highlight” technology. Using your mouse, please click on the sentences in the profile below that strongly positively or negatively influence you to prescribe this product to your patients. You can select as many items in the profile as you like. You do not need to highlight everything, only what strongly influences you.
S|Product P Profile 
 Weighted Total^TN^1
 Sample Size for "BOX WARNING: SERIOUS INFECTIONS, MALIGNANCY AND THROMBOSIS"^D4_PROF_P_24(0-2)^HR
 Sample Size for Rest of Options                                             ^D4_PROF_P_1(0-2)^HR
 Sample Size for "BOX WARNING: SERIOUS INFECTIONS, MALIGNANCY AND THROMBOSIS"^D4_PROF_P_24(0-2)^SB,DW
 Sample Size for Rest of Options                                             ^D4_PROF_P_1(0-2)^SB,DW

 Positive Influence Summary: 
 Mechanism of Action:
 Oral small molecule – a JAK inhibitor selective for JAK1, JAK2 and TYK2 over JAK3^D4_PROF_P_1(1)
 Indication:
 Treatment of adult patients with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable^D4_PROF_P_2(1)
 Dosing and Administration:
 Once daily, oral tablet^                               D4_PROF_P_3(1)
 Can be used with or without topical corticosteroids^   D4_PROF_P_4(1)
 Monitoring for lipids, liver enzymes and blood values^ D4_PROF_P_5(1)
 Efficacy:
 % of patients achieving IGA 0 or 1^                    D4_PROF_P_25(1)
 % of patients achieving EASI-75^                       D4_PROF_P_26(1)
 Mean change (%) in EASI^                               D4_PROF_P_27(1)
 % of patients achieving >=4 point reduction in peak pruritus NRS^D4_PROF_P_28(1)
 Onset of itch relief^                                  D4_PROF_P_29(1)
 16%, 5%^                                               D4_PROF_P_6(1)
 31%, 15%^                                              D4_PROF_P_7(1)
 23%, 8%^                                               D4_PROF_P_8(1)
 48%, 23%^                                              D4_PROF_P_9(1)
 -57%, -32%^                                            D4_PROF_P_10(1)
 -66%, -43%^                                            D4_PROF_P_11(1)
 21%, 6%^                                               D4_PROF_P_12(1)
 44%, 20%^                                              D4_PROF_P_13(1)
 QD - Within 1 week, Placebo - N/A^                     D4_PROF_P_14(1)
 QD + TCS - Within 1 week, Placebo + TCS - N/A^         D4_PROF_P_15(1)
 Safety:
 Headaches,^                                            D4_PROF_P_16(1)
 Nasopharyngitis,^                                      D4_PROF_P_17(1)
 Increased blood CPK^                                   D4_PROF_P_18(1)
 Herpes Simplex^                                        D4_PROF_P_19(1)
 1%, 3%^                                                D4_PROF_P_20(1)
 32%, 24%^                                              D4_PROF_P_21(1)
 1%, 1%^                                                D4_PROF_P_22(1)
 BOX WARNING: SERIOUS INFECTIONS, MALIGNANCY AND THROMBOSIS[Show only for US]^D4_PROF_P_24(1)^3
 % patients with serious AE^                            D4_PROF_P_30(1)
 % patients with serious infection^                     D4_PROF_P_31(1)
 % patients with conjunctivitis^                        D4_PROF_P_32(1)
 Insurance:
 Product P has similar insurance coverage to current systemic treatments.^D4_PROF_P_23(1)

 Negative Influence Summary:
 Mechanism of Action:
 Oral small molecule – a JAK inhibitor selective for JAK1, JAK2 and TYK2 over JAK3^D4_PROF_P_1(2)
 Indication:
 Treatment of adult patients with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable^D4_PROF_P_2(2)
 Dosing and Administration:
 Once daily, oral tablet^                               D4_PROF_P_3(2)
 Can be used with or without topical corticosteroids^   D4_PROF_P_4(2)
 Monitoring for lipids, liver enzymes and blood values^ D4_PROF_P_5(2)
 Efficacy:
 % of patients achieving IGA 0 or 1^                    D4_PROF_P_25(2)
 % of patients achieving EASI-75^                       D4_PROF_P_26(2)
 Mean change (%) in EASI^                               D4_PROF_P_27(2)
 % of patients achieving >=4 point reduction in peak pruritus NRS^D4_PROF_P_28(2)
 Onset of itch relief^                                  D4_PROF_P_29(2)
 16%, 5%^                                               D4_PROF_P_6(2)
 31%, 15%^                                              D4_PROF_P_7(2)
 23%, 8%^                                               D4_PROF_P_8(2)
 48%, 23%^                                              D4_PROF_P_9(2)
 -57%, -32%^                                            D4_PROF_P_10(2)
 -66%, -43%^                                            D4_PROF_P_11(2)
 21%, 6%^                                               D4_PROF_P_12(2)
 44%, 20%^                                              D4_PROF_P_13(2)
 QD - Within 1 week, Placebo - N/A^                     D4_PROF_P_14(2)
 QD + TCS - Within 1 week, Placebo + TCS - N/A^         D4_PROF_P_15(2)
 Safety:
 Headaches,^                                            D4_PROF_P_16(2)
 Nasopharyngitis,^                                      D4_PROF_P_17(2)
 Increased blood CPK^                                   D4_PROF_P_18(2)
 Herpes Simplex^                                        D4_PROF_P_19(2)
 1%, 3%^                                                D4_PROF_P_20(2)
 32%, 24%^                                              D4_PROF_P_21(2)
 1%, 1%^                                                D4_PROF_P_22(2)
 BOX WARNING: SERIOUS INFECTIONS, MALIGNANCY AND THROMBOSIS[Show only for US]^D4_PROF_P_24(2)^3
 % patients with serious AE^                            D4_PROF_P_30(2)
 % patients with serious infection^                     D4_PROF_P_31(2)
 % patients with conjunctivitis^                        D4_PROF_P_32(2)
 Insurance:
 Product P has similar insurance coverage to current systemic treatments.^D4_PROF_P_23(2)

 Clear Summary:
 Mechanism of Action:
 Oral small molecule – a JAK inhibitor selective for JAK1, JAK2 and TYK2 over JAK3^D4_PROF_P_1(0)
 Indication:
 Treatment of adult patients with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable^D4_PROF_P_2(0)
 Dosing and Administration:
 Once daily, oral tablet^                               D4_PROF_P_3(0)
 Can be used with or without topical corticosteroids^   D4_PROF_P_4(0)
 Monitoring for lipids, liver enzymes and blood values^ D4_PROF_P_5(0)
 Efficacy:
 % of patients achieving IGA 0 or 1^                    D4_PROF_P_25(0)
 % of patients achieving EASI-75^                       D4_PROF_P_26(0)
 Mean change (%) in EASI^                               D4_PROF_P_27(0)
 % of patients achieving >=4 point reduction in peak pruritus NRS^D4_PROF_P_28(0)
 Onset of itch relief^                                  D4_PROF_P_29(0)
 16%, 5%^                                               D4_PROF_P_6(0)
 31%, 15%^                                              D4_PROF_P_7(0)
 23%, 8%^                                               D4_PROF_P_8(0)
 48%, 23%^                                              D4_PROF_P_9(0)
 -57%, -32%^                                            D4_PROF_P_10(0)
 -66%, -43%^                                            D4_PROF_P_11(0)
 21%, 6%^                                               D4_PROF_P_12(0)
 44%, 20%^                                              D4_PROF_P_13(0)
 QD - Within 1 week, Placebo - N/A^                     D4_PROF_P_14(0)
 QD + TCS - Within 1 week, Placebo + TCS - N/A^         D4_PROF_P_15(0)
 Safety:
 Headaches,^                                            D4_PROF_P_16(0)
 Nasopharyngitis,^                                      D4_PROF_P_17(0)
 Increased blood CPK^                                   D4_PROF_P_18(0)
 Herpes Simplex^                                        D4_PROF_P_19(0)
 1%, 3%^                                                D4_PROF_P_20(0)
 32%, 24%^                                              D4_PROF_P_21(0)
 1%, 1%^                                                D4_PROF_P_22(0)
 BOX WARNING: SERIOUS INFECTIONS, MALIGNANCY AND THROMBOSIS[Show only for US]^D4_PROF_P_24(0)^3
 % patients with serious AE^                            D4_PROF_P_30(0)
 % patients with serious infection^                     D4_PROF_P_31(0)
 % patients with conjunctivitis^                        D4_PROF_P_32(0)
 Insurance:
 Product P has similar insurance coverage to current systemic treatments.^D4_PROF_P_23(0)

 Nothing in this profile influences me^ D4_CH_1(1)

TD4_a1^50
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 D4_a1 - Now, please review the same profile again using our “click and highlight” technology. Using your mouse, please click on the sentences in the profile below that strongly positively or negatively influence you to prescribe this product to your patients. You can select as many items in the profile as you like. You do not need to highlight everything, only what strongly influences you.
S|[BY PARAGRAPH] /[Product P Profile]
 Weighted Total^TN^1
 Positive Influence Summary:
 Mechanism of Action^D4_PROF_P_1(1)
 Indication^D4_PROF_P_2(1)
 Dosing and Administration^D4_PROF_P_3 S3(1)
 Efficacy^D4_PROF_P_6 S9(1) OR D4_PROF_P_25(1) OR D4_PROF_P_26(1) OR D4_PROF_P_27(1) OR D4_PROF_P_28(1) OR D4_PROF_P_29(1)
 Safety^D4_PROF_P_16 S7 (1) OR D4_PROF_P_24(1) OR D4_PROF_P_30(1) OR D4_PROF_P_31(1) OR D4_PROF_P_32(1) 
 Insurance^D4_PROF_P_23(1)

 Negative Influence Summary:
 Mechanism of Action^D4_PROF_P_1(2)
 Indication^D4_PROF_P_2(2)
 Dosing and Administration^D4_PROF_P_3 S3(2)
 Efficacy^D4_PROF_P_6 S9(2) OR D4_PROF_P_25(2) OR D4_PROF_P_26(2) OR D4_PROF_P_27(2) OR D4_PROF_P_28(2) OR D4_PROF_P_29(2)
 Safety^D4_PROF_P_16 S7 (2) OR D4_PROF_P_24(2) OR D4_PROF_P_30(2) OR D4_PROF_P_31(2) OR D4_PROF_P_32(2) 
 Insurance^D4_PROF_P_23(2)

 Clear Summary:
 Mechanism of Action^D4_PROF_P_1(0)
 Indication^D4_PROF_P_2(0)
 Dosing and Administration^D4_PROF_P_3 S3(0)
 Efficacy^D4_PROF_P_6 S9(0) OR D4_PROF_P_25(0) OR D4_PROF_P_26(0) OR D4_PROF_P_27(0) OR D4_PROF_P_28(0) OR D4_PROF_P_29(0)
 Safety^D4_PROF_P_16 S7 (0) OR D4_PROF_P_24(0) OR D4_PROF_P_30(0) OR D4_PROF_P_31(0) OR D4_PROF_P_32(0) 
 Insurance^D4_PROF_P_23(0)

 Overall Influence Summary:
 Positive^                              D4_PROF_P_1 S32(1)
 Negative^                              D4_PROF_P_1 S32(2)
 No Influence^                          D4_PROF_P_1 E32(0) 

 Nothing in this profile influences me^ D4_CH_1(1)

TD4a_a1^51
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST,FU
 D4a_a1 - Now, please review the same profile again using our “click and highlight” technology. Using your mouse, please click on the sentences in the profile below that strongly positively or negatively influence you to prescribe this product to your patients. You can select as many items in the profile as you like. You do not need to highlight everything, only what strongly influences you.
S|Product Q/R Profile  
 Weighted Total^TN^1
 Sample Size for "BOX WARNING: SERIOUS INFECTIONS, MALIGNANCY AND THROMBOSIS"^D4_PROF_QR_32(0-2)^HR
 Sample Size for Rest of Options                                             ^D4_PROF_QR_1(0-2)^HR
 Sample Size for "BOX WARNING: SERIOUS INFECTIONS, MALIGNANCY AND THROMBOSIS"^D4_PROF_QR_32(0-2)^SB,DW
 Sample Size for Rest of Options^                                             D4_PROF_QR_1(0-2)^SB,DW  
 
 Positive Influence Summary:
 Mechanism of Action:
 Oral small molecule – a JAK inhibitor selective for the subtype JAK1 over JAK2 ,TYK2 and JAK3^ D4_PROF_QR_1(1)
 Indication:
 Treatment of adult patients with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable^D4_PROF_QR_2(1)
 Dosing & Administration:
 Once daily, oral tablet^                                                                       D4_PROF_QR_3(1)
 Can be used with or without topical corticosteroids^                                           D4_PROF_QR_4(1)
 Monitoring for lipids, liver enzymes and blood values^                                         D4_PROF_QR_5(1)
 Efficacy:
 50%, 2%^                                                                                       D4_PROF_QR_6(1)
 59%, 12%^                                                                                      D4_PROF_QR_7(1)
 69%, 10%^                                                                                      D4_PROF_QR_8(1)
 93%, 23%^                                                                                      D4_PROF_QR_9(1)
 -74%, -23%^                                                                                    D4_PROF_QR_10(1)
 -92%, -43%^                                                                                    D4_PROF_QR_11(1)
 59%, 6%^                                                                                       D4_PROF_QR_12(1)
 85%, 20%^                                                                                      D4_PROF_QR_13(1)
 QD - Within 1 week, Placebo - N/A^                                                             D4_PROF_QR_14(1)
 QD + TCS - Within 1 week, Placebo + TCS - N/A^                                                 D4_PROF_QR_15(1)
 % of patients achieving IGA 0 or 1^                                                            D4_PROF_QR_33(1)
 % of patients achieving EASI-75^                                                               D4_PROF_QR_34(1)
 Mean change (%) in EASI^                                                                       D4_PROF_QR_35(1) 
 % of patients achieving >=4 point reduction in peak pruritus NRS^                              D4_PROF_QR_36(1) 
 Onset of itch relief^                                                                          D4_PROF_QR_37(1)
 Safety:
 Upper respiratory tract infection,^                                                            D4_PROF_QR_16(1)
 AD worsening,^                                                                                 D4_PROF_QR_17(1)
 Acne,^                                                                                         D4_PROF_QR_18(1)
 Increased Blood level of creatine phosphokinase,^                                              D4_PROF_QR_19(1)
 Neutropenia,^                                                                                  D4_PROF_QR_20(1)
 Urinary tract infection,^                                                                      D4_PROF_QR_21(1)
 Nausea,^                                                                                       D4_PROF_QR_22(1)
 Headache,^                                                                                     D4_PROF_QR_23(1)
 Hyperlipidaemia,^                                                                              D4_PROF_QR_24(1)
 Gastroenteritis,^                                                                              D4_PROF_QR_25(1)
 Pyrexia^                                                                                       D4_PROF_QR_26(1)
 Herpes zoster^                                                                                 D4_PROF_QR_27(1)
 0%, 3%^                                                                                        D4_PROF_QR_28(1)
 41%, 20%^                                                                                      D4_PROF_QR_29(1)
 0%, 0%^                                                                                        D4_PROF_QR_30(1)
 % patients with serious AE^                                                                    D4_PROF_QR_38(1)
 % patients with any infection^                                                                 D4_PROF_QR_39(1)
 % patients with serious infection^                                                             D4_PROF_QR_40(1)
 BOX WARNING: SERIOUS INFECTIONS, MALIGNANCY AND THROMBOSIS^                                    D4_PROF_QR_32(1)^3
 Insurance:
 Product Q/R has similar insurance coverage to current systemic treatments^                     D4_PROF_QR_31(1)
 
 Negative Influence Summary:
 Mechanism of Action:
 Oral small molecule – a JAK inhibitor selective for the subtype JAK1 over JAK2 ,TYK2 and JAK3^ D4_PROF_QR_1(2)
 Indication:
 Treatment of adult patients with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable^D4_PROF_QR_2(2)
 Dosing & Administration:
 Once daily, oral tablet^                                                                       D4_PROF_QR_3(2)
 Can be used with or without topical corticosteroids^                                           D4_PROF_QR_4(2)
 Monitoring for lipids, liver enzymes and blood values^                                         D4_PROF_QR_5(2)
 Efficacy:
 50%, 2%^                                                                                       D4_PROF_QR_6(2)
 59%, 12%^                                                                                      D4_PROF_QR_7(2)
 69%, 10%^                                                                                      D4_PROF_QR_8(2)
 93%, 23%^                                                                                      D4_PROF_QR_9(2)
 -74%, -23%^                                                                                    D4_PROF_QR_10(2)
 -92%, -43%^                                                                                    D4_PROF_QR_11(2)
 59%, 6%^                                                                                       D4_PROF_QR_12(2)
 85%, 20%^                                                                                      D4_PROF_QR_13(2)
 QD - Within 1 week, Placebo - N/A^                                                             D4_PROF_QR_14(2)
 QD + TCS - Within 1 week, Placebo + TCS - N/A^                                                 D4_PROF_QR_15(2)
 % of patients achieving IGA 0 or 1^                                                            D4_PROF_QR_33(2)
 % of patients achieving EASI-75^                                                               D4_PROF_QR_34(2)
 Mean change (%) in EASI^                                                                       D4_PROF_QR_35(2) 
 % of patients achieving >=4 point reduction in peak pruritus NRS^                              D4_PROF_QR_36(2) 
 Onset of itch relief^                                                                          D4_PROF_QR_37(2)
 Safety:
 Upper respiratory tract infection,^                                                            D4_PROF_QR_16(2)
 AD worsening,^                                                                                 D4_PROF_QR_17(2)
 Acne,^                                                                                         D4_PROF_QR_18(2)
 Increased Blood level of creatine phosphokinase,^                                              D4_PROF_QR_19(2)
 Neutropenia,^                                                                                  D4_PROF_QR_20(2)
 Urinary tract infection,^                                                                      D4_PROF_QR_21(2)
 Nausea,^                                                                                       D4_PROF_QR_22(2)
 Headache,^                                                                                     D4_PROF_QR_23(2)
 Hyperlipidaemia,^                                                                              D4_PROF_QR_24(2)
 Gastroenteritis,^                                                                              D4_PROF_QR_25(2)
 Pyrexia^                                                                                       D4_PROF_QR_26(2)
 Herpes zoster^                                                                                 D4_PROF_QR_27(2)
 0%, 3%^                                                                                        D4_PROF_QR_28(2)
 41%, 20%^                                                                                      D4_PROF_QR_29(2)
 0%, 0%^                                                                                        D4_PROF_QR_30(2)
 % patients with serious AE^                                                                    D4_PROF_QR_38(2)
 % patients with any infection^                                                                 D4_PROF_QR_39(2)
 % patients with serious infection^                                                             D4_PROF_QR_40(2)
 BOX WARNING: SERIOUS INFECTIONS, MALIGNANCY AND THROMBOSIS^                                    D4_PROF_QR_32(2)^3
 Insurance:
 Product Q/R has similar insurance coverage to current systemic treatments^                     D4_PROF_QR_31(2)

 Clear Summary:
 Mechanism of Action:
 Oral small molecule – a JAK inhibitor selective for the subtype JAK1 over JAK2 ,TYK2 and JAK3^ D4_PROF_QR_1(0)
 Indication:
 Treatment of adult patients with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable^D4_PROF_QR_2(0)
 Dosing & Administration:
 Once daily, oral tablet^                                                                       D4_PROF_QR_3(0)
 Can be used with or without topical corticosteroids^                                           D4_PROF_QR_4(0)
 Monitoring for lipids, liver enzymes and blood values^                                         D4_PROF_QR_5(0)
 Efficacy:
 50%, 2%^                                                                                       D4_PROF_QR_6(0)
 59%, 12%^                                                                                      D4_PROF_QR_7(0)
 69%, 10%^                                                                                      D4_PROF_QR_8(0)
 93%, 23%^                                                                                      D4_PROF_QR_9(0)
 -74%, -23%^                                                                                    D4_PROF_QR_10(0)
 -92%, -43%^                                                                                    D4_PROF_QR_11(0)
 59%, 6%^                                                                                       D4_PROF_QR_12(0)
 85%, 20%^                                                                                      D4_PROF_QR_13(0)
 QD - Within 1 week, Placebo - N/A^                                                             D4_PROF_QR_14(0)
 QD + TCS - Within 1 week, Placebo + TCS - N/A^                                                 D4_PROF_QR_15(0)
 % of patients achieving IGA 0 or 1^                                                            D4_PROF_QR_33(0)
 % of patients achieving EASI-75^                                                               D4_PROF_QR_34(0)
 Mean change (%) in EASI^                                                                       D4_PROF_QR_35(0) 
 % of patients achieving >=4 point reduction in peak pruritus NRS^                              D4_PROF_QR_36(0) 
 Onset of itch relief^                                                                          D4_PROF_QR_37(0)
 Safety:
 Upper respiratory tract infection,^                                                            D4_PROF_QR_16(0)
 AD worsening,^                                                                                 D4_PROF_QR_17(0)
 Acne,^                                                                                         D4_PROF_QR_18(0)
 Increased Blood level of creatine phosphokinase,^                                              D4_PROF_QR_19(0)
 Neutropenia,^                                                                                  D4_PROF_QR_20(0)
 Urinary tract infection,^                                                                      D4_PROF_QR_21(0)
 Nausea,^                                                                                       D4_PROF_QR_22(0)
 Headache,^                                                                                     D4_PROF_QR_23(0)
 Hyperlipidaemia,^                                                                              D4_PROF_QR_24(0)
 Gastroenteritis,^                                                                              D4_PROF_QR_25(0)
 Pyrexia^                                                                                       D4_PROF_QR_26(0)
 Herpes zoster^                                                                                 D4_PROF_QR_27(0)
 0%, 3%^                                                                                        D4_PROF_QR_28(0)
 41%, 20%^                                                                                      D4_PROF_QR_29(0)
 0%, 0%^                                                                                        D4_PROF_QR_30(0)
 % patients with serious AE^                                                                    D4_PROF_QR_38(0)
 % patients with any infection^                                                                 D4_PROF_QR_39(0)
 % patients with serious infection^                                                             D4_PROF_QR_40(0)
 BOX WARNING: SERIOUS INFECTIONS, MALIGNANCY AND THROMBOSIS^                                    D4_PROF_QR_32(0)^3
 Insurance:
 Product Q/R has similar insurance coverage to current systemic treatments^                     D4_PROF_QR_31(0)

 Nothing in this profile influences me^ D4A_CH_1(1)

TD4a_a1^52
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 D4a_a1 - Now, please review the same profile again using our “click and highlight” technology. Using your mouse, please click on the sentences in the profile below that strongly positively or negatively influence you to prescribe this product to your patients. You can select as many items in the profile as you like. You do not need to highlight everything, only what strongly influences you.
S|[BY PARAGRAPH] /Product Q/R Profile  
 Weighted Total^TN^1
 Positive Influence Summary:
 Mechanism of Action^D4_PROF_QR_1(1)
 Indication^D4_PROF_QR_2(1)
 Dosing and Administration^D4_PROF_QR_3 S3(1)
 Efficacy^D4_PROF_QR_6 S10(1) OR D4_PROF_QR_33 S5(1) 
 Safety^D4_PROF_QR_16 S15 (1) OR D4_PROF_QR_38(1) OR D4_PROF_QR_39(1) OR D4_PROF_QR_40(1) OR D4_PROF_QR_32(1) 
 Insurance^D4_PROF_QR_32(1)

 Negative Influence Summary:
 Mechanism of Action^D4_PROF_QR_1(2)
 Indication^D4_PROF_QR_2(2)
 Dosing and Administration^D4_PROF_QR_3 S3(2)
 Efficacy^D4_PROF_QR_6 S10(2) OR D4_PROF_QR_33 S5(2) 
 Safety^D4_PROF_QR_16 S15 (2) OR D4_PROF_QR_38(2) OR D4_PROF_QR_39(2) OR D4_PROF_QR_40(2) OR D4_PROF_QR_32(2) 
 Insurance^D4_PROF_QR_32(2)

 Clear Summary:
 Mechanism of Action^D4_PROF_QR_1(0)
 Indication^D4_PROF_QR_2(0)
 Dosing and Administration^D4_PROF_QR_3 S3(0)
 Efficacy^D4_PROF_QR_6 S10(0) OR D4_PROF_QR_33 S5(0) 
 Safety^D4_PROF_QR_16 S15 (0) OR D4_PROF_QR_38(0) OR D4_PROF_QR_39(0) OR D4_PROF_QR_40(0) OR D4_PROF_QR_32(0)  
 Insurance^D4_PROF_QR_32(0)

 Overall Influence Summary:
 Positive^                              D4_PROF_QR_1 S40(1)
 Negative^                              D4_PROF_QR_1 S40(2)
 No Influence^                          D4_PROF_QR_1 E40(0) 

 Nothing in this profile influences me^ D4A_CH_1(1)

TE1_COMB_2^53
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,FU,ST
 E1 - [Moderate Atopic Dermatitis Patients] Please think of all your moderate and severe Atopic Dermatitis patients who are biologic candidates and you will treat in the next 6 months.what percent of these patients with Atopic Dermatitis will receive the following prescription therapies?Please consider both your controlled and uncontrolled patients whom you will treat with any of the below therapies alone or in combination with another therapy.
S|Percent of Biologic / JAK-I-Naïve Patients
 Weighted Total^TN^1
 Sample Size for Product 'PQR'^E1_1_2(0-100)^HR
 Sample Size for Oral Corticosteroids^E1_10_2(0-100)^HR
 Sample Size for Product 'PQR'^E1_1_2(0-100)^SB,DW
 Sample Size for Oral Corticosteroids^E1_10_2(0-100)^SB,DW
 
 Mean Summary:
 Biologics:
 Product Z^                                        E1_4_2(0-100)^SM
 Dupixent® (dupilumab) ^                           E1_5_2(0-100)^SM
 JAK-Is:
 Product P^                                        E1_1_2(0-100)^SM
 Product Q^                                        E1_2_2(0-100)^SM
 Product R^                                        E1_3_2(0-100)^SM
 Oral Systemics:
 Oral Systemics (e.g., cyclosporine, methotrexate)^E1_6_2(0-100)^SM
 Prescription Topical Medications:
 Prescription Topical Corticosteroids (TCS)^       E1_7_2(0-100)^SM
 Prescription Topical Calcineurin Inhibitors (TCI)^E1_8_2(0-100)^SM
 Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole))^E1_9_2(0-100)^SM
 Other Prescription Therapies:
 Oral Corticosteroids [Show in US only]^           E1_10_2(0-100)^SM
 Other Prescription Therapies^                     E1_OTHER_2(0-100)^SM

 STD DEV Summary:
 Biologics:
 Product Z^                                        E1_4_2(0-100)^SV
 Dupixent® (dupilumab) ^                           E1_5_2(0-100)^SV
 JAK-Is:
 Product P^                                        E1_1_2(0-100)^SV
 Product Q^                                        E1_2_2(0-100)^SV
 Product R^                                        E1_3_2(0-100)^SV
 Oral Systemics:
 Oral Systemics (e.g., cyclosporine, methotrexate)^E1_6_2(0-100)^SV
 Prescription Topical Medications:
 Prescription Topical Corticosteroids (TCS)^       E1_7_2(0-100)^SV
 Prescription Topical Calcineurin Inhibitors (TCI)^E1_8_2(0-100)^SV
 Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole))^E1_9_2(0-100)^SV
 Other Prescription Therapies:
 Oral Corticosteroids [Show in US only]^           E1_10_2(0-100)^SV
 Other Prescription Therapies^                     E1_OTHER_2(0-100)^SV

TE1_COMB_4^54
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,FU,ST
 E1 - [Moderate Atopic Dermatitis Patients] Please think of all your moderate and severe Atopic Dermatitis patients who are biologic candidates and you will treat in the next 6 months.what percent of these patients with Atopic Dermatitis will receive the following prescription therapies?Please consider both your controlled and uncontrolled patients whom you will treat with any of the below therapies alone or in combination with another therapy.
S|Percent of Biologic / JAK-I-Experienced Patients 
 Weighted Total^TN^1
 Sample Size for Product 'PQR'^E1_1_4(0-100)^HR
 Sample Size for Oral Corticosteroids^E1_10_4(0-100)^HR
 Sample Size for Product 'PQR'^E1_1_4(0-100)^SB,DW
 Sample Size for Oral Corticosteroids^E1_10_4(0-100)^SB,DW
 
 Mean Summary:
 Biologics:
 Product Z^                                        E1_4_4(0-100)^SM
 Dupixent® (dupilumab) ^                           E1_5_4(0-100)^SM
 JAK-Is:
 Product P^                                        E1_1_4(0-100)^SM
 Product Q^                                        E1_2_4(0-100)^SM
 Product R^                                        E1_3_4(0-100)^SM
 Oral Systemics:
 Oral Systemics (e.g., cyclosporine, methotrexate)^E1_6_4(0-100)^SM
 Prescription Topical Medications:
 Prescription Topical Corticosteroids (TCS)^       E1_7_4(0-100)^SM
 Prescription Topical Calcineurin Inhibitors (TCI)^E1_8_4(0-100)^SM
 Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole))^E1_9_4(0-100)^SM
 Other Prescription Therapies:
 Oral Corticosteroids [Show in US only]^           E1_10_4(0-100)^SM
 Other Prescription Therapies^                     E1_OTHER_4(0-100)^SM

 STD DEV Summary:
 Biologics:
 Product Z^                                        E1_4_4(0-100)^SV
 Dupixent® (dupilumab) ^                           E1_5_4(0-100)^SV
 JAK-Is:
 Product P^                                        E1_1_4(0-100)^SV
 Product Q^                                        E1_2_4(0-100)^SV
 Product R^                                        E1_3_4(0-100)^SV
 Oral Systemics:
 Oral Systemics (e.g., cyclosporine, methotrexate)^E1_6_4(0-100)^SV
 Prescription Topical Medications:
 Prescription Topical Corticosteroids (TCS)^       E1_7_4(0-100)^SV
 Prescription Topical Calcineurin Inhibitors (TCI)^E1_8_4(0-100)^SV
 Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole))^E1_9_4(0-100)^SV
 Other Prescription Therapies:
 Oral Corticosteroids [Show in US only]^           E1_10_4(0-100)^SV
 Other Prescription Therapies^                     E1_OTHER_4(0-100)^SV

TE1_COMB_6^55
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,FU,ST
 E1 - [Severe Atopic Dermatitis Patients] Please think of all your moderate and severe Atopic Dermatitis patients who are biologic candidates and you will treat in the next 6 months.what percent of these patients with Atopic Dermatitis will receive the following prescription therapies?Please consider both your controlled and uncontrolled patients whom you will treat with any of the below therapies alone or in combination with another therapy.
S|Percent of Biologic / JAK-I-Naïve Patients
 Weighted Total^TN^1
 Sample Size for Product 'PQR'^E1_1_6(0-100)^HR
 Sample Size for Oral Corticosteroids^E1_10_6(0-100)^HR
 Sample Size for Product 'PQR'^E1_1_6(0-100)^SB,DW
 Sample Size for Oral Corticosteroids^E1_10_6(0-100)^SB,DW
 
 Mean Summary:
 Biologics:
 Product Z^                                        E1_4_6(0-100)^SM
 Dupixent® (dupilumab) ^                           E1_5_6(0-100)^SM
 JAK-Is:
 Product P^                                        E1_1_6(0-100)^SM
 Product Q^                                        E1_2_6(0-100)^SM
 Product R^                                        E1_3_6(0-100)^SM
 Oral Systemics:
 Oral Systemics (e.g., cyclosporine, methotrexate)^E1_6_6(0-100)^SM
 Prescription Topical Medications:
 Prescription Topical Corticosteroids (TCS)^       E1_7_6(0-100)^SM
 Prescription Topical Calcineurin Inhibitors (TCI)^E1_8_6(0-100)^SM
 Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole))^E1_9_6(0-100)^SM
 Other Prescription Therapies:
 Oral Corticosteroids [Show in US only]^           E1_10_6(0-100)^SM
 Other Prescription Therapies^                     E1_OTHER_6(0-100)^SM

 STD DEV Summary:
 Biologics:
 Product Z^                                        E1_4_6(0-100)^SV
 Dupixent® (dupilumab) ^                           E1_5_6(0-100)^SV
 JAK-Is:
 Product P^                                        E1_1_6(0-100)^SV
 Product Q^                                        E1_2_6(0-100)^SV
 Product R^                                        E1_3_6(0-100)^SV
 Oral Systemics:
 Oral Systemics (e.g., cyclosporine, methotrexate)^E1_6_6(0-100)^SV
 Prescription Topical Medications:
 Prescription Topical Corticosteroids (TCS)^       E1_7_6(0-100)^SV
 Prescription Topical Calcineurin Inhibitors (TCI)^E1_8_6(0-100)^SV
 Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole))^E1_9_6(0-100)^SV
 Other Prescription Therapies:
 Oral Corticosteroids [Show in US only]^           E1_10_6(0-100)^SV
 Other Prescription Therapies^                     E1_OTHER_6(0-100)^SV


TE1_COMB_8^56
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,FU,ST
 E1 - [Severe Atopic Dermatitis Patients] Please think of all your moderate and severe Atopic Dermatitis patients who are biologic candidates and you will treat in the next 6 months.what percent of these patients with Atopic Dermatitis will receive the following prescription therapies?Please consider both your controlled and uncontrolled patients whom you will treat with any of the below therapies alone or in combination with another therapy.
S|Percent of Biologic / JAK-I-Experienced Patients
 Weighted Total^TN^1
 Sample Size for Product 'PQR'^E1_1_8(0-100)^HR
 Sample Size for Oral Corticosteroids^E1_10_8(0-100)^HR
 Sample Size for Product 'PQR'^E1_1_8(0-100)^SB,DW
 Sample Size for Oral Corticosteroids^E1_10_8(0-100)^SB,DW
 
 Mean Summary:
 Biologics:
 Product Z^                                        E1_4_8(0-100)^SM
 Dupixent® (dupilumab) ^                           E1_5_8(0-100)^SM
 JAK-Is:
 Product P^                                        E1_1_8(0-100)^SM
 Product Q^                                        E1_2_8(0-100)^SM
 Product R^                                        E1_3_8(0-100)^SM
 Oral Systemics:
 Oral Systemics (e.g., cyclosporine, methotrexate)^E1_6_8(0-100)^SM
 Prescription Topical Medications:
 Prescription Topical Corticosteroids (TCS)^       E1_7_8(0-100)^SM
 Prescription Topical Calcineurin Inhibitors (TCI)^E1_8_8(0-100)^SM
 Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole))^E1_9_8(0-100)^SM
 Other Prescription Therapies:
 Oral Corticosteroids [Show in US only]^           E1_10_8(0-100)^SM
 Other Prescription Therapies^                     E1_OTHER_8(0-100)^SM

 STD DEV Summary:
 Biologics:
 Product Z^                                        E1_4_8(0-100)^SV
 Dupixent® (dupilumab) ^                           E1_5_8(0-100)^SV
 JAK-Is:
 Product P^                                        E1_1_8(0-100)^SV
 Product Q^                                        E1_2_8(0-100)^SV
 Product R^                                        E1_3_8(0-100)^SV
 Oral Systemics:
 Oral Systemics (e.g., cyclosporine, methotrexate)^E1_6_8(0-100)^SV
 Prescription Topical Medications:
 Prescription Topical Corticosteroids (TCS)^       E1_7_8(0-100)^SV
 Prescription Topical Calcineurin Inhibitors (TCI)^E1_8_8(0-100)^SV
 Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole))^E1_9_8(0-100)^SV
 Other Prescription Therapies:
 Oral Corticosteroids [Show in US only]^           E1_10_8(0-100)^SV
 Other Prescription Therapies^                     E1_OTHER_8(0-100)^SV

TE2_COMB_1^57
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 E2 - [Moderate Atopic Dermatitis Patients in NEXT 6 Months] Please think of your [Show moderate and severe dynamically based on E1_a > 0%] Atopic Dermatitis patients whom you will treat in the next 6 months with Product Z. What percent of patients do you envision prescribing Product Z as a monotherapy versus in combination with another prescription therapy?
S|[Biologic-Naïve Patients]/Ask E2 if any one of the columns >0% for E1_a
 Weighted Total^TN^1
 Mean Summary:
 Monotherapy^E2_1_1(0-100)^SM
 Combination with another prescription therapy^E2_2_1(0-100)^SM

 STD DEV Summary:
 Monotherapy^E2_1_1(0-100)^SV
 Combination with another prescription therapy^E2_2_1(0-100)^SV

TE2_COMB_2^58
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 E2 - [Moderate Atopic Dermatitis Patients in NEXT 6 Months] Please think of your [Show moderate and severe dynamically based on E1_a > 0%] Atopic Dermatitis patients whom you will treat in the next 6 months with Product Z. What percent of patients do you envision prescribing Product Z as a monotherapy versus in combination with another prescription therapy?
S|[Biologic-Experienced Patients]/Ask E2 if any one of the columns >0% for E1_a
 Weighted Total^TN^1
 Mean Summary:
 Monotherapy^E2_1_2(0-100)^SM
 Combination with another prescription therapy^E2_2_2(0-100)^SM

 STD DEV Summary:
 Monotherapy^E2_1_2(0-100)^SV
 Combination with another prescription therapy^E2_2_2(0-100)^SV

TE2_COMB_3^59
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 E2 - [Moderate Atopic Dermatitis Patients in NEXT 6 Months] Please think of your [Show moderate and severe dynamically based on E1_a > 0%] Atopic Dermatitis patients whom you will treat in the next 6 months with Product Z. What percent of patients do you envision prescribing Product Z as a monotherapy versus in combination with another prescription therapy?
S|[Biologic-Experienced Patients]/Ask E2 if any one of the columns >0% for E1_a
 Weighted Total^TN^1
 Mean Summary:
 Monotherapy^E2_1_3(0-100)^SM
 Combination with another prescription therapy^E2_2_3(0-100)^SM

 STD DEV Summary:
 Monotherapy^E2_1_3(0-100)^SV
 Combination with another prescription therapy^E2_2_3(0-100)^SV

TE2_COMB_4^60
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 E2 - [Moderate Atopic Dermatitis Patients in NEXT 6 Months] Please think of your [Show moderate and severe dynamically based on E1_a > 0%] Atopic Dermatitis patients whom you will treat in the next 6 months with Product Z. What percent of patients do you envision prescribing Product Z as a monotherapy versus in combination with another prescription therapy?
S|[Biologic-Experienced Patients]/Ask E2 if any one of the columns >0% for E1_a
 Weighted Total^TN^1
 Mean Summary:
 Monotherapy^E2_1_4(0-100)^SM
 Combination with another prescription therapy^E2_2_4(0-100)^SM

 STD DEV Summary:
 Monotherapy^E2_1_4(0-100)^SV
 Combination with another prescription therapy^E2_2_4(0-100)^SV

TE4_a1^61
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 E4 - Now, please review the same profile again using our “click and highlight” technology. Using your mouse, please click on the sentences in the profile below that strongly positively or negatively influence you to prescribe this product to your patients. You can select as many items in the profile as you like. You do not need to highlight everything, only what strongly influences you.
 Weighted Total^TN^1
 Positive Influence Summary:
 Mechanism of Action:
 Biologic - specific inhibitor of IL-13 by binding to the cytokine^                                 E4_A1(1)
 Indication:
 Treatment of adult patients with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.^E4_A2(1)
 Dosing & Administration:
 Initial dose of 4 injections followed by 2 injections every second week administered subcutaneous^ E4_A3(1)
 Can be used with or without topical corticosteroids^                                               E4_A4(1)
 Efficacy:
 % of patients achieving IGA 0 or 1^                                                                E4_A34(1)
 19%, 9%^                                                                                           E4_A5(1)
 39%, 26%^                                                                                          E4_A6(1)
 % of patients achieving EASI-75^                                                                   E4_A35(1)
 29%, 12%^                                                                                          E4_A7(1)
 56% (69% at week 24), 36%^                                                                         E4_A8(1)
 Mean change (%) in EASI^                                                                           E4_A36(1)
  -54%, -25%^                                                                                       E4_A9(1)
  -71%, -55%^                                                                                       E4_A10(1)
 % of patients achieving >=4 point reduction in peak pruritus NRS^                                  E4_A37(1)
  - 22%, 10%^                                                                                       E4_A11(1)
  - 45%, 34%^                                                                                       E4_A12(1)
 Onset of itch relief^                                                                              E4_A38(1)
 Q2W - Within 3 weeks, Placebo - N/A^                                                               E4_A13(1)
 Q2W + TCS - Within 3 weeks, Placebo + TCS - N/A^                                                   E4_A14(1)
 IGA 0/1^                                                                                           E4_A39(1)
 56% at week 52, 34% at week 52^                                                                    E4_A15(1)
 90% at week 32^                                                                                    E4_A16(1)
 EASI-75^                                                                                           E4_A40(1)
 57% at week 52, 26% at week 52^                                                                    E4_A17(1)
 93% at week 32^                                                                                    E4_A18(1)
 Safety:
 Upper respiratory tract infection,^                                                                E4_A19(1)
 conjunctivitis^                                                                                    E4_A20(1)
 Injection site reactions^                                                                          E4_A21(1)
 headache^                                                                                          E4_A22(1)
 Diarrhea^                                                                                          E4_A23(1)
 sinusitis^                                                                                         E4_A24(1)
 nasopharyngitis^                                                                                   E4_A25(1)
 fatigue^                                                                                           E4_A26(1)
 % patients with serious AE^                                                                        E4_A41(1)
 2.6%, 2.8%^                                                                                        E4_A27(1)
 0.8%, 3.2%^                                                                                        E4_A28(1)
 % patients with serious infection^                                                                 E4_A42(1)
 0.4%, 0.5%^                                                                                        E4_A29(1)
 0.0%, 2.3%^                                                                                        E4_A30(1)
 % patients with conjunctivitis^                                                                    E4_A43(1)
 8.0%, 3.3%^                                                                                        E4_A31(1)
 13.1%, 5.6%^                                                                                       E4_A32(1)
 Insurance: 
 Product Z has similar insurance coverage to current systemic treatments.^                          E4_A33(1)

 Negative Influence Summary:
 Mechanism of Action:
 Biologic - specific inhibitor of IL-13 by binding to the cytokine^                                 E4_A1(2)
 Indication:
 Treatment of adult patients with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.^E4_A2(2)
 Dosing & Administration:
 Initial dose of 4 injections followed by 2 injections every second week administered subcutaneous^ E4_A3(2)
 Can be used with or without topical corticosteroids^                                               E4_A4(2)
 Efficacy:
 % of patients achieving IGA 0 or 1^                                                                E4_A34(2)
 19%, 9%^                                                                                           E4_A5(2)
 39%, 26%^                                                                                          E4_A6(2)
 % of patients achieving EASI-75^                                                                   E4_A35(2)
 29%, 12%^                                                                                          E4_A7(2)
 56% (69% at week 24), 36%^                                                                         E4_A8(2)
 Mean change (%) in EASI^                                                                           E4_A36(2)
  -54%, -25%^                                                                                       E4_A9(2)
  -71%, -55%^                                                                                       E4_A10(2)
 % of patients achieving >=4 point reduction in peak pruritus NRS^                                  E4_A37(2)
  - 22%, 10%^                                                                                       E4_A11(2)
  - 45%, 34%^                                                                                       E4_A12(2)
 Onset of itch relief^                                                                              E4_A38(2)
 Q2W - Within 3 weeks, Placebo - N/A^                                                               E4_A13(2)
 Q2W + TCS - Within 3 weeks, Placebo + TCS - N/A^                                                   E4_A14(2)
 IGA 0/1^                                                                                           E4_A39(2)
 56% at week 52, 34% at week 52^                                                                    E4_A15(2)
 90% at week 32^                                                                                    E4_A16(2)
 EASI-75^                                                                                           E4_A40(2)
 57% at week 52, 26% at week 52^                                                                    E4_A17(2)
 93% at week 32^                                                                                    E4_A18(2)
 Safety:
 Upper respiratory tract infection,^                                                                E4_A19(2)
 conjunctivitis^                                                                                    E4_A20(2)
 Injection site reactions^                                                                          E4_A21(2)
 headache^                                                                                          E4_A22(2)
 Diarrhea^                                                                                          E4_A23(2)
 sinusitis^                                                                                         E4_A24(2)
 nasopharyngitis^                                                                                   E4_A25(2)
 fatigue^                                                                                           E4_A26(2)
 % patients with serious AE^                                                                        E4_A41(2)
 2.6%, 2.8%^                                                                                        E4_A27(2)
 0.8%, 3.2%^                                                                                        E4_A28(2)
 % patients with serious infection^                                                                 E4_A42(2)
 0.4%, 0.5%^                                                                                        E4_A29(2)
 0.0%, 2.3%^                                                                                        E4_A30(2)
 % patients with conjunctivitis^                                                                    E4_A43(2)
 8.0%, 3.3%^                                                                                        E4_A31(2)
 13.1%, 5.6%^                                                                                       E4_A32(2)
 Insurance: 
 Product Z has similar insurance coverage to current systemic treatments.^                          E4_A33(2)


 Clear Summary:
 Mechanism of Action:
 Biologic - specific inhibitor of IL-13 by binding to the cytokine^                                 E4_A1(0)
 Indication:
 Treatment of adult patients with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.^E4_A2(0)
 Dosing & Administration:
 Initial dose of 4 injections followed by 2 injections every second week administered subcutaneous^ E4_A3(0)
 Can be used with or without topical corticosteroids^                                               E4_A4(0)
 Efficacy:
 % of patients achieving IGA 0 or 1^                                                                E4_A34(0)
 19%, 9%^                                                                                           E4_A5(0)
 39%, 26%^                                                                                          E4_A6(0)
 % of patients achieving EASI-75^                                                                   E4_A35(0)
 29%, 12%^                                                                                          E4_A7(0)
 56% (69% at week 24), 36%^                                                                         E4_A8(0)
 Mean change (%) in EASI^                                                                           E4_A36(0)
  -54%, -25%^                                                                                       E4_A9(0)
  -71%, -55%^                                                                                       E4_A10(0)
 % of patients achieving >=4 point reduction in peak pruritus NRS^                                  E4_A37(0)
  - 22%, 10%^                                                                                       E4_A11(0)
  - 45%, 34%^                                                                                       E4_A12(0)
 Onset of itch relief^                                                                              E4_A38(0)
 Q2W - Within 3 weeks, Placebo - N/A^                                                               E4_A13(0)
 Q2W + TCS - Within 3 weeks, Placebo + TCS - N/A^                                                   E4_A14(0)
 IGA 0/1^                                                                                           E4_A39(0)
 56% at week 52, 34% at week 52^                                                                    E4_A15(0)
 90% at week 32^                                                                                    E4_A16(0)
 EASI-75^                                                                                           E4_A40(0)
 57% at week 52, 26% at week 52^                                                                    E4_A17(0)
 93% at week 32^                                                                                    E4_A18(0)
 Safety:
 Upper respiratory tract infection,^                                                                E4_A19(0)
 conjunctivitis^                                                                                    E4_A20(0)
 Injection site reactions^                                                                          E4_A21(0)
 headache^                                                                                          E4_A22(0)
 Diarrhea^                                                                                          E4_A23(0)
 sinusitis^                                                                                         E4_A24(0)
 nasopharyngitis^                                                                                   E4_A25(0)
 fatigue^                                                                                           E4_A26(0)
 % patients with serious AE^                                                                        E4_A41(0)
 2.6%, 2.8%^                                                                                        E4_A27(0)
 0.8%, 3.2%^                                                                                        E4_A28(0)
 % patients with serious infection^                                                                 E4_A42(0)
 0.4%, 0.5%^                                                                                        E4_A29(0)
 0.0%, 2.3%^                                                                                        E4_A30(0)
 % patients with conjunctivitis^                                                                    E4_A43(0)
 8.0%, 3.3%^                                                                                        E4_A31(0)
 13.1%, 5.6%^                                                                                       E4_A32(0)
 Insurance: 
 Product Z has similar insurance coverage to current systemic treatments.^                          E4_A33(0)

 Nothing in this profile influences me^                                                             E4_CH_1(1)

TE4_a1^62
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST
 E4 - Now, please review the same profile again using our “click and highlight” technology. Using your mouse, please click on the sentences in the profile below that strongly positively or negatively influence you to prescribe this product to your patients. You can select as many items in the profile as you like. You do not need to highlight everything, only what strongly influences you.
S|[BY PARAGRAPH] /Product Z Profile   
 Weighted Total^TN^1
 Positive Influence Summary:
 Mechanism of Action^E4_A1(1)
 Indication^E4_A2(1)
 Dosing and Administration^E4_A3 S2(1)
 Efficacy^E4_A34 S21(1) 
 Safety^E4_A19 S17 (1)  
 Insurance^D4_PROF_QR_32(1)

 Negative Influence Summary:
 Mechanism of Action^E4_A1(2)
 Indication^E4_A2(2)
 Dosing and Administration^E4_A3 S2(2)
 Efficacy^E4_A34 S21(2) 
 Safety^E4_A19 S17 (2)  
 Insurance^D4_PROF_QR_32(2)

 Clear Summary:
 Mechanism of Action^E4_A1(0)
 Indication^E4_A2(0)
 Dosing and Administration^E4_A3 S2(0)
 Efficacy^E4_A34 S21(0) 
 Safety^E4_A19 S17 (0)  
 Insurance^D4_PROF_QR_32(0)

 Overall Influence Summary:
 Positive^                              E4_A1 S43(1)
 Negative^                              E4_A1 S43(2)
 No Influence^                          E4_A1 E43(0) 


 Nothing in this profile influences me^                                                             E4_CH_1(1)

TE5_NEW^63
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 E5 - When do you expect to start regularly using Product Z for your moderate-to-severe Atopic Dermatitis patients who are biologic candidates?
 Total^TN^1
 Within 6 months of launch^        E5_NEW (1)
 7-12 months after launch^         E5_NEW (2)
 13-24 months after launch^        E5_NEW (3)
 25-36 months after launch^        E5_NEW (4)
 More than 36 months after launch^ E5_NEW (5)
 Never^                            E5_NEW (6)

TE6_1^64
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP,ST,FU
 E6 - How appropriate would Product Z be for the following patient types?Please rate on a 7-point scale, where 1 = “Not at all Appropriate” and 7 = “Extremely Appropriate” for each patient type. 
S|Only show options e-h to respondents who see Product Z section second 
 Weighted Total^TN^1
 Sample Size for Options E-H^E6_5(1-7)^HR
 Sample Size for Rest of Options^E6_1(1-7)^HR
 Sample Size for E-H^E6_5(1-7)^SB,DW
 Sample Size for Rest of Options^E6_1(1-7)^SB,DW

 Category I:
 Bottom-2-Box Summary(1-2):
 Patient controlled on another biologic^                                          E6_1(1-2)
 Patient with a partial response to a biologic and is currently uncontrolled^     E6_2(1-2)
 Patient with initial response to a biologic but is currently uncontrolled ^      E6_3(1-2)
 Patient never responded to biologic treatment and is currently uncontrolled^     E6_4(1-2)
 Patient controlled on a JAK-inhibitor^                                           E6_5(1-2)^3
 Patient with a partial response to a JAK-inhibitor and is currently uncontrolled^E6_6(1-2)
 Patient with initial response to a JAK-inhibitor but is currently uncontrolled^  E6_7(1-2)
 Patient never responded to a JAK-inhibitor and is currently uncontrolled^        E6_8(1-2)

 Middle-3-Box Summary(3-5):
 Patient controlled on another biologic^                                          E6_1(3-5)
 Patient with a partial response to a biologic and is currently uncontrolled^     E6_2(3-5)
 Patient with initial response to a biologic but is currently uncontrolled ^      E6_3(3-5)
 Patient never responded to biologic treatment and is currently uncontrolled^     E6_4(3-5)
 Patient controlled on a JAK-inhibitor^                                           E6_5(3-5)^3
 Patient with a partial response to a JAK-inhibitor and is currently uncontrolled^E6_6(3-5)
 Patient with initial response to a JAK-inhibitor but is currently uncontrolled^  E6_7(3-5)
 Patient never responded to a JAK-inhibitor and is currently uncontrolled^        E6_8(3-5)

 Top-2-Box Summary(6-7):
 Patient controlled on another biologic^                                          E6_1(6-7)
 Patient with a partial response to a biologic and is currently uncontrolled^     E6_2(6-7)
 Patient with initial response to a biologic but is currently uncontrolled ^      E6_3(6-7)
 Patient never responded to biologic treatment and is currently uncontrolled^     E6_4(6-7)
 Patient controlled on a JAK-inhibitor^                                           E6_5(6-7)^3
 Patient with a partial response to a JAK-inhibitor and is currently uncontrolled^E6_6(6-7)
 Patient with initial response to a JAK-inhibitor but is currently uncontrolled^  E6_7(6-7)
 Patient never responded to a JAK-inhibitor and is currently uncontrolled^        E6_8(6-7)

 Category II:
 Bottom-2-Box Summary(1-3):
 Patient controlled on another biologic^                                          E6_1(1-3)
 Patient with a partial response to a biologic and is currently uncontrolled^     E6_2(1-3)
 Patient with initial response to a biologic but is currently uncontrolled ^      E6_3(1-3)
 Patient never responded to biologic treatment and is currently uncontrolled^     E6_4(1-3)
 Patient controlled on a JAK-inhibitor^                                           E6_5(1-3)^3
 Patient with a partial response to a JAK-inhibitor and is currently uncontrolled^E6_6(1-3)^3
 Patient with initial response to a JAK-inhibitor but is currently uncontrolled^  E6_7(1-3)^3
 Patient never responded to a JAK-inhibitor and is currently uncontrolled^        E6_8(1-3)^3

 Middle-3-Box Summary(4):
 Patient controlled on another biologic^                                          E6_1(4)
 Patient with a partial response to a biologic and is currently uncontrolled^     E6_2(4)
 Patient with initial response to a biologic but is currently uncontrolled ^      E6_3(4)
 Patient never responded to biologic treatment and is currently uncontrolled^     E6_4(4)
 Patient controlled on a JAK-inhibitor^                                           E6_5(4)^3
 Patient with a partial response to a JAK-inhibitor and is currently uncontrolled^E6_6(4)^3
 Patient with initial response to a JAK-inhibitor but is currently uncontrolled^  E6_7(4)^3
 Patient never responded to a JAK-inhibitor and is currently uncontrolled^        E6_8(4)^3

 Top-2-Box Summary(5-7):
 Patient controlled on another biologic^                                          E6_1(5-7)
 Patient with a partial response to a biologic and is currently uncontrolled^     E6_2(5-7)
 Patient with initial response to a biologic but is currently uncontrolled ^      E6_3(5-7)
 Patient never responded to biologic treatment and is currently uncontrolled^     E6_4(5-7)
 Patient controlled on a JAK-inhibitor^                                           E6_5(5-7)^3
 Patient with a partial response to a JAK-inhibitor and is currently uncontrolled^E6_6(5-7)^3
 Patient with initial response to a JAK-inhibitor but is currently uncontrolled^  E6_7(5-7)^3
 Patient never responded to a JAK-inhibitor and is currently uncontrolled^        E6_8(5-7)^3

TF1_1^65
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F1. Please think of your [PN: Show moderate and severe dynamically based on D1_d (table 2) or E1_a > 0%] Atopic Dermatitis patients who you will treat with Product Z in the next 6 months. How will you prescribe Product Z to manage your patients’ symptoms?
 Total^TN^1
 Treatment of flares-ups^  F1_1 (1)
 As a maintenance therapy^ F1_1 (2)
TF1_2^66
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F1 - Use of Product Z Moderate Atopic Dermatitis Patients in NEXT 6 Months Biologic / JAK-I-Experienced Patients
 Total^TN^1
 Treatment of flares-ups^  F1_2 (1)
 As a maintenance therapy^ F1_2 (2)
TF1_3^67
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F1 - Use of Product Z Severe Atopic Dermatitis Patients in NEXT 6 Months Biologic / JAK-I-Naïve Patients
 Total^TN^1
 Treatment of flares-ups^  F1_3 (1)
 As a maintenance therapy^ F1_3 (2)
TF1_4^68
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F1 - Use of Product Z Severe Atopic Dermatitis Patients in NEXT 6 Months Biologic / JAK-I-Experienced Patients
 Total^TN^1
 Treatment of flares-ups^  F1_4 (1)
 As a maintenance therapy^ F1_4 (2)
TF2_1^69
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F2 - Use of Product P, Product Q, and/or Product R Moderate Atopic Dermatitis Patients in NEXT 6 Months Biologic / JAK-I-Naïve Patients
 Total^TN^1
 Treatment of flares-ups^  F2_1 (1)
 As a maintenance therapy^ F2_1 (2)
TF2_2^70
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F2 - Use of Product P, Product Q, and/or Product R Moderate Atopic Dermatitis Patients in NEXT 6 Months Biologic / JAK-I-Experienced Patients
 Total^TN^1
 Treatment of flares-ups^  F2_2 (1)
 As a maintenance therapy^ F2_2 (2)
TF2_3^71
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F2 - Use of Product P, Product Q, and/or Product R Severe Atopic Dermatitis Patients in NEXT 6 Months Biologic / JAK-I-Naïve Patients
 Total^TN^1
 Treatment of flares-ups^  F2_3 (1)
 As a maintenance therapy^ F2_3 (2)
TF2_4^72
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F2 - Use of Product P, Product Q, and/or Product R Severe Atopic Dermatitis Patients in NEXT 6 Months Biologic / JAK-I-Experienced Patients
 Total^TN^1
 Treatment of flares-ups^  F2_4 (1)
 As a maintenance therapy^ F2_4 (2)
TF3_1_1^73
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F3 - Maintenance Therapy Moderate Atopic Dermatitis Patients on Product P, Product Q, or Product R Continue using Product P, Product Q, or Product R
 Total^TN^1
 0^   F3_1_1 (0)
 4^   F3_1_1 (4)
 5^   F3_1_1 (5)
 10^  F3_1_1 (10)
 15^  F3_1_1 (15)
 20^  F3_1_1 (20)
 25^  F3_1_1 (25)
 30^  F3_1_1 (30)
 34^  F3_1_1 (34)
 35^  F3_1_1 (35)
 40^  F3_1_1 (40)
 50^  F3_1_1 (50)
 55^  F3_1_1 (55)
 60^  F3_1_1 (60)
 65^  F3_1_1 (65)
 75^  F3_1_1 (75)
 80^  F3_1_1 (80)
 90^  F3_1_1 (90)
 99^  F3_1_1 (99)
 100^ F3_1_1 (100)
TF3_2_1^74
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F3 - Maintenance Therapy Moderate Atopic Dermatitis Patients on Product P, Product Q, or Product R Switch to Dupixent ® (dupilumab)
 Total^TN^1
 0^   F3_2_1 (0)
 5^   F3_2_1 (5)
 10^  F3_2_1 (10)
 15^  F3_2_1 (15)
 20^  F3_2_1 (20)
 25^  F3_2_1 (25)
 26^  F3_2_1 (26)
 30^  F3_2_1 (30)
 33^  F3_2_1 (33)
 35^  F3_2_1 (35)
 40^  F3_2_1 (40)
 43^  F3_2_1 (43)
 45^  F3_2_1 (45)
 50^  F3_2_1 (50)
 55^  F3_2_1 (55)
 60^  F3_2_1 (60)
 65^  F3_2_1 (65)
 75^  F3_2_1 (75)
 80^  F3_2_1 (80)
 90^  F3_2_1 (90)
 100^ F3_2_1 (100)
TF3_3_1^75
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F3 - Maintenance Therapy Moderate Atopic Dermatitis Patients on Product P, Product Q, or Product R Switch to an oral systemic
 Total^TN^1
 0^  F3_3_1 (0)
 2^  F3_3_1 (2)
 5^  F3_3_1 (5)
 8^  F3_3_1 (8)
 10^ F3_3_1 (10)
 15^ F3_3_1 (15)
 20^ F3_3_1 (20)
 25^ F3_3_1 (25)
 26^ F3_3_1 (26)
 30^ F3_3_1 (30)
 35^ F3_3_1 (35)
 40^ F3_3_1 (40)
 50^ F3_3_1 (50)
 55^ F3_3_1 (55)
 70^ F3_3_1 (70)
 95^ F3_3_1 (95)
TF3_4_1^76
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F3 - Maintenance Therapy Moderate Atopic Dermatitis Patients on Product P, Product Q, or Product R Switch to Product Z
 Total^TN^1
 0^  F3_4_1 (0)
 1^  F3_4_1 (1)
 5^  F3_4_1 (5)
 10^ F3_4_1 (10)
 15^ F3_4_1 (15)
 18^ F3_4_1 (18)
 20^ F3_4_1 (20)
 23^ F3_4_1 (23)
 25^ F3_4_1 (25)
 30^ F3_4_1 (30)
 35^ F3_4_1 (35)
 40^ F3_4_1 (40)
 45^ F3_4_1 (45)
 50^ F3_4_1 (50)
 65^ F3_4_1 (65)
 70^ F3_4_1 (70)
TF3_1_2^77
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F3 - Maintenance Therapy Severe Atopic Dermatitis Patients on Product P, Product Q, or Product R Continue using Product P, Product Q, or Product R
 Total^TN^1
 0^   F3_1_2 (0)
 10^  F3_1_2 (10)
 12^  F3_1_2 (12)
 15^  F3_1_2 (15)
 18^  F3_1_2 (18)
 20^  F3_1_2 (20)
 25^  F3_1_2 (25)
 30^  F3_1_2 (30)
 35^  F3_1_2 (35)
 40^  F3_1_2 (40)
 45^  F3_1_2 (45)
 50^  F3_1_2 (50)
 55^  F3_1_2 (55)
 60^  F3_1_2 (60)
 70^  F3_1_2 (70)
 75^  F3_1_2 (75)
 90^  F3_1_2 (90)
 100^ F3_1_2 (100)
TF3_2_2^78
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F3 - Maintenance Therapy Severe Atopic Dermatitis Patients on Product P, Product Q, or Product R Switch to Dupixent ® (dupilumab)
 Total^TN^1
 0^   F3_2_2 (0)
 5^   F3_2_2 (5)
 8^   F3_2_2 (8)
 10^  F3_2_2 (10)
 15^  F3_2_2 (15)
 18^  F3_2_2 (18)
 20^  F3_2_2 (20)
 25^  F3_2_2 (25)
 30^  F3_2_2 (30)
 35^  F3_2_2 (35)
 40^  F3_2_2 (40)
 45^  F3_2_2 (45)
 50^  F3_2_2 (50)
 55^  F3_2_2 (55)
 65^  F3_2_2 (65)
 75^  F3_2_2 (75)
 80^  F3_2_2 (80)
 90^  F3_2_2 (90)
 100^ F3_2_2 (100)
TF3_3_2^79
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F3 - Maintenance Therapy Severe Atopic Dermatitis Patients on Product P, Product Q, or Product R Switch to an oral systemic
 Total^TN^1
 0^  F3_3_2 (0)
 2^  F3_3_2 (2)
 5^  F3_3_2 (5)
 10^ F3_3_2 (10)
 13^ F3_3_2 (13)
 15^ F3_3_2 (15)
 20^ F3_3_2 (20)
 25^ F3_3_2 (25)
 30^ F3_3_2 (30)
 35^ F3_3_2 (35)
 40^ F3_3_2 (40)
 55^ F3_3_2 (55)
 60^ F3_3_2 (60)
 70^ F3_3_2 (70)
TF3_4_2^80
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F3 - Maintenance Therapy Severe Atopic Dermatitis Patients on Product P, Product Q, or Product R Switch to Product Z
 Total^TN^1
 0^  F3_4_2 (0)
 5^  F3_4_2 (5)
 10^ F3_4_2 (10)
 15^ F3_4_2 (15)
 19^ F3_4_2 (19)
 20^ F3_4_2 (20)
 25^ F3_4_2 (25)
 30^ F3_4_2 (30)
 35^ F3_4_2 (35)
 40^ F3_4_2 (40)
 45^ F3_4_2 (45)
 50^ F3_4_2 (50)
 70^ F3_4_2 (70)
TF5_4_2^81
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F5 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and alternate dosing scenario) Product Z
 Total^TN^1
 0^  F5_4_2 (0)
 1^  F5_4_2 (1)
 2^  F5_4_2 (2)
 3^  F5_4_2 (3)
 4^  F5_4_2 (4)
 5^  F5_4_2 (5)
 8^  F5_4_2 (8)
 9^  F5_4_2 (9)
 10^ F5_4_2 (10)
 13^ F5_4_2 (13)
 15^ F5_4_2 (15)
 20^ F5_4_2 (20)
 22^ F5_4_2 (22)
 25^ F5_4_2 (25)
 30^ F5_4_2 (30)
 35^ F5_4_2 (35)
 40^ F5_4_2 (40)
 50^ F5_4_2 (50)
 55^ F5_4_2 (55)
 90^ F5_4_2 (90)
TF5_4_4^82
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F5 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and alternate dosing scenario) Product Z
 Total^TN^1
 0^  F5_4_4 (0)
 1^  F5_4_4 (1)
 2^  F5_4_4 (2)
 3^  F5_4_4 (3)
 4^  F5_4_4 (4)
 5^  F5_4_4 (5)
 6^  F5_4_4 (6)
 7^  F5_4_4 (7)
 9^  F5_4_4 (9)
 10^ F5_4_4 (10)
 12^ F5_4_4 (12)
 15^ F5_4_4 (15)
 16^ F5_4_4 (16)
 20^ F5_4_4 (20)
 25^ F5_4_4 (25)
 30^ F5_4_4 (30)
 35^ F5_4_4 (35)
 40^ F5_4_4 (40)
 45^ F5_4_4 (45)
 50^ F5_4_4 (50)
 55^ F5_4_4 (55)
 60^ F5_4_4 (60)
 90^ F5_4_4 (90)
TF5_4_6^83
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F5 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and alternate dosing scenario) Product Z
 Total^TN^1
 0^  F5_4_6 (0)
 1^  F5_4_6 (1)
 2^  F5_4_6 (2)
 3^  F5_4_6 (3)
 4^  F5_4_6 (4)
 5^  F5_4_6 (5)
 6^  F5_4_6 (6)
 7^  F5_4_6 (7)
 8^  F5_4_6 (8)
 9^  F5_4_6 (9)
 10^ F5_4_6 (10)
 12^ F5_4_6 (12)
 14^ F5_4_6 (14)
 15^ F5_4_6 (15)
 16^ F5_4_6 (16)
 18^ F5_4_6 (18)
 20^ F5_4_6 (20)
 25^ F5_4_6 (25)
 28^ F5_4_6 (28)
 30^ F5_4_6 (30)
 35^ F5_4_6 (35)
 40^ F5_4_6 (40)
 45^ F5_4_6 (45)
 50^ F5_4_6 (50)
 60^ F5_4_6 (60)
 65^ F5_4_6 (65)
 90^ F5_4_6 (90)
TF5_4_8^84
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F5 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and alternate dosing scenario) Product Z
 Total^TN^1
 0^  F5_4_8 (0)
 1^  F5_4_8 (1)
 2^  F5_4_8 (2)
 3^  F5_4_8 (3)
 5^  F5_4_8 (5)
 6^  F5_4_8 (6)
 9^  F5_4_8 (9)
 10^ F5_4_8 (10)
 11^ F5_4_8 (11)
 14^ F5_4_8 (14)
 15^ F5_4_8 (15)
 17^ F5_4_8 (17)
 19^ F5_4_8 (19)
 20^ F5_4_8 (20)
 21^ F5_4_8 (21)
 22^ F5_4_8 (22)
 25^ F5_4_8 (25)
 30^ F5_4_8 (30)
 35^ F5_4_8 (35)
 40^ F5_4_8 (40)
 45^ F5_4_8 (45)
 50^ F5_4_8 (50)
 60^ F5_4_8 (60)
 65^ F5_4_8 (65)
 70^ F5_4_8 (70)
 85^ F5_4_8 (85)
 90^ F5_4_8 (90)
TF6_4_2^85
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product Z
 Total^TN^1
 0^   F6_4_2 (0)
 1^   F6_4_2 (1)
 2^   F6_4_2 (2)
 3^   F6_4_2 (3)
 5^   F6_4_2 (5)
 7^   F6_4_2 (7)
 8^   F6_4_2 (8)
 10^  F6_4_2 (10)
 13^  F6_4_2 (13)
 15^  F6_4_2 (15)
 20^  F6_4_2 (20)
 25^  F6_4_2 (25)
 30^  F6_4_2 (30)
 50^  F6_4_2 (50)
 60^  F6_4_2 (60)
 100^ F6_4_2 (100)
TF6_5_2^86
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Dupixent® (dupilumab) / dupilumab
 Total^TN^1
 0^   F6_5_2 (0)
 2^   F6_5_2 (2)
 3^   F6_5_2 (3)
 5^   F6_5_2 (5)
 10^  F6_5_2 (10)
 13^  F6_5_2 (13)
 15^  F6_5_2 (15)
 20^  F6_5_2 (20)
 24^  F6_5_2 (24)
 25^  F6_5_2 (25)
 30^  F6_5_2 (30)
 32^  F6_5_2 (32)
 35^  F6_5_2 (35)
 37^  F6_5_2 (37)
 40^  F6_5_2 (40)
 45^  F6_5_2 (45)
 50^  F6_5_2 (50)
 75^  F6_5_2 (75)
 80^  F6_5_2 (80)
 95^  F6_5_2 (95)
 100^ F6_5_2 (100)
TF6_1_2^87
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product P
 Total^TN^1
 0^  F6_1_2 (0)
 1^  F6_1_2 (1)
 3^  F6_1_2 (3)
 4^  F6_1_2 (4)
 5^  F6_1_2 (5)
 9^  F6_1_2 (9)
 10^ F6_1_2 (10)
 15^ F6_1_2 (15)
 20^ F6_1_2 (20)
 25^ F6_1_2 (25)
 30^ F6_1_2 (30)
 50^ F6_1_2 (50)
TF6_2_2^88
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product Q
 Total^TN^1
 0^  F6_2_2 (0)
 1^  F6_2_2 (1)
 3^  F6_2_2 (3)
 5^  F6_2_2 (5)
 6^  F6_2_2 (6)
 9^  F6_2_2 (9)
 10^ F6_2_2 (10)
 15^ F6_2_2 (15)
 20^ F6_2_2 (20)
 25^ F6_2_2 (25)
 50^ F6_2_2 (50)
TF6_3_2^89
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product R
 Total^TN^1
 0^   F6_3_2 (0)
 1^   F6_3_2 (1)
 2^   F6_3_2 (2)
 3^   F6_3_2 (3)
 5^   F6_3_2 (5)
 7^   F6_3_2 (7)
 9^   F6_3_2 (9)
 10^  F6_3_2 (10)
 15^  F6_3_2 (15)
 20^  F6_3_2 (20)
 25^  F6_3_2 (25)
 30^  F6_3_2 (30)
 35^  F6_3_2 (35)
 40^  F6_3_2 (40)
 50^  F6_3_2 (50)
 60^  F6_3_2 (60)
 100^ F6_3_2 (100)
TF6_6_2^90
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Oral Systemics (e.g., cyclosporine, methotrexate)
 Total^TN^1
 0^  F6_6_2 (0)
 2^  F6_6_2 (2)
 4^  F6_6_2 (4)
 5^  F6_6_2 (5)
 9^  F6_6_2 (9)
 10^ F6_6_2 (10)
 12^ F6_6_2 (12)
 20^ F6_6_2 (20)
 25^ F6_6_2 (25)
 40^ F6_6_2 (40)
TF6_7_2^91
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Prescription Topical Corticosteroids (TCS)
 Total^TN^1
 0^   F6_7_2 (0)
 2^   F6_7_2 (2)
 4^   F6_7_2 (4)
 5^   F6_7_2 (5)
 10^  F6_7_2 (10)
 14^  F6_7_2 (14)
 20^  F6_7_2 (20)
 25^  F6_7_2 (25)
 30^  F6_7_2 (30)
 35^  F6_7_2 (35)
 40^  F6_7_2 (40)
 50^  F6_7_2 (50)
 55^  F6_7_2 (55)
 60^  F6_7_2 (60)
 65^  F6_7_2 (65)
 70^  F6_7_2 (70)
 75^  F6_7_2 (75)
 80^  F6_7_2 (80)
 85^  F6_7_2 (85)
 90^  F6_7_2 (90)
 95^  F6_7_2 (95)
 100^ F6_7_2 (100)
TF6_8_2^92
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Prescription Topical Calcineurin Inhibitors (TCI)
 Total^TN^1
 0^   F6_8_2 (0)
 1^   F6_8_2 (1)
 3^   F6_8_2 (3)
 5^   F6_8_2 (5)
 8^   F6_8_2 (8)
 10^  F6_8_2 (10)
 15^  F6_8_2 (15)
 20^  F6_8_2 (20)
 25^  F6_8_2 (25)
 30^  F6_8_2 (30)
 35^  F6_8_2 (35)
 40^  F6_8_2 (40)
 45^  F6_8_2 (45)
 50^  F6_8_2 (50)
 60^  F6_8_2 (60)
 65^  F6_8_2 (65)
 100^ F6_8_2 (100)
TF6_9_2^93
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate .... NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole)) / Other Prescription Topical Medications
 Total^TN^1
 0^   F6_9_2 (0)
 2^   F6_9_2 (2)
 5^   F6_9_2 (5)
 7^   F6_9_2 (7)
 10^  F6_9_2 (10)
 15^  F6_9_2 (15)
 20^  F6_9_2 (20)
 25^  F6_9_2 (25)
 30^  F6_9_2 (30)
 35^  F6_9_2 (35)
 45^  F6_9_2 (45)
 50^  F6_9_2 (50)
 100^ F6_9_2 (100)
TF6_10_2^94
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Oral Corticosteroids
 Total^TN^1
 0^  F6_10_2 (0)
 1^  F6_10_2 (1)
 2^  F6_10_2 (2)
 3^  F6_10_2 (3)
 5^  F6_10_2 (5)
 6^  F6_10_2 (6)
 10^ F6_10_2 (10)
 13^ F6_10_2 (13)
 15^ F6_10_2 (15)
 20^ F6_10_2 (20)
 25^ F6_10_2 (25)
 30^ F6_10_2 (30)
 35^ F6_10_2 (35)
 40^ F6_10_2 (40)
 50^ F6_10_2 (50)
 75^ F6_10_2 (75)
TF6_12_2^95
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ C1_11_other ]
 Total^TN^1
 0^  F6_12_2 (0)
 5^  F6_12_2 (5)
 25^ F6_12_2 (25)
TF6_15_2^96
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ C2_11_other ]
 Total^TN^1
 0^  F6_15_2 (0)
 10^ F6_15_2 (10)
 15^ F6_15_2 (15)
TF6_13_2^97
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ D1_11_other ]
 Total^TN^1
TF6_14_2^98
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ E1_11_other ]
 Total^TN^1
TF6_11_2^99
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Other Prescription Therapies (Please specify)
 Total^TN^1
 0^ F6_11_2 (0)
TF6_4_4^100
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product Z
 Total^TN^1
 0^   F6_4_4 (0)
 2^   F6_4_4 (2)
 5^   F6_4_4 (5)
 6^   F6_4_4 (6)
 7^   F6_4_4 (7)
 8^   F6_4_4 (8)
 10^  F6_4_4 (10)
 15^  F6_4_4 (15)
 16^  F6_4_4 (16)
 20^  F6_4_4 (20)
 25^  F6_4_4 (25)
 30^  F6_4_4 (30)
 35^  F6_4_4 (35)
 50^  F6_4_4 (50)
 60^  F6_4_4 (60)
 100^ F6_4_4 (100)
TF6_5_4^101
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Dupixent® (dupilumab) / dupilumab
 Total^TN^1
 0^   F6_5_4 (0)
 3^   F6_5_4 (3)
 5^   F6_5_4 (5)
 7^   F6_5_4 (7)
 10^  F6_5_4 (10)
 15^  F6_5_4 (15)
 17^  F6_5_4 (17)
 20^  F6_5_4 (20)
 21^  F6_5_4 (21)
 25^  F6_5_4 (25)
 30^  F6_5_4 (30)
 40^  F6_5_4 (40)
 45^  F6_5_4 (45)
 50^  F6_5_4 (50)
 55^  F6_5_4 (55)
 60^  F6_5_4 (60)
 65^  F6_5_4 (65)
 70^  F6_5_4 (70)
 75^  F6_5_4 (75)
 80^  F6_5_4 (80)
 85^  F6_5_4 (85)
 90^  F6_5_4 (90)
 91^  F6_5_4 (91)
 100^ F6_5_4 (100)
TF6_1_4^102
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product P
 Total^TN^1
 0^  F6_1_4 (0)
 1^  F6_1_4 (1)
 3^  F6_1_4 (3)
 5^  F6_1_4 (5)
 7^  F6_1_4 (7)
 8^  F6_1_4 (8)
 9^  F6_1_4 (9)
 10^ F6_1_4 (10)
 15^ F6_1_4 (15)
 20^ F6_1_4 (20)
 25^ F6_1_4 (25)
 30^ F6_1_4 (30)
 50^ F6_1_4 (50)
TF6_2_4^103
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product Q
 Total^TN^1
 0^  F6_2_4 (0)
 1^  F6_2_4 (1)
 2^  F6_2_4 (2)
 3^  F6_2_4 (3)
 5^  F6_2_4 (5)
 7^  F6_2_4 (7)
 8^  F6_2_4 (8)
 9^  F6_2_4 (9)
 10^ F6_2_4 (10)
 13^ F6_2_4 (13)
 15^ F6_2_4 (15)
 20^ F6_2_4 (20)
 25^ F6_2_4 (25)
 30^ F6_2_4 (30)
 50^ F6_2_4 (50)
TF6_3_4^104
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product R
 Total^TN^1
 0^   F6_3_4 (0)
 1^   F6_3_4 (1)
 2^   F6_3_4 (2)
 3^   F6_3_4 (3)
 5^   F6_3_4 (5)
 7^   F6_3_4 (7)
 8^   F6_3_4 (8)
 9^   F6_3_4 (9)
 10^  F6_3_4 (10)
 13^  F6_3_4 (13)
 15^  F6_3_4 (15)
 20^  F6_3_4 (20)
 25^  F6_3_4 (25)
 30^  F6_3_4 (30)
 35^  F6_3_4 (35)
 40^  F6_3_4 (40)
 45^  F6_3_4 (45)
 50^  F6_3_4 (50)
 60^  F6_3_4 (60)
 100^ F6_3_4 (100)
TF6_6_4^105
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Oral Systemics (e.g., cyclosporine, methotrexate)
 Total^TN^1
 0^  F6_6_4 (0)
 1^  F6_6_4 (1)
 2^  F6_6_4 (2)
 5^  F6_6_4 (5)
 6^  F6_6_4 (6)
 10^ F6_6_4 (10)
 11^ F6_6_4 (11)
 15^ F6_6_4 (15)
 18^ F6_6_4 (18)
 20^ F6_6_4 (20)
 25^ F6_6_4 (25)
 40^ F6_6_4 (40)
TF6_7_4^106
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Prescription Topical Corticosteroids (TCS)
 Total^TN^1
 0^   F6_7_4 (0)
 10^  F6_7_4 (10)
 11^  F6_7_4 (11)
 12^  F6_7_4 (12)
 15^  F6_7_4 (15)
 20^  F6_7_4 (20)
 25^  F6_7_4 (25)
 30^  F6_7_4 (30)
 40^  F6_7_4 (40)
 50^  F6_7_4 (50)
 55^  F6_7_4 (55)
 60^  F6_7_4 (60)
 70^  F6_7_4 (70)
 75^  F6_7_4 (75)
 80^  F6_7_4 (80)
 90^  F6_7_4 (90)
 95^  F6_7_4 (95)
 100^ F6_7_4 (100)
TF6_8_4^107
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Prescription Topical Calcineurin Inhibitors (TCI)
 Total^TN^1
 0^   F6_8_4 (0)
 5^   F6_8_4 (5)
 7^   F6_8_4 (7)
 8^   F6_8_4 (8)
 10^  F6_8_4 (10)
 15^  F6_8_4 (15)
 20^  F6_8_4 (20)
 25^  F6_8_4 (25)
 30^  F6_8_4 (30)
 35^  F6_8_4 (35)
 40^  F6_8_4 (40)
 50^  F6_8_4 (50)
 60^  F6_8_4 (60)
 70^  F6_8_4 (70)
 75^  F6_8_4 (75)
 100^ F6_8_4 (100)
TF6_9_4^108
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate .... NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole)) / Other Prescription Topical Medications
 Total^TN^1
 0^   F6_9_4 (0)
 3^   F6_9_4 (3)
 4^   F6_9_4 (4)
 5^   F6_9_4 (5)
 8^   F6_9_4 (8)
 10^  F6_9_4 (10)
 15^  F6_9_4 (15)
 20^  F6_9_4 (20)
 25^  F6_9_4 (25)
 30^  F6_9_4 (30)
 35^  F6_9_4 (35)
 45^  F6_9_4 (45)
 50^  F6_9_4 (50)
 100^ F6_9_4 (100)
TF6_10_4^109
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Oral Corticosteroids
 Total^TN^1
 0^  F6_10_4 (0)
 1^  F6_10_4 (1)
 2^  F6_10_4 (2)
 3^  F6_10_4 (3)
 5^  F6_10_4 (5)
 10^ F6_10_4 (10)
 15^ F6_10_4 (15)
 18^ F6_10_4 (18)
 20^ F6_10_4 (20)
 23^ F6_10_4 (23)
 25^ F6_10_4 (25)
 50^ F6_10_4 (50)
TF6_12_4^110
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ C1_11_other ]
 Total^TN^1
 0^  F6_12_4 (0)
 5^  F6_12_4 (5)
 25^ F6_12_4 (25)
TF6_15_4^111
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ C2_11_other ]
 Total^TN^1
 0^  F6_15_4 (0)
 10^ F6_15_4 (10)
 15^ F6_15_4 (15)
TF6_13_4^112
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ D1_11_other ]
 Total^TN^1
TF6_14_4^113
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ E1_11_other ]
 Total^TN^1
TF6_11_4^114
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Other Prescription Therapies (Please specify)
 Total^TN^1
 0^ F6_11_4 (0)
TF6_4_6^115
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product Z
 Total^TN^1
 0^   F6_4_6 (0)
 2^   F6_4_6 (2)
 3^   F6_4_6 (3)
 5^   F6_4_6 (5)
 6^   F6_4_6 (6)
 10^  F6_4_6 (10)
 14^  F6_4_6 (14)
 15^  F6_4_6 (15)
 20^  F6_4_6 (20)
 25^  F6_4_6 (25)
 30^  F6_4_6 (30)
 40^  F6_4_6 (40)
 45^  F6_4_6 (45)
 50^  F6_4_6 (50)
 60^  F6_4_6 (60)
 100^ F6_4_6 (100)
TF6_5_6^116
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Dupixent® (dupilumab) / dupilumab
 Total^TN^1
 0^   F6_5_6 (0)
 5^   F6_5_6 (5)
 10^  F6_5_6 (10)
 15^  F6_5_6 (15)
 18^  F6_5_6 (18)
 20^  F6_5_6 (20)
 25^  F6_5_6 (25)
 30^  F6_5_6 (30)
 35^  F6_5_6 (35)
 37^  F6_5_6 (37)
 40^  F6_5_6 (40)
 41^  F6_5_6 (41)
 45^  F6_5_6 (45)
 50^  F6_5_6 (50)
 60^  F6_5_6 (60)
 70^  F6_5_6 (70)
 75^  F6_5_6 (75)
 85^  F6_5_6 (85)
 90^  F6_5_6 (90)
 95^  F6_5_6 (95)
 100^ F6_5_6 (100)
TF6_1_6^117
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product P
 Total^TN^1
 0^  F6_1_6 (0)
 1^  F6_1_6 (1)
 2^  F6_1_6 (2)
 3^  F6_1_6 (3)
 5^  F6_1_6 (5)
 7^  F6_1_6 (7)
 8^  F6_1_6 (8)
 10^ F6_1_6 (10)
 15^ F6_1_6 (15)
 20^ F6_1_6 (20)
 22^ F6_1_6 (22)
 25^ F6_1_6 (25)
 30^ F6_1_6 (30)
 40^ F6_1_6 (40)
 45^ F6_1_6 (45)
 60^ F6_1_6 (60)
TF6_2_6^118
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product Q
 Total^TN^1
 0^  F6_2_6 (0)
 1^  F6_2_6 (1)
 2^  F6_2_6 (2)
 3^  F6_2_6 (3)
 5^  F6_2_6 (5)
 8^  F6_2_6 (8)
 10^ F6_2_6 (10)
 11^ F6_2_6 (11)
 12^ F6_2_6 (12)
 15^ F6_2_6 (15)
 20^ F6_2_6 (20)
 25^ F6_2_6 (25)
 30^ F6_2_6 (30)
 35^ F6_2_6 (35)
 50^ F6_2_6 (50)
 60^ F6_2_6 (60)
TF6_3_6^119
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product R
 Total^TN^1
 0^   F6_3_6 (0)
 1^   F6_3_6 (1)
 2^   F6_3_6 (2)
 3^   F6_3_6 (3)
 5^   F6_3_6 (5)
 8^   F6_3_6 (8)
 10^  F6_3_6 (10)
 13^  F6_3_6 (13)
 15^  F6_3_6 (15)
 20^  F6_3_6 (20)
 25^  F6_3_6 (25)
 30^  F6_3_6 (30)
 35^  F6_3_6 (35)
 39^  F6_3_6 (39)
 40^  F6_3_6 (40)
 50^  F6_3_6 (50)
 70^  F6_3_6 (70)
 100^ F6_3_6 (100)
TF6_6_6^120
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Oral Systemics (e.g., cyclosporine, methotrexate)
 Total^TN^1
 0^  F6_6_6 (0)
 2^  F6_6_6 (2)
 3^  F6_6_6 (3)
 5^  F6_6_6 (5)
 10^ F6_6_6 (10)
 11^ F6_6_6 (11)
 15^ F6_6_6 (15)
 18^ F6_6_6 (18)
 20^ F6_6_6 (20)
 25^ F6_6_6 (25)
 50^ F6_6_6 (50)
TF6_7_6^121
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Prescription Topical Corticosteroids (TCS)
 Total^TN^1
 0^   F6_7_6 (0)
 1^   F6_7_6 (1)
 5^   F6_7_6 (5)
 10^  F6_7_6 (10)
 12^  F6_7_6 (12)
 15^  F6_7_6 (15)
 19^  F6_7_6 (19)
 20^  F6_7_6 (20)
 25^  F6_7_6 (25)
 30^  F6_7_6 (30)
 35^  F6_7_6 (35)
 40^  F6_7_6 (40)
 45^  F6_7_6 (45)
 50^  F6_7_6 (50)
 55^  F6_7_6 (55)
 60^  F6_7_6 (60)
 65^  F6_7_6 (65)
 70^  F6_7_6 (70)
 75^  F6_7_6 (75)
 85^  F6_7_6 (85)
 90^  F6_7_6 (90)
 95^  F6_7_6 (95)
 97^  F6_7_6 (97)
 100^ F6_7_6 (100)
TF6_8_6^122
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Prescription Topical Calcineurin Inhibitors (TCI)
 Total^TN^1
 0^   F6_8_6 (0)
 5^   F6_8_6 (5)
 6^   F6_8_6 (6)
 8^   F6_8_6 (8)
 10^  F6_8_6 (10)
 15^  F6_8_6 (15)
 20^  F6_8_6 (20)
 25^  F6_8_6 (25)
 30^  F6_8_6 (30)
 40^  F6_8_6 (40)
 45^  F6_8_6 (45)
 50^  F6_8_6 (50)
 60^  F6_8_6 (60)
 75^  F6_8_6 (75)
 85^  F6_8_6 (85)
 100^ F6_8_6 (100)
TF6_9_6^123
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe .... NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole)) / Other Prescription Topical Medications
 Total^TN^1
 0^   F6_9_6 (0)
 1^   F6_9_6 (1)
 4^   F6_9_6 (4)
 5^   F6_9_6 (5)
 10^  F6_9_6 (10)
 15^  F6_9_6 (15)
 20^  F6_9_6 (20)
 25^  F6_9_6 (25)
 30^  F6_9_6 (30)
 50^  F6_9_6 (50)
 55^  F6_9_6 (55)
 100^ F6_9_6 (100)
TF6_10_6^124
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Oral Corticosteroids
 Total^TN^1
 0^  F6_10_6 (0)
 1^  F6_10_6 (1)
 2^  F6_10_6 (2)
 5^  F6_10_6 (5)
 7^  F6_10_6 (7)
 8^  F6_10_6 (8)
 10^ F6_10_6 (10)
 15^ F6_10_6 (15)
 20^ F6_10_6 (20)
 25^ F6_10_6 (25)
 40^ F6_10_6 (40)
 50^ F6_10_6 (50)
 70^ F6_10_6 (70)
TF6_12_6^125
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ C1_11_other ]
 Total^TN^1
 5^  F6_12_6 (5)
 10^ F6_12_6 (10)
 25^ F6_12_6 (25)
TF6_15_6^126
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ C2_11_other ]
 Total^TN^1
 0^  F6_15_6 (0)
 10^ F6_15_6 (10)
TF6_13_6^127
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ D1_11_other ]
 Total^TN^1
TF6_14_6^128
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ E1_11_other ]
 Total^TN^1
TF6_11_6^129
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Other Prescription Therapies (Please specify)
 Total^TN^1
 0^ F6_11_6 (0)
TF6_4_8^130
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product Z
 Total^TN^1
 0^   F6_4_8 (0)
 2^   F6_4_8 (2)
 3^   F6_4_8 (3)
 5^   F6_4_8 (5)
 8^   F6_4_8 (8)
 10^  F6_4_8 (10)
 15^  F6_4_8 (15)
 17^  F6_4_8 (17)
 20^  F6_4_8 (20)
 25^  F6_4_8 (25)
 30^  F6_4_8 (30)
 40^  F6_4_8 (40)
 50^  F6_4_8 (50)
 60^  F6_4_8 (60)
 100^ F6_4_8 (100)
TF6_5_8^131
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Dupixent® (dupilumab) / dupilumab
 Total^TN^1
 0^   F6_5_8 (0)
 3^   F6_5_8 (3)
 5^   F6_5_8 (5)
 10^  F6_5_8 (10)
 15^  F6_5_8 (15)
 20^  F6_5_8 (20)
 25^  F6_5_8 (25)
 28^  F6_5_8 (28)
 30^  F6_5_8 (30)
 35^  F6_5_8 (35)
 40^  F6_5_8 (40)
 50^  F6_5_8 (50)
 55^  F6_5_8 (55)
 60^  F6_5_8 (60)
 65^  F6_5_8 (65)
 70^  F6_5_8 (70)
 75^  F6_5_8 (75)
 80^  F6_5_8 (80)
 90^  F6_5_8 (90)
 91^  F6_5_8 (91)
 92^  F6_5_8 (92)
 95^  F6_5_8 (95)
 100^ F6_5_8 (100)
TF6_1_8^132
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product P
 Total^TN^1
 0^  F6_1_8 (0)
 1^  F6_1_8 (1)
 2^  F6_1_8 (2)
 3^  F6_1_8 (3)
 5^  F6_1_8 (5)
 9^  F6_1_8 (9)
 10^ F6_1_8 (10)
 15^ F6_1_8 (15)
 20^ F6_1_8 (20)
 25^ F6_1_8 (25)
 30^ F6_1_8 (30)
 45^ F6_1_8 (45)
TF6_2_8^133
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product Q
 Total^TN^1
 0^  F6_2_8 (0)
 1^  F6_2_8 (1)
 2^  F6_2_8 (2)
 3^  F6_2_8 (3)
 5^  F6_2_8 (5)
 7^  F6_2_8 (7)
 10^ F6_2_8 (10)
 15^ F6_2_8 (15)
 20^ F6_2_8 (20)
 25^ F6_2_8 (25)
 30^ F6_2_8 (30)
 40^ F6_2_8 (40)
 50^ F6_2_8 (50)
 65^ F6_2_8 (65)
TF6_3_8^134
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product R
 Total^TN^1
 0^   F6_3_8 (0)
 1^   F6_3_8 (1)
 2^   F6_3_8 (2)
 3^   F6_3_8 (3)
 4^   F6_3_8 (4)
 5^   F6_3_8 (5)
 8^   F6_3_8 (8)
 10^  F6_3_8 (10)
 15^  F6_3_8 (15)
 20^  F6_3_8 (20)
 25^  F6_3_8 (25)
 30^  F6_3_8 (30)
 35^  F6_3_8 (35)
 40^  F6_3_8 (40)
 50^  F6_3_8 (50)
 70^  F6_3_8 (70)
 75^  F6_3_8 (75)
 100^ F6_3_8 (100)
TF6_6_8^135
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Oral Systemics (e.g., cyclosporine, methotrexate)
 Total^TN^1
 0^  F6_6_8 (0)
 1^  F6_6_8 (1)
 2^  F6_6_8 (2)
 5^  F6_6_8 (5)
 8^  F6_6_8 (8)
 9^  F6_6_8 (9)
 10^ F6_6_8 (10)
 12^ F6_6_8 (12)
 15^ F6_6_8 (15)
 18^ F6_6_8 (18)
 20^ F6_6_8 (20)
 25^ F6_6_8 (25)
 30^ F6_6_8 (30)
 50^ F6_6_8 (50)
TF6_7_8^136
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Prescription Topical Corticosteroids (TCS)
 Total^TN^1
 0^   F6_7_8 (0)
 5^   F6_7_8 (5)
 7^   F6_7_8 (7)
 8^   F6_7_8 (8)
 10^  F6_7_8 (10)
 11^  F6_7_8 (11)
 20^  F6_7_8 (20)
 25^  F6_7_8 (25)
 30^  F6_7_8 (30)
 40^  F6_7_8 (40)
 50^  F6_7_8 (50)
 55^  F6_7_8 (55)
 65^  F6_7_8 (65)
 70^  F6_7_8 (70)
 75^  F6_7_8 (75)
 80^  F6_7_8 (80)
 85^  F6_7_8 (85)
 90^  F6_7_8 (90)
 95^  F6_7_8 (95)
 97^  F6_7_8 (97)
 100^ F6_7_8 (100)
TF6_8_8^137
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Prescription Topical Calcineurin Inhibitors (TCI)
 Total^TN^1
 0^   F6_8_8 (0)
 1^   F6_8_8 (1)
 5^   F6_8_8 (5)
 7^   F6_8_8 (7)
 10^  F6_8_8 (10)
 15^  F6_8_8 (15)
 20^  F6_8_8 (20)
 25^  F6_8_8 (25)
 30^  F6_8_8 (30)
 40^  F6_8_8 (40)
 45^  F6_8_8 (45)
 50^  F6_8_8 (50)
 60^  F6_8_8 (60)
 65^  F6_8_8 (65)
 70^  F6_8_8 (70)
 80^  F6_8_8 (80)
 100^ F6_8_8 (100)
TF6_9_8^138
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe ....  NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole)) / Other Prescription Topical Medications
 Total^TN^1
 0^   F6_9_8 (0)
 1^   F6_9_8 (1)
 3^   F6_9_8 (3)
 4^   F6_9_8 (4)
 5^   F6_9_8 (5)
 10^  F6_9_8 (10)
 15^  F6_9_8 (15)
 20^  F6_9_8 (20)
 25^  F6_9_8 (25)
 40^  F6_9_8 (40)
 50^  F6_9_8 (50)
 100^ F6_9_8 (100)
TF6_10_8^139
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Oral Corticosteroids
 Total^TN^1
 0^  F6_10_8 (0)
 2^  F6_10_8 (2)
 3^  F6_10_8 (3)
 5^  F6_10_8 (5)
 10^ F6_10_8 (10)
 18^ F6_10_8 (18)
 20^ F6_10_8 (20)
 23^ F6_10_8 (23)
 25^ F6_10_8 (25)
 30^ F6_10_8 (30)
 50^ F6_10_8 (50)
TF6_12_8^140
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ C1_11_other ]
 Total^TN^1
 0^  F6_12_8 (0)
 25^ F6_12_8 (25)
TF6_15_8^141
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ C2_11_other ]
 Total^TN^1
 0^  F6_15_8 (0)
 5^  F6_15_8 (5)
 10^ F6_15_8 (10)
 15^ F6_15_8 (15)
 25^ F6_15_8 (25)
TF6_13_8^142
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ D1_11_other ]
 Total^TN^1
TF6_14_8^143
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ E1_11_other ]
 Total^TN^1
TF6_11_8^144
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Other Prescription Therapies (Please specify)
 Total^TN^1
 0^ F6_11_8 (0)
TF6_11_other^145
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Other Prescription Therapies (Please specify)
 Total^TN^1
TF7a_1^146
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F7a - Please indicate how important the below statement is to your clinical practice.
 Total^TN^1
 Not at all Important to My Clinical Practice 1^ F7A_1 (1)
 2^                                              F7A_1 (2)
 3^                                              F7A_1 (3)
 4^                                              F7A_1 (4)
 5^                                              F7A_1 (5)
 6^                                              F7A_1 (6)
 Extremely Important to My Clinical Practice 7^  F7A_1 (7)
TF7b^147
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F7b - Please indicate why you rated the below statement a [ F7a_1 ].
 Total^TN^1
 Überzeugende Wirkung mit sehr gutem Prei-Nutzung Profil, was ein neues Ära Inder Therapie von Atopisches Ekzem^                                                                                       F7B (ÜBERZEUGENDE)
 69% est un résultat remarquable^                                                                                                                                                                      F7B (69% EST UN R)
 69% improvement is beneficial in that time frame^                                                                                                                                                     F7B (69% IMPROVEM)
 70% clearance in 24 weeks seems like a long time to wait for relief^                                                                                                                                  F7B (70% CLEARANC)
 AD derm patients are all still using topicals^                                                                                                                                                        F7B (AD DERM PATI)
 Allows me to evaluate efficacy and make a comparison to dupixent^                                                                                                                                     F7B (ALLOWS ME TO)
 Atopic dermatitis is often very difficult for me to treat to the satisfaction of my patients and anything that can give me this level of clinical response is more than w3elcome^                     F7B (ATOPIC DERMA)
 At the present time, I can achieve a higher EASI-75 Dupixent. I would have only low numbers of patients I would consider changing.^                                                                   F7B (AT THE PRESE)
 Aussage belegt die überlegene Wirksamkeit von Präparat Z in Kombination mit topischen Kortikosteroiden^                                                                                               F7B (AUSSAGE BELE)
 Based on the fact that almost 70% of patients will reach EASI-75^                                                                                                                                     F7B (BASED ON THE)
 Because 69% response is significant^                                                                                                                                                                  F7B (BECAUSE 69%)
 Because of the patients that received EASI 75 at week 24 was 69%^                                                                                                                                     F7B (BECAUSE OF T)
 Better efficacy but not groundbreaking^                                                                                                                                                               F7B (BETTER EFFIC)
 better than topical treatment.^                                                                                                                                                                       F7B (BETTER THAN)
 car c'est un très bon résultat mais je 'ai pas mis 7 car comparé à 2 des inhibiteurs Jak, le résultat est un peu moins bon^                                                                           F7B (CAR C'EST UN)
 Clear improvement that is sustained, however we do not know the sustained response rate to  placebo^                                                                                                  F7B (CLEAR IMPROV)
 Clinical efficacy manifest with dual therapy has synergistic clinical results^                                                                                                                        F7B (CLINICAL EFF)
 combination therapy would likely be a certainty^                                                                                                                                                      F7B (COMBINATION)
 Definitely responsive but I am very happy with Dupixent which is anti IL4, 13 and is single injection every 2 weeks.Why Z?^                                                                           F7B (DEFINITELY R)
 Dermatologists always know that adding steroids to a particular line of therapy increases clearance rates, just as adding phototherapy to this would also increase clearance rates.^                  F7B (DERMATOLOGIS)
 der Präparat Z erscheint effektiv zu sein^                                                                                                                                                            F7B (DER PRÄPARAT)
 die adten sind sehr überzeugend, endlich atrenative zu dupi^                                                                                                                                          F7B (DIE ADTEN SI)
 Don't see a big benefit over Dupixent^                                                                                                                                                                F7B (DON'T SEE A)
 Dupixent works and appears safer^                                                                                                                                                                     F7B (DUPIXENT WOR)
 Easi  70 atteint^                                                                                                                                                                                     F7B (EASI  70 ATT)
 effectiveness in combination^                                                                                                                                                                         F7B (EFFECTIVENES)
 efficacité chez 2/3 des patients^                                                                                                                                                                     F7B (EFFICACITÉ C)
 efficacité du produit au long cours^                                                                                                                                                                  F7B (EFFICACITÉ D)
 EFFICACITE DU TRAITEMENT^                                                                                                                                                                             F7B (EFFICACITE D)
 efficacy data encouraging^                                                                                                                                                                            F7B (EFFICACY DAT)
 efficacy is most important, if it doesn't work really well, not work injecting or risking side effects^                                                                                               F7B (EFFICACY IS)
 EFFICACY OF THE PRODUCT^                                                                                                                                                                              F7B (EFFICACY OF)
 eine einfach zu lesende und verständliche Grafik, das Ergebnis einer Therapie mit Präp- Z ist gut ablesbar, anch 24 Wochen (also einem halben Jahr) mehr als 2/3 der Patienten mit sehr guten Werten^ F7B (EINE EINFACH)
 Ein hoher EASI ist relevant für die Therapie schwer erkrankter AD Patienten^                                                                                                                          F7B (EIN HOHER EA)
 Es ist besser^                                                                                                                                                                                        F7B (ES IST BESSE)
 Essentially, the majority of people using the product had improvement.^                                                                                                                               F7B (ESSENTIALLY,)
 excellent EASI score response, in a short time frame^                                                                                                                                                 F7B (EXCELLENT EA)
 excellent response with this new biologic^                                                                                                                                                            F7B (EXCELLENT RE)
 exciting huge improvemnet^                                                                                                                                                                            F7B (EXCITING HUG)
 gleichbleibende gute wirkung^                                                                                                                                                                         F7B (GLEICHBLEIBE)
 Good efficacy seen with treatment^                                                                                                                                                                    F7B (GOOD EFFICAC)
 good evidence the drug will work but efficacy seems to be less than other comounds^                                                                                                                   F7B (GOOD EVIDENC)
 good improvement but not 100% so did not give it full 7^                                                                                                                                              F7B (GOOD IMPROVE)
 good response but not quick^                                                                                                                                                                          F7B (GOOD RESPONS)
 GOOD TOTAL IMPROVEMENT^                                                                                                                                                                               F7B (GOOD TOTAL I)
 good tx efficacy^                                                                                                                                                                                     F7B (GOOD TX EFFI)
 graphical visualiation of data^                                                                                                                                                                       F7B (GRAPHICAL VI)
 graph is not clear I'm not sure which line refers to which data^                                                                                                                                      F7B (GRAPH IS NOT)
 great efficacy and safe^                                                                                                                                                                              F7B (GREAT EFFICA)
 great response to this medication^                                                                                                                                                                    F7B (GREAT RESPON)
 Gutes ansprechen des Präparats gegenüber der Placebo Gruppe^                                                                                                                                          F7B (GUTES ANSPRE)
 Gutes EASI 75 Ansprechen^                                                                                                                                                                             F7B (GUTES EASI 7)
 gute wirksamkeit der wirksamkeitsbehandlung^                                                                                                                                                          F7B (GUTE WIRKSAM)
 higher efficacy than others^                                                                                                                                                                          F7B (HIGHER EFFIC)
 higher response with combination which will be useful for better  clinical outcome^                                                                                                                   F7B (HIGHER RESPO)
 Hohe abheilung in Kombination^                                                                                                                                                                        F7B (HOHE ABHEILU)
 I'd like to see significantly greater clearance considering the risk/benefit ratio^                                                                                                                   F7B (I'D LIKE TO)
 I'm hesitant with safety profiles. Shows response, but not sure often I'd actually prescribe^                                                                                                         F7B (I'M HESITANT)
 I am neutral about the rate of achieving EASI^                                                                                                                                                        F7B (I AM NEUTRAL)
 I am satisfied with clinical efficacy of product Z, but I assume some drug would be even better^                                                                                                      F7B (I AM SATISFI)
 I believe I would need a little bit more details and patient trial information before I can make a decision. I like to have more details.^                                                            F7B (I BELIEVE I)
 Ich halte dies für relevant^                                                                                                                                                                          F7B (ICH HALTE DI)
 ideally we want maintenance therapy without topical steroids^                                                                                                                                         F7B (IDEALLY WE W)
 I do not plan on prescribing this product^                                                                                                                                                            F7B (I DO NOT PLA)
 i do not think IL 13 only biologic is enough for AD.^                                                                                                                                                 F7B (I DO NOT THI)
 I know steroids in combination will give extra efficacy! This is obvious!^                                                                                                                            F7B (I KNOW STERO)
 I liked the quicker timeframe in achieving EASI 75^                                                                                                                                                   F7B (I LIKED THE)
 Important to see clinical data which shows efficacy at 16 weeks and beyond.^                                                                                                                          F7B (IMPORTANT TO)
 IMPROVED AND MORE HELPFUL^                                                                                                                                                                            F7B (IMPROVED AND)
 Improved efficacy with combination therapy, but the percentage improvement isn't massive.^                                                                                                            F7B (IMPROVED EFF)
 Improvement compared to placebo with TCS, this simulates a real world scenario and proves medication is effective^                                                                                    F7B (IMPROVEMENT)
 increased efficacy with combination therapy^                                                                                                                                                          F7B (INCREASED EF)
 indicates clinical efficacy^                                                                                                                                                                          F7B (INDICATES CL)
 In real world experience, typically combined a TCS with a systemic agent^                                                                                                                             F7B (IN REAL WORL)
 Ist interessant, überzeugt mich aber nicht. Die JAK Inhibitoren sind weitaus effektiver^                                                                                                              F7B (IST INTERESS)
 It's important to know that this product can be used with TCS, and not only that, but increases efficacy^                                                                                             F7B (IT'S IMPORTA)
 It's more important how it does on it's own. It's really more only a year's worth of data, so for a year it is safe in combination but we do not afterward^                                           F7B (IT'S MORE IM)
 It's relevant to my practice.^                                                                                                                                                                        F7B (IT'S RELEVAN)
 It has good efficacy and safety profile^                                                                                                                                                              F7B (IT HAS GOOD)
 it has improved the EASI 75 score but not very dramatically^                                                                                                                                          F7B (IT HAS IMPRO)
 I think it shows that it is not that much better than topical steroids alone and influences me to not use product Z^                                                                                  F7B (I THINK IT S)
 It indicates that the results are stronger with PRoduct Z and topical steorids than as monotherapy.^                                                                                                  F7B (IT INDICATES)
 it is a clear response but comparing to jak inhibitor data not as good^                                                                                                                               F7B (IT IS A CLEA)
 it is effective^                                                                                                                                                                                      F7B (IT IS EFFECT)
 It is important to see how the response rate is in comparison to placebo, but at the same time, there is a significant amount of data missing for 16 weeks^                                           F7B (IT IS IMPORT)
 it is still used with TCI^                                                                                                                                                                            F7B (IT IS STILL)
 It looks very similar to dupixent and thus offers no advantages but has no significant disadvantages^                                                                                                 F7B (IT LOOKS VER)
 It seems safe and easy to use^                                                                                                                                                                        F7B (IT SEEMS SAF)
 its good data, but lacks error bars or power indicaiton^                                                                                                                                              F7B (ITS GOOD DAT)
 It shows an excellent EASI 75 response^                                                                                                                                                               F7B (IT SHOWS AN)
 it shows that there are good results at week 24^                                                                                                                                                      F7B (IT SHOWS THA)
 its very important to know that this medication can work synergistically^                                                                                                                             F7B (ITS VERY IMP)
 it will have a significant impact on my prescribing due to its EASI75 improvement^                                                                                                                    F7B (IT WILL HAVE)
 it works well^                                                                                                                                                                                        F7B (IT WORKS WEL)
 It would be nice to get better results without TCS^                                                                                                                                                   F7B (IT WOULD BE)
 I would like to see a larger response^                                                                                                                                                                F7B (I WOULD LIKE)
 i would prescribe with topical corticosteroids^                                                                                                                                                       F7B (I WOULD PRES)
 I would want to review the actual study design in more detail but it seems to be true.^                                                                                                               F7B (I WOULD WANT)
 je suis impatient d'avoir de tels resultats^                                                                                                                                                          F7B (JE SUIS IMPA)
 keine Ahnung ich weiß nicht warum^                                                                                                                                                                    F7B (KEINE AHNUNG)
 klinisch bedeutender Unterschied verglichen zu Placebo^                                                                                                                                               F7B (KLINISCH BED)
 le maintien de l'efficacité à long-terme^                                                                                                                                                             F7B (LE MAINTIEN)
 Le produit semble efficace.^                                                                                                                                                                          F7B (LE PRODUIT S)
 les resultats sont statistiquement significatifs donc meilleure efficacite de Z avec les dC efficacité équivalente au dupixent^                                                                       F7B (LES RESULTAT)
 like the longer time data^                                                                                                                                                                            F7B (LIKE THE LON)
 long term risks^                                                                                                                                                                                      F7B (LONG TERM RI)
 Looks effective for the vast majority of patients when used with steroid creams^                                                                                                                      F7B (LOOKS EFFECT)
 Looks greatly effective^                                                                                                                                                                              F7B (LOOKS GREATL)
 Mässige  Relevanz der Aussage^                                                                                                                                                                        F7B (MÄSSIGE  REL)
 Mit topischen Kortikosteroiden gute Wirksamkeit^                                                                                                                                                      F7B (MIT TOPISCHE)
 Moderate effectiveness, improved with TCS^                                                                                                                                                            F7B (MODERATE EFF)
 Monotherapie wird favorisiert, hier überzeugende Wirksamkeit nur mittels Kombinationsgabe^                                                                                                            F7B (MONOTHERAPIE)
 Most patients desire complete clearance.^                                                                                                                                                             F7B (MOST PATIENT)
 nach 16 Wochen geht die schere wieter auf, aber sie flacht auch ab, der sealing Effekt wird erreicht, kein weitere zusatznutzen^                                                                      F7B (NACH 16 WOCH)
 need to know to get maximum benefit works best with Steroid combination^                                                                                                                              F7B (NEED TO KNOW)
 need to use topical steroid to reach higher percentage^                                                                                                                                               F7B (NEED TO USE)
 Nette amélioration ds patients sous produit Z 69% atteignent l’ EASi 75^                                                                                                                              F7B (NETTE AMÉLIO)
 nice rates here^                                                                                                                                                                                      F7B (NICE RATES H)
 no flares up^                                                                                                                                                                                         F7B (NO FLARES UP)
 none indicated and has no influence^                                                                                                                                                                  F7B (NONE INDICAT)
 No placebo response rate after 16 weeks, why? Not sure if this Med is better than Dupixent^                                                                                                           F7B (NO PLACEBO R)
 not an impressive difference between  placebo and amount of efficacy with z and tcs vs tcs alone-ie much of efficacy  due to tcs component, so may not be worth the frequent injections, se's etc^    F7B (NOT AN IMPRE)
 Not groundbreaking results^                                                                                                                                                                           F7B (NOT GROUNDBR)
 not significantly efficient compared to other treatments^                                                                                                                                             F7B (NOT SIGNIFIC)
 Not so sure of the value of this stTistic^                                                                                                                                                            F7B (NOT SO SURE)
 Not too relevant or too irrelevant^                                                                                                                                                                   F7B (NOT TOO RELE)
 Obviously such better clearance and response rates^                                                                                                                                                   F7B (OBVIOUSLY SU)
 patient achieving at week24^                                                                                                                                                                          F7B (PATIENT ACHI)
 patient want relieve and there needs to be a real exception for when benefit will be achieved - this graph displays nicely the significant benefit of the product^                                    F7B (PATIENT WANT)
 peu significatif à mon avis^                                                                                                                                                                          F7B (PEU SIGNIFIC)
 Pourcentage élevé EASI75^                                                                                                                                                                             F7B (POURCENTAGE)
 probablement par ce que efficacé et bien tolere^                                                                                                                                                      F7B (PROBABLEMENT)
 Product Z does provide improvement compared to placebo however it was not monotherapy^                                                                                                                F7B (PRODUCT Z DO)
 Product Z effective - we know this^                                                                                                                                                                   F7B (PRODUCT Z EF)
 Product Z in combination with topical corticosteroids (TCS) shows 69% of patients achieve EASI-75 at week 24. Rated 7 because 69 % achieved EASI 75 whereas 36% with placebo at 32 weeks^             F7B (PRODUCT Z IN)
 Product Z is beneficial to AD patients without JAK side effects^                                                                                                                                      F7B (PRODUCT Z IS)
 Prozentauler Anteil der Patienten^                                                                                                                                                                    F7B (PROZENTAULER)
 Pt experiencing progressive and sustained improvement through week 32. Rapid improvement by week 16^                                                                                                  F7B (PT EXPERIENC)
 Qdie Kombination mit einem tropischen  Präparat lässt in der Praxis ein Stufenprogramm zu, mit dem man unterschiedliche Therapieoptionen verbinden kann^                                              F7B (QDIE KOMBINA)
 Quick upstroke and number achieving East 75^                                                                                                                                                          F7B (QUICK UPSTRO)
 Réponse thérapeutique significative^                                                                                                                                                                  F7B (RÉPONSE THÉR)
 Reasonable clinical improvement but hard to determine how much of the improvement was due to product z vs steroid used.^                                                                              F7B (REASONABLE C)
 Response period over 32 week period achieced EASI-75^                                                                                                                                                 F7B (RESPONSE PER)
 RESULTATS A LONG-TERM^                                                                                                                                                                                F7B (RESULTATS A)
 Safe and effective^                                                                                                                                                                                   F7B (SAFE AND EFF)
 safe med that is effective^                                                                                                                                                                           F7B (SAFE MED THA)
 schnelle ansprechrate, hohe clearance^                                                                                                                                                                F7B (SCHNELLE ANS)
 Seems better than Dupixent but not a game changer.^                                                                                                                                                   F7B (SEEMS BETTER)
 Seems to have decent efficacy compared to topical steroids alone. However, this data is just one data point when evaluating the efficacy of a medication. Need more information^                      F7B (SEEMS TO HAV)
 sehr gutes Gesamtergebnis, ab 4. Monat weitere Steigerung der Wirkung^                                                                                                                                F7B (SEHR GUTES G)
 Sehr wirkungsvolle Therapieoption mit erheblicher Verbesserung der Lebensqualität^                                                                                                                    F7B (SEHR WIRKUNG)
 Showed improvement on medication^                                                                                                                                                                     F7B (SHOWED IMPRO)
 shows a significant response^                                                                                                                                                                         F7B (SHOWS A SIGN)
 Shows continued improvement and improvement over placebo^                                                                                                                                             F7B (SHOWS CONTIN)
 Shows good effect over long-term^                                                                                                                                                                     F7B (SHOWS GOOD E)
 shows moderately good efficacy^                                                                                                                                                                       F7B (SHOWS MODERA)
 shows much  greater achievement of easi75 in tcs^                                                                                                                                                     F7B (SHOWS MUCH)
 side effect profile^                                                                                                                                                                                  F7B (SIDE EFFECT)
 Significant data vs placebo^                                                                                                                                                                          F7B (SIGNIFICANT)
 Signifikante Wirksamkeit bereits nach 16 Wochen^                                                                                                                                                      F7B (SIGNIFIKANTE)
 slow onset, questionable side effect profile,^                                                                                                                                                        F7B (SLOW ONSET,)
 Somewhat important to my practice^                                                                                                                                                                    F7B (SOMEWHAT IMP)
 Statistically significant benefits, but I would like to see clinical outcomes in my patients^                                                                                                         F7B (STATISTICALL)
 statistics support the decision^                                                                                                                                                                      F7B (STATISTICS S)
 Takes a long time to work Probably won’t be funded after 4 months^                                                                                                                                    F7B (TAKES A LONG)
 That is a great response in EASI^                                                                                                                                                                     F7B (THAT IS A GR)
 That is significant for any patient with moderate to severe atopic dermatitis who may have not been controlled on dupilumab or other JAK inhibitors.^                                                 F7B (THAT IS SIGN)
 the chart is amazin and compleling^                                                                                                                                                                   F7B (THE CHART IS)
 The efficacy data is impressive over 24 weeks^                                                                                                                                                        F7B (THE EFFICACY)
 the improvement is very important to my clinical practice and pt population^                                                                                                                          F7B (THE IMPROVEM)
 There is a huge level of improvement compared to placebo + TCS^                                                                                                                                       F7B (THERE IS A H)
 the responder rates are not impressive^                                                                                                                                                               F7B (THE RESPONDE)
 The response shown is a good response but not an outstanding response and so I give it a 5.^                                                                                                          F7B (THE RESPONSE)
 The result is expected^                                                                                                                                                                               F7B (THE RESULT I)
 the sustained efficacy^                                                                                                                                                                               F7B (THE SUSTAINE)
 This graphic Lea demonstrates the efficacy of the medication^                                                                                                                                         F7B (THIS GRAPHIC)
 This improvement is very good but not outstanding. Therefore I give it a 5.^                                                                                                                          F7B (THIS IMPROVE)
 This is extremely important because it displays the strong efficacy of the medication and shows that the majority of patients will have a meaningful improvement by 24 weeks.^                        F7B (THIS IS EXTR)
 this is solid response data that makes me want to try^                                                                                                                                                F7B (THIS IS SOLI)
 this offers a viable oral option to control atopic dermatitis with a topical^                                                                                                                         F7B (THIS OFFERS)
 this would be used if it worked as well as proposed in this graph^                                                                                                                                    F7B (THIS WOULD B)
 those are good numbers^                                                                                                                                                                               F7B (THOSE ARE GO)
 Topical is working^                                                                                                                                                                                   F7B (TOPICAL IS W)
 Topical steroids are inexpensive and adding them to product Z greatly enhances the success, so it is easy to do in clinical practice.^                                                                F7B (TOPICAL STER)
 Valuable info that shows benefit over placebo^                                                                                                                                                        F7B (VALUABLE INF)
 various different characteristics^                                                                                                                                                                    F7B (VARIOUS DIFF)
 Verbessertes Ansprechen im Vergleich zu bisherigen Modalitäten^                                                                                                                                       F7B (VERBESSERTES)
 Verglichen mit der Standardtherapie gute Wirksamkeit^                                                                                                                                                 F7B (VERGLICHEN M)
 very applicable to real life scenario for patients^                                                                                                                                                   F7B (VERY APPLICA)
 Very difficult to know where to place this^                                                                                                                                                           F7B (VERY DIFFICU)
 very good efficacy, 70% is very good, better than dupixant but not 100 %^                                                                                                                             F7B (VERY GOOD EF)
 Very high efficacy and predictable response^                                                                                                                                                          F7B (VERY HIGH EF)
 Very successful outcome^                                                                                                                                                                              F7B (VERY SUCCESS)
 Wegen der Relevanz^                                                                                                                                                                                   F7B (WEGEN DER RE)
 Weil das Ergebnis sich nicht viel vom Placebo unterscheidet und weil es Daten fehlen^                                                                                                                 F7B (WEIL DAS ERG)
 Weil das für die Patientengruppe ein sehr deutliche Verbesserung darstellt.^                                                                                                                          F7B (WEIL DAS FÜR)
 weil es zumindest gegenüber Placebo eine deutliche Verbesserung bedeutet^                                                                                                                             F7B (WEIL ES ZUMI)
 wichtig und entscheidend für die Verordnung ist die Wirksamkeit als Monotherapie, nicht die Wirksamkeit in Kombination mit TCS^                                                                       F7B (WICHTIG UND)
 Wirksamkeitsdaten monotherapie wären interessant oder zumindest steroidsparpotential^                                                                                                                 F7B (WIRKSAMKEITS)
 Wish efficacy numbers were higher at 24 weeks.^                                                                                                                                                       F7B (WISH EFFICAC)
 With good oral bioavailability and lack of immunogenicity, they address some of the limitations of biologics.^                                                                                        F7B (WITH GOOD OR)
 would like to see a higher clearance rate especially with use in conjunction with topicals^                                                                                                           F7B (WOULD LIKE T)
 yes it appears promising^                                                                                                                                                                             F7B (YES IT APPEA)
TF8_1^148
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F8 - Part of an Accountable Care Organization (ACO)
 Total^TN^1
 Yes^          F8_1 (1)
 No^           F8_1 (2)
 I Don’t Know^ F8_1 (3)
TF8_2^149
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F8 - Part of an Integrated Health Organization
 Total^TN^1
 Yes^          F8_2 (1)
 No^           F8_2 (2)
 I Don’t Know^ F8_2 (3)
TF1_1_1^150
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F1 - Use of Product Z Moderate Atopic Dermatitis Patients in NEXT 6 Months Biologic / JAK-I-Naïve Patients
 Total^TN^1
 Treatment of flares-ups^  F1_1 (1)
 As a maintenance therapy^ F1_1 (2)
TF1_2_1^151
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F1 - Use of Product Z Moderate Atopic Dermatitis Patients in NEXT 6 Months Biologic / JAK-I-Experienced Patients
 Total^TN^1
 Treatment of flares-ups^  F1_2 (1)
 As a maintenance therapy^ F1_2 (2)
TF1_3_1^152
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F1 - Use of Product Z Severe Atopic Dermatitis Patients in NEXT 6 Months Biologic / JAK-I-Naïve Patients
 Total^TN^1
 Treatment of flares-ups^  F1_3 (1)
 As a maintenance therapy^ F1_3 (2)
TF1_4_1^153
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F1 - Use of Product Z Severe Atopic Dermatitis Patients in NEXT 6 Months Biologic / JAK-I-Experienced Patients
 Total^TN^1
 Treatment of flares-ups^  F1_4 (1)
 As a maintenance therapy^ F1_4 (2)
TF2_1_1^154
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F2 - Use of Product P, Product Q, and/or Product R Moderate Atopic Dermatitis Patients in NEXT 6 Months Biologic / JAK-I-Naïve Patients
 Total^TN^1
 Treatment of flares-ups^  F2_1 (1)
 As a maintenance therapy^ F2_1 (2)
TF2_2_1^155
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F2 - Use of Product P, Product Q, and/or Product R Moderate Atopic Dermatitis Patients in NEXT 6 Months Biologic / JAK-I-Experienced Patients
 Total^TN^1
 Treatment of flares-ups^  F2_2 (1)
 As a maintenance therapy^ F2_2 (2)
TF2_3_1^156
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F2 - Use of Product P, Product Q, and/or Product R Severe Atopic Dermatitis Patients in NEXT 6 Months Biologic / JAK-I-Naïve Patients
 Total^TN^1
 Treatment of flares-ups^  F2_3 (1)
 As a maintenance therapy^ F2_3 (2)
TF2_4_1^157
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F2 - Use of Product P, Product Q, and/or Product R Severe Atopic Dermatitis Patients in NEXT 6 Months Biologic / JAK-I-Experienced Patients
 Total^TN^1
 Treatment of flares-ups^  F2_4 (1)
 As a maintenance therapy^ F2_4 (2)
TF3_1_1_1^158
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F3 - Maintenance Therapy Moderate Atopic Dermatitis Patients on Product P, Product Q, or Product R Continue using Product P, Product Q, or Product R
 Total^TN^1
 0^   F3_1_1 (0)
 4^   F3_1_1 (4)
 5^   F3_1_1 (5)
 10^  F3_1_1 (10)
 15^  F3_1_1 (15)
 20^  F3_1_1 (20)
 25^  F3_1_1 (25)
 30^  F3_1_1 (30)
 34^  F3_1_1 (34)
 35^  F3_1_1 (35)
 40^  F3_1_1 (40)
 50^  F3_1_1 (50)
 55^  F3_1_1 (55)
 60^  F3_1_1 (60)
 65^  F3_1_1 (65)
 75^  F3_1_1 (75)
 80^  F3_1_1 (80)
 90^  F3_1_1 (90)
 99^  F3_1_1 (99)
 100^ F3_1_1 (100)
TF3_2_1_1^159
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F3 - Maintenance Therapy Moderate Atopic Dermatitis Patients on Product P, Product Q, or Product R Switch to Dupixent ® (dupilumab)
 Total^TN^1
 0^   F3_2_1 (0)
 5^   F3_2_1 (5)
 10^  F3_2_1 (10)
 15^  F3_2_1 (15)
 20^  F3_2_1 (20)
 25^  F3_2_1 (25)
 26^  F3_2_1 (26)
 30^  F3_2_1 (30)
 33^  F3_2_1 (33)
 35^  F3_2_1 (35)
 40^  F3_2_1 (40)
 43^  F3_2_1 (43)
 45^  F3_2_1 (45)
 50^  F3_2_1 (50)
 55^  F3_2_1 (55)
 60^  F3_2_1 (60)
 65^  F3_2_1 (65)
 75^  F3_2_1 (75)
 80^  F3_2_1 (80)
 90^  F3_2_1 (90)
 100^ F3_2_1 (100)
TF3_3_1_1^160
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F3 - Maintenance Therapy Moderate Atopic Dermatitis Patients on Product P, Product Q, or Product R Switch to an oral systemic
 Total^TN^1
 0^  F3_3_1 (0)
 2^  F3_3_1 (2)
 5^  F3_3_1 (5)
 8^  F3_3_1 (8)
 10^ F3_3_1 (10)
 15^ F3_3_1 (15)
 20^ F3_3_1 (20)
 25^ F3_3_1 (25)
 26^ F3_3_1 (26)
 30^ F3_3_1 (30)
 35^ F3_3_1 (35)
 40^ F3_3_1 (40)
 50^ F3_3_1 (50)
 55^ F3_3_1 (55)
 70^ F3_3_1 (70)
 95^ F3_3_1 (95)
TF3_4_1_1^161
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F3 - Maintenance Therapy Moderate Atopic Dermatitis Patients on Product P, Product Q, or Product R Switch to Product Z
 Total^TN^1
 0^  F3_4_1 (0)
 1^  F3_4_1 (1)
 5^  F3_4_1 (5)
 10^ F3_4_1 (10)
 15^ F3_4_1 (15)
 18^ F3_4_1 (18)
 20^ F3_4_1 (20)
 23^ F3_4_1 (23)
 25^ F3_4_1 (25)
 30^ F3_4_1 (30)
 35^ F3_4_1 (35)
 40^ F3_4_1 (40)
 45^ F3_4_1 (45)
 50^ F3_4_1 (50)
 65^ F3_4_1 (65)
 70^ F3_4_1 (70)
TF3_1_2_1^162
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F3 - Maintenance Therapy Severe Atopic Dermatitis Patients on Product P, Product Q, or Product R Continue using Product P, Product Q, or Product R
 Total^TN^1
 0^   F3_1_2 (0)
 10^  F3_1_2 (10)
 12^  F3_1_2 (12)
 15^  F3_1_2 (15)
 18^  F3_1_2 (18)
 20^  F3_1_2 (20)
 25^  F3_1_2 (25)
 30^  F3_1_2 (30)
 35^  F3_1_2 (35)
 40^  F3_1_2 (40)
 45^  F3_1_2 (45)
 50^  F3_1_2 (50)
 55^  F3_1_2 (55)
 60^  F3_1_2 (60)
 70^  F3_1_2 (70)
 75^  F3_1_2 (75)
 90^  F3_1_2 (90)
 100^ F3_1_2 (100)
TF3_2_2_1^163
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F3 - Maintenance Therapy Severe Atopic Dermatitis Patients on Product P, Product Q, or Product R Switch to Dupixent ® (dupilumab)
 Total^TN^1
 0^   F3_2_2 (0)
 5^   F3_2_2 (5)
 8^   F3_2_2 (8)
 10^  F3_2_2 (10)
 15^  F3_2_2 (15)
 18^  F3_2_2 (18)
 20^  F3_2_2 (20)
 25^  F3_2_2 (25)
 30^  F3_2_2 (30)
 35^  F3_2_2 (35)
 40^  F3_2_2 (40)
 45^  F3_2_2 (45)
 50^  F3_2_2 (50)
 55^  F3_2_2 (55)
 65^  F3_2_2 (65)
 75^  F3_2_2 (75)
 80^  F3_2_2 (80)
 90^  F3_2_2 (90)
 100^ F3_2_2 (100)
TF3_3_2_1^164
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F3 - Maintenance Therapy Severe Atopic Dermatitis Patients on Product P, Product Q, or Product R Switch to an oral systemic
 Total^TN^1
 0^  F3_3_2 (0)
 2^  F3_3_2 (2)
 5^  F3_3_2 (5)
 10^ F3_3_2 (10)
 13^ F3_3_2 (13)
 15^ F3_3_2 (15)
 20^ F3_3_2 (20)
 25^ F3_3_2 (25)
 30^ F3_3_2 (30)
 35^ F3_3_2 (35)
 40^ F3_3_2 (40)
 55^ F3_3_2 (55)
 60^ F3_3_2 (60)
 70^ F3_3_2 (70)
TF3_4_2_1^165
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F3 - Maintenance Therapy Severe Atopic Dermatitis Patients on Product P, Product Q, or Product R Switch to Product Z
 Total^TN^1
 0^  F3_4_2 (0)
 5^  F3_4_2 (5)
 10^ F3_4_2 (10)
 15^ F3_4_2 (15)
 19^ F3_4_2 (19)
 20^ F3_4_2 (20)
 25^ F3_4_2 (25)
 30^ F3_4_2 (30)
 35^ F3_4_2 (35)
 40^ F3_4_2 (40)
 45^ F3_4_2 (45)
 50^ F3_4_2 (50)
 70^ F3_4_2 (70)
TF5_4_2_1^166
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F5 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and alternate dosing scenario) Product Z
 Total^TN^1
 0^  F5_4_2 (0)
 1^  F5_4_2 (1)
 2^  F5_4_2 (2)
 3^  F5_4_2 (3)
 4^  F5_4_2 (4)
 5^  F5_4_2 (5)
 8^  F5_4_2 (8)
 9^  F5_4_2 (9)
 10^ F5_4_2 (10)
 13^ F5_4_2 (13)
 15^ F5_4_2 (15)
 20^ F5_4_2 (20)
 22^ F5_4_2 (22)
 25^ F5_4_2 (25)
 30^ F5_4_2 (30)
 35^ F5_4_2 (35)
 40^ F5_4_2 (40)
 50^ F5_4_2 (50)
 55^ F5_4_2 (55)
 90^ F5_4_2 (90)
TF5_4_4_1^167
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F5 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and alternate dosing scenario) Product Z
 Total^TN^1
 0^  F5_4_4 (0)
 1^  F5_4_4 (1)
 2^  F5_4_4 (2)
 3^  F5_4_4 (3)
 4^  F5_4_4 (4)
 5^  F5_4_4 (5)
 6^  F5_4_4 (6)
 7^  F5_4_4 (7)
 9^  F5_4_4 (9)
 10^ F5_4_4 (10)
 12^ F5_4_4 (12)
 15^ F5_4_4 (15)
 16^ F5_4_4 (16)
 20^ F5_4_4 (20)
 25^ F5_4_4 (25)
 30^ F5_4_4 (30)
 35^ F5_4_4 (35)
 40^ F5_4_4 (40)
 45^ F5_4_4 (45)
 50^ F5_4_4 (50)
 55^ F5_4_4 (55)
 60^ F5_4_4 (60)
 90^ F5_4_4 (90)
TF5_4_6_1^168
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F5 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and alternate dosing scenario) Product Z
 Total^TN^1
 0^  F5_4_6 (0)
 1^  F5_4_6 (1)
 2^  F5_4_6 (2)
 3^  F5_4_6 (3)
 4^  F5_4_6 (4)
 5^  F5_4_6 (5)
 6^  F5_4_6 (6)
 7^  F5_4_6 (7)
 8^  F5_4_6 (8)
 9^  F5_4_6 (9)
 10^ F5_4_6 (10)
 12^ F5_4_6 (12)
 14^ F5_4_6 (14)
 15^ F5_4_6 (15)
 16^ F5_4_6 (16)
 18^ F5_4_6 (18)
 20^ F5_4_6 (20)
 25^ F5_4_6 (25)
 28^ F5_4_6 (28)
 30^ F5_4_6 (30)
 35^ F5_4_6 (35)
 40^ F5_4_6 (40)
 45^ F5_4_6 (45)
 50^ F5_4_6 (50)
 60^ F5_4_6 (60)
 65^ F5_4_6 (65)
 90^ F5_4_6 (90)
TF5_4_8_1^169
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F5 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and alternate dosing scenario) Product Z
 Total^TN^1
 0^  F5_4_8 (0)
 1^  F5_4_8 (1)
 2^  F5_4_8 (2)
 3^  F5_4_8 (3)
 5^  F5_4_8 (5)
 6^  F5_4_8 (6)
 9^  F5_4_8 (9)
 10^ F5_4_8 (10)
 11^ F5_4_8 (11)
 14^ F5_4_8 (14)
 15^ F5_4_8 (15)
 17^ F5_4_8 (17)
 19^ F5_4_8 (19)
 20^ F5_4_8 (20)
 21^ F5_4_8 (21)
 22^ F5_4_8 (22)
 25^ F5_4_8 (25)
 30^ F5_4_8 (30)
 35^ F5_4_8 (35)
 40^ F5_4_8 (40)
 45^ F5_4_8 (45)
 50^ F5_4_8 (50)
 60^ F5_4_8 (60)
 65^ F5_4_8 (65)
 70^ F5_4_8 (70)
 85^ F5_4_8 (85)
 90^ F5_4_8 (90)
TF6_4_2_1^170
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product Z
 Total^TN^1
 0^   F6_4_2 (0)
 1^   F6_4_2 (1)
 2^   F6_4_2 (2)
 3^   F6_4_2 (3)
 5^   F6_4_2 (5)
 7^   F6_4_2 (7)
 8^   F6_4_2 (8)
 10^  F6_4_2 (10)
 13^  F6_4_2 (13)
 15^  F6_4_2 (15)
 20^  F6_4_2 (20)
 25^  F6_4_2 (25)
 30^  F6_4_2 (30)
 50^  F6_4_2 (50)
 60^  F6_4_2 (60)
 100^ F6_4_2 (100)
TF6_5_2_1^171
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Dupixent® (dupilumab) / dupilumab
 Total^TN^1
 0^   F6_5_2 (0)
 2^   F6_5_2 (2)
 3^   F6_5_2 (3)
 5^   F6_5_2 (5)
 10^  F6_5_2 (10)
 13^  F6_5_2 (13)
 15^  F6_5_2 (15)
 20^  F6_5_2 (20)
 24^  F6_5_2 (24)
 25^  F6_5_2 (25)
 30^  F6_5_2 (30)
 32^  F6_5_2 (32)
 35^  F6_5_2 (35)
 37^  F6_5_2 (37)
 40^  F6_5_2 (40)
 45^  F6_5_2 (45)
 50^  F6_5_2 (50)
 75^  F6_5_2 (75)
 80^  F6_5_2 (80)
 95^  F6_5_2 (95)
 100^ F6_5_2 (100)
TF6_1_2_1^172
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product P
 Total^TN^1
 0^  F6_1_2 (0)
 1^  F6_1_2 (1)
 3^  F6_1_2 (3)
 4^  F6_1_2 (4)
 5^  F6_1_2 (5)
 9^  F6_1_2 (9)
 10^ F6_1_2 (10)
 15^ F6_1_2 (15)
 20^ F6_1_2 (20)
 25^ F6_1_2 (25)
 30^ F6_1_2 (30)
 50^ F6_1_2 (50)
TF6_2_2_1^173
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product Q
 Total^TN^1
 0^  F6_2_2 (0)
 1^  F6_2_2 (1)
 3^  F6_2_2 (3)
 5^  F6_2_2 (5)
 6^  F6_2_2 (6)
 9^  F6_2_2 (9)
 10^ F6_2_2 (10)
 15^ F6_2_2 (15)
 20^ F6_2_2 (20)
 25^ F6_2_2 (25)
 50^ F6_2_2 (50)
TF6_3_2_1^174
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product R
 Total^TN^1
 0^   F6_3_2 (0)
 1^   F6_3_2 (1)
 2^   F6_3_2 (2)
 3^   F6_3_2 (3)
 5^   F6_3_2 (5)
 7^   F6_3_2 (7)
 9^   F6_3_2 (9)
 10^  F6_3_2 (10)
 15^  F6_3_2 (15)
 20^  F6_3_2 (20)
 25^  F6_3_2 (25)
 30^  F6_3_2 (30)
 35^  F6_3_2 (35)
 40^  F6_3_2 (40)
 50^  F6_3_2 (50)
 60^  F6_3_2 (60)
 100^ F6_3_2 (100)
TF6_6_2_1^175
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Oral Systemics (e.g., cyclosporine, methotrexate)
 Total^TN^1
 0^  F6_6_2 (0)
 2^  F6_6_2 (2)
 4^  F6_6_2 (4)
 5^  F6_6_2 (5)
 9^  F6_6_2 (9)
 10^ F6_6_2 (10)
 12^ F6_6_2 (12)
 20^ F6_6_2 (20)
 25^ F6_6_2 (25)
 40^ F6_6_2 (40)
TF6_7_2_1^176
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Prescription Topical Corticosteroids (TCS)
 Total^TN^1
 0^   F6_7_2 (0)
 2^   F6_7_2 (2)
 4^   F6_7_2 (4)
 5^   F6_7_2 (5)
 10^  F6_7_2 (10)
 14^  F6_7_2 (14)
 20^  F6_7_2 (20)
 25^  F6_7_2 (25)
 30^  F6_7_2 (30)
 35^  F6_7_2 (35)
 40^  F6_7_2 (40)
 50^  F6_7_2 (50)
 55^  F6_7_2 (55)
 60^  F6_7_2 (60)
 65^  F6_7_2 (65)
 70^  F6_7_2 (70)
 75^  F6_7_2 (75)
 80^  F6_7_2 (80)
 85^  F6_7_2 (85)
 90^  F6_7_2 (90)
 95^  F6_7_2 (95)
 100^ F6_7_2 (100)
TF6_8_2_1^177
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Prescription Topical Calcineurin Inhibitors (TCI)
 Total^TN^1
 0^   F6_8_2 (0)
 1^   F6_8_2 (1)
 3^   F6_8_2 (3)
 5^   F6_8_2 (5)
 8^   F6_8_2 (8)
 10^  F6_8_2 (10)
 15^  F6_8_2 (15)
 20^  F6_8_2 (20)
 25^  F6_8_2 (25)
 30^  F6_8_2 (30)
 35^  F6_8_2 (35)
 40^  F6_8_2 (40)
 45^  F6_8_2 (45)
 50^  F6_8_2 (50)
 60^  F6_8_2 (60)
 65^  F6_8_2 (65)
 100^ F6_8_2 (100)
TF6_9_2_1^178
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate .... NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole)) / Other Prescription Topical Medications
 Total^TN^1
 0^   F6_9_2 (0)
 2^   F6_9_2 (2)
 5^   F6_9_2 (5)
 7^   F6_9_2 (7)
 10^  F6_9_2 (10)
 15^  F6_9_2 (15)
 20^  F6_9_2 (20)
 25^  F6_9_2 (25)
 30^  F6_9_2 (30)
 35^  F6_9_2 (35)
 45^  F6_9_2 (45)
 50^  F6_9_2 (50)
 100^ F6_9_2 (100)
TF6_10_2_1^179
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Oral Corticosteroids
 Total^TN^1
 0^  F6_10_2 (0)
 1^  F6_10_2 (1)
 2^  F6_10_2 (2)
 3^  F6_10_2 (3)
 5^  F6_10_2 (5)
 6^  F6_10_2 (6)
 10^ F6_10_2 (10)
 13^ F6_10_2 (13)
 15^ F6_10_2 (15)
 20^ F6_10_2 (20)
 25^ F6_10_2 (25)
 30^ F6_10_2 (30)
 35^ F6_10_2 (35)
 40^ F6_10_2 (40)
 50^ F6_10_2 (50)
 75^ F6_10_2 (75)
TF6_12_2_1^180
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ C1_11_other ]
 Total^TN^1
 0^  F6_12_2 (0)
 5^  F6_12_2 (5)
 25^ F6_12_2 (25)
TF6_15_2_1^181
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ C2_11_other ]
 Total^TN^1
 0^  F6_15_2 (0)
 10^ F6_15_2 (10)
 15^ F6_15_2 (15)
TF6_13_2_1^182
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ D1_11_other ]
 Total^TN^1
TF6_14_2_1^183
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ E1_11_other ]
 Total^TN^1
TF6_11_2_1^184
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Other Prescription Therapies (Please specify)
 Total^TN^1
 0^ F6_11_2 (0)
TF6_4_4_1^185
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product Z
 Total^TN^1
 0^   F6_4_4 (0)
 2^   F6_4_4 (2)
 5^   F6_4_4 (5)
 6^   F6_4_4 (6)
 7^   F6_4_4 (7)
 8^   F6_4_4 (8)
 10^  F6_4_4 (10)
 15^  F6_4_4 (15)
 16^  F6_4_4 (16)
 20^  F6_4_4 (20)
 25^  F6_4_4 (25)
 30^  F6_4_4 (30)
 35^  F6_4_4 (35)
 50^  F6_4_4 (50)
 60^  F6_4_4 (60)
 100^ F6_4_4 (100)
TF6_5_4_1^186
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Dupixent® (dupilumab) / dupilumab
 Total^TN^1
 0^   F6_5_4 (0)
 3^   F6_5_4 (3)
 5^   F6_5_4 (5)
 7^   F6_5_4 (7)
 10^  F6_5_4 (10)
 15^  F6_5_4 (15)
 17^  F6_5_4 (17)
 20^  F6_5_4 (20)
 21^  F6_5_4 (21)
 25^  F6_5_4 (25)
 30^  F6_5_4 (30)
 40^  F6_5_4 (40)
 45^  F6_5_4 (45)
 50^  F6_5_4 (50)
 55^  F6_5_4 (55)
 60^  F6_5_4 (60)
 65^  F6_5_4 (65)
 70^  F6_5_4 (70)
 75^  F6_5_4 (75)
 80^  F6_5_4 (80)
 85^  F6_5_4 (85)
 90^  F6_5_4 (90)
 91^  F6_5_4 (91)
 100^ F6_5_4 (100)
TF6_1_4_1^187
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product P
 Total^TN^1
 0^  F6_1_4 (0)
 1^  F6_1_4 (1)
 3^  F6_1_4 (3)
 5^  F6_1_4 (5)
 7^  F6_1_4 (7)
 8^  F6_1_4 (8)
 9^  F6_1_4 (9)
 10^ F6_1_4 (10)
 15^ F6_1_4 (15)
 20^ F6_1_4 (20)
 25^ F6_1_4 (25)
 30^ F6_1_4 (30)
 50^ F6_1_4 (50)
TF6_2_4_1^188
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product Q
 Total^TN^1
 0^  F6_2_4 (0)
 1^  F6_2_4 (1)
 2^  F6_2_4 (2)
 3^  F6_2_4 (3)
 5^  F6_2_4 (5)
 7^  F6_2_4 (7)
 8^  F6_2_4 (8)
 9^  F6_2_4 (9)
 10^ F6_2_4 (10)
 13^ F6_2_4 (13)
 15^ F6_2_4 (15)
 20^ F6_2_4 (20)
 25^ F6_2_4 (25)
 30^ F6_2_4 (30)
 50^ F6_2_4 (50)
TF6_3_4_1^189
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product R
 Total^TN^1
 0^   F6_3_4 (0)
 1^   F6_3_4 (1)
 2^   F6_3_4 (2)
 3^   F6_3_4 (3)
 5^   F6_3_4 (5)
 7^   F6_3_4 (7)
 8^   F6_3_4 (8)
 9^   F6_3_4 (9)
 10^  F6_3_4 (10)
 13^  F6_3_4 (13)
 15^  F6_3_4 (15)
 20^  F6_3_4 (20)
 25^  F6_3_4 (25)
 30^  F6_3_4 (30)
 35^  F6_3_4 (35)
 40^  F6_3_4 (40)
 45^  F6_3_4 (45)
 50^  F6_3_4 (50)
 60^  F6_3_4 (60)
 100^ F6_3_4 (100)
TF6_6_4_1^190
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Oral Systemics (e.g., cyclosporine, methotrexate)
 Total^TN^1
 0^  F6_6_4 (0)
 1^  F6_6_4 (1)
 2^  F6_6_4 (2)
 5^  F6_6_4 (5)
 6^  F6_6_4 (6)
 10^ F6_6_4 (10)
 11^ F6_6_4 (11)
 15^ F6_6_4 (15)
 18^ F6_6_4 (18)
 20^ F6_6_4 (20)
 25^ F6_6_4 (25)
 40^ F6_6_4 (40)
TF6_7_4_1^191
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Prescription Topical Corticosteroids (TCS)
 Total^TN^1
 0^   F6_7_4 (0)
 10^  F6_7_4 (10)
 11^  F6_7_4 (11)
 12^  F6_7_4 (12)
 15^  F6_7_4 (15)
 20^  F6_7_4 (20)
 25^  F6_7_4 (25)
 30^  F6_7_4 (30)
 40^  F6_7_4 (40)
 50^  F6_7_4 (50)
 55^  F6_7_4 (55)
 60^  F6_7_4 (60)
 70^  F6_7_4 (70)
 75^  F6_7_4 (75)
 80^  F6_7_4 (80)
 90^  F6_7_4 (90)
 95^  F6_7_4 (95)
 100^ F6_7_4 (100)
TF6_8_4_1^192
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Prescription Topical Calcineurin Inhibitors (TCI)
 Total^TN^1
 0^   F6_8_4 (0)
 5^   F6_8_4 (5)
 7^   F6_8_4 (7)
 8^   F6_8_4 (8)
 10^  F6_8_4 (10)
 15^  F6_8_4 (15)
 20^  F6_8_4 (20)
 25^  F6_8_4 (25)
 30^  F6_8_4 (30)
 35^  F6_8_4 (35)
 40^  F6_8_4 (40)
 50^  F6_8_4 (50)
 60^  F6_8_4 (60)
 70^  F6_8_4 (70)
 75^  F6_8_4 (75)
 100^ F6_8_4 (100)
TF6_9_4_1^193
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate .... NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole)) / Other Prescription Topical Medications
 Total^TN^1
 0^   F6_9_4 (0)
 3^   F6_9_4 (3)
 4^   F6_9_4 (4)
 5^   F6_9_4 (5)
 8^   F6_9_4 (8)
 10^  F6_9_4 (10)
 15^  F6_9_4 (15)
 20^  F6_9_4 (20)
 25^  F6_9_4 (25)
 30^  F6_9_4 (30)
 35^  F6_9_4 (35)
 45^  F6_9_4 (45)
 50^  F6_9_4 (50)
 100^ F6_9_4 (100)
TF6_10_4_1^194
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Oral Corticosteroids
 Total^TN^1
 0^  F6_10_4 (0)
 1^  F6_10_4 (1)
 2^  F6_10_4 (2)
 3^  F6_10_4 (3)
 5^  F6_10_4 (5)
 10^ F6_10_4 (10)
 15^ F6_10_4 (15)
 18^ F6_10_4 (18)
 20^ F6_10_4 (20)
 23^ F6_10_4 (23)
 25^ F6_10_4 (25)
 50^ F6_10_4 (50)
TF6_12_4_1^195
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ C1_11_other ]
 Total^TN^1
 0^  F6_12_4 (0)
 5^  F6_12_4 (5)
 25^ F6_12_4 (25)
TF6_15_4_1^196
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ C2_11_other ]
 Total^TN^1
 0^  F6_15_4 (0)
 10^ F6_15_4 (10)
 15^ F6_15_4 (15)
TF6_13_4_1^197
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ D1_11_other ]
 Total^TN^1
TF6_14_4_1^198
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ E1_11_other ]
 Total^TN^1
TF6_11_4_1^199
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Moderate Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Other Prescription Therapies (Please specify)
 Total^TN^1
 0^ F6_11_4 (0)
TF6_4_6_1^200
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product Z
 Total^TN^1
 0^   F6_4_6 (0)
 2^   F6_4_6 (2)
 3^   F6_4_6 (3)
 5^   F6_4_6 (5)
 6^   F6_4_6 (6)
 10^  F6_4_6 (10)
 14^  F6_4_6 (14)
 15^  F6_4_6 (15)
 20^  F6_4_6 (20)
 25^  F6_4_6 (25)
 30^  F6_4_6 (30)
 40^  F6_4_6 (40)
 45^  F6_4_6 (45)
 50^  F6_4_6 (50)
 60^  F6_4_6 (60)
 100^ F6_4_6 (100)
TF6_5_6_1^201
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Dupixent® (dupilumab) / dupilumab
 Total^TN^1
 0^   F6_5_6 (0)
 5^   F6_5_6 (5)
 10^  F6_5_6 (10)
 15^  F6_5_6 (15)
 18^  F6_5_6 (18)
 20^  F6_5_6 (20)
 25^  F6_5_6 (25)
 30^  F6_5_6 (30)
 35^  F6_5_6 (35)
 37^  F6_5_6 (37)
 40^  F6_5_6 (40)
 41^  F6_5_6 (41)
 45^  F6_5_6 (45)
 50^  F6_5_6 (50)
 60^  F6_5_6 (60)
 70^  F6_5_6 (70)
 75^  F6_5_6 (75)
 85^  F6_5_6 (85)
 90^  F6_5_6 (90)
 95^  F6_5_6 (95)
 100^ F6_5_6 (100)
TF6_1_6_1^202
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product P
 Total^TN^1
 0^  F6_1_6 (0)
 1^  F6_1_6 (1)
 2^  F6_1_6 (2)
 3^  F6_1_6 (3)
 5^  F6_1_6 (5)
 7^  F6_1_6 (7)
 8^  F6_1_6 (8)
 10^ F6_1_6 (10)
 15^ F6_1_6 (15)
 20^ F6_1_6 (20)
 22^ F6_1_6 (22)
 25^ F6_1_6 (25)
 30^ F6_1_6 (30)
 40^ F6_1_6 (40)
 45^ F6_1_6 (45)
 60^ F6_1_6 (60)
TF6_2_6_1^203
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product Q
 Total^TN^1
 0^  F6_2_6 (0)
 1^  F6_2_6 (1)
 2^  F6_2_6 (2)
 3^  F6_2_6 (3)
 5^  F6_2_6 (5)
 8^  F6_2_6 (8)
 10^ F6_2_6 (10)
 11^ F6_2_6 (11)
 12^ F6_2_6 (12)
 15^ F6_2_6 (15)
 20^ F6_2_6 (20)
 25^ F6_2_6 (25)
 30^ F6_2_6 (30)
 35^ F6_2_6 (35)
 50^ F6_2_6 (50)
 60^ F6_2_6 (60)
TF6_3_6_1^204
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product R
 Total^TN^1
 0^   F6_3_6 (0)
 1^   F6_3_6 (1)
 2^   F6_3_6 (2)
 3^   F6_3_6 (3)
 5^   F6_3_6 (5)
 8^   F6_3_6 (8)
 10^  F6_3_6 (10)
 13^  F6_3_6 (13)
 15^  F6_3_6 (15)
 20^  F6_3_6 (20)
 25^  F6_3_6 (25)
 30^  F6_3_6 (30)
 35^  F6_3_6 (35)
 39^  F6_3_6 (39)
 40^  F6_3_6 (40)
 50^  F6_3_6 (50)
 70^  F6_3_6 (70)
 100^ F6_3_6 (100)
TF6_6_6_1^205
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Oral Systemics (e.g., cyclosporine, methotrexate)
 Total^TN^1
 0^  F6_6_6 (0)
 2^  F6_6_6 (2)
 3^  F6_6_6 (3)
 5^  F6_6_6 (5)
 10^ F6_6_6 (10)
 11^ F6_6_6 (11)
 15^ F6_6_6 (15)
 18^ F6_6_6 (18)
 20^ F6_6_6 (20)
 25^ F6_6_6 (25)
 50^ F6_6_6 (50)
TF6_7_6_1^206
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Prescription Topical Corticosteroids (TCS)
 Total^TN^1
 0^   F6_7_6 (0)
 1^   F6_7_6 (1)
 5^   F6_7_6 (5)
 10^  F6_7_6 (10)
 12^  F6_7_6 (12)
 15^  F6_7_6 (15)
 19^  F6_7_6 (19)
 20^  F6_7_6 (20)
 25^  F6_7_6 (25)
 30^  F6_7_6 (30)
 35^  F6_7_6 (35)
 40^  F6_7_6 (40)
 45^  F6_7_6 (45)
 50^  F6_7_6 (50)
 55^  F6_7_6 (55)
 60^  F6_7_6 (60)
 65^  F6_7_6 (65)
 70^  F6_7_6 (70)
 75^  F6_7_6 (75)
 85^  F6_7_6 (85)
 90^  F6_7_6 (90)
 95^  F6_7_6 (95)
 97^  F6_7_6 (97)
 100^ F6_7_6 (100)
TF6_8_6_1^207
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Prescription Topical Calcineurin Inhibitors (TCI)
 Total^TN^1
 0^   F6_8_6 (0)
 5^   F6_8_6 (5)
 6^   F6_8_6 (6)
 8^   F6_8_6 (8)
 10^  F6_8_6 (10)
 15^  F6_8_6 (15)
 20^  F6_8_6 (20)
 25^  F6_8_6 (25)
 30^  F6_8_6 (30)
 40^  F6_8_6 (40)
 45^  F6_8_6 (45)
 50^  F6_8_6 (50)
 60^  F6_8_6 (60)
 75^  F6_8_6 (75)
 85^  F6_8_6 (85)
 100^ F6_8_6 (100)
TF6_9_6_1^208
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe .... NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole)) / Other Prescription Topical Medications
 Total^TN^1
 0^   F6_9_6 (0)
 1^   F6_9_6 (1)
 4^   F6_9_6 (4)
 5^   F6_9_6 (5)
 10^  F6_9_6 (10)
 15^  F6_9_6 (15)
 20^  F6_9_6 (20)
 25^  F6_9_6 (25)
 30^  F6_9_6 (30)
 50^  F6_9_6 (50)
 55^  F6_9_6 (55)
 100^ F6_9_6 (100)
TF6_10_6_1^209
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Oral Corticosteroids
 Total^TN^1
 0^  F6_10_6 (0)
 1^  F6_10_6 (1)
 2^  F6_10_6 (2)
 5^  F6_10_6 (5)
 7^  F6_10_6 (7)
 8^  F6_10_6 (8)
 10^ F6_10_6 (10)
 15^ F6_10_6 (15)
 20^ F6_10_6 (20)
 25^ F6_10_6 (25)
 40^ F6_10_6 (40)
 50^ F6_10_6 (50)
 70^ F6_10_6 (70)
TF6_12_6_1^210
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ C1_11_other ]
 Total^TN^1
 5^  F6_12_6 (5)
 10^ F6_12_6 (10)
 25^ F6_12_6 (25)
TF6_15_6_1^211
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ C2_11_other ]
 Total^TN^1
 0^  F6_15_6 (0)
 10^ F6_15_6 (10)
TF6_13_6_1^212
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ D1_11_other ]
 Total^TN^1
TF6_14_6_1^213
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ E1_11_other ]
 Total^TN^1
TF6_11_6_1^214
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Naïve Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Other Prescription Therapies (Please specify)
 Total^TN^1
 0^ F6_11_6 (0)
TF6_4_8_1^215
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product Z
 Total^TN^1
 0^   F6_4_8 (0)
 2^   F6_4_8 (2)
 3^   F6_4_8 (3)
 5^   F6_4_8 (5)
 8^   F6_4_8 (8)
 10^  F6_4_8 (10)
 15^  F6_4_8 (15)
 17^  F6_4_8 (17)
 20^  F6_4_8 (20)
 25^  F6_4_8 (25)
 30^  F6_4_8 (30)
 40^  F6_4_8 (40)
 50^  F6_4_8 (50)
 60^  F6_4_8 (60)
 100^ F6_4_8 (100)
TF6_5_8_1^216
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Dupixent® (dupilumab) / dupilumab
 Total^TN^1
 0^   F6_5_8 (0)
 3^   F6_5_8 (3)
 5^   F6_5_8 (5)
 10^  F6_5_8 (10)
 15^  F6_5_8 (15)
 20^  F6_5_8 (20)
 25^  F6_5_8 (25)
 28^  F6_5_8 (28)
 30^  F6_5_8 (30)
 35^  F6_5_8 (35)
 40^  F6_5_8 (40)
 50^  F6_5_8 (50)
 55^  F6_5_8 (55)
 60^  F6_5_8 (60)
 65^  F6_5_8 (65)
 70^  F6_5_8 (70)
 75^  F6_5_8 (75)
 80^  F6_5_8 (80)
 90^  F6_5_8 (90)
 91^  F6_5_8 (91)
 92^  F6_5_8 (92)
 95^  F6_5_8 (95)
 100^ F6_5_8 (100)
TF6_1_8_1^217
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product P
 Total^TN^1
 0^  F6_1_8 (0)
 1^  F6_1_8 (1)
 2^  F6_1_8 (2)
 3^  F6_1_8 (3)
 5^  F6_1_8 (5)
 9^  F6_1_8 (9)
 10^ F6_1_8 (10)
 15^ F6_1_8 (15)
 20^ F6_1_8 (20)
 25^ F6_1_8 (25)
 30^ F6_1_8 (30)
 45^ F6_1_8 (45)
TF6_2_8_1^218
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product Q
 Total^TN^1
 0^  F6_2_8 (0)
 1^  F6_2_8 (1)
 2^  F6_2_8 (2)
 3^  F6_2_8 (3)
 5^  F6_2_8 (5)
 7^  F6_2_8 (7)
 10^ F6_2_8 (10)
 15^ F6_2_8 (15)
 20^ F6_2_8 (20)
 25^ F6_2_8 (25)
 30^ F6_2_8 (30)
 40^ F6_2_8 (40)
 50^ F6_2_8 (50)
 65^ F6_2_8 (65)
TF6_3_8_1^219
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Product R
 Total^TN^1
 0^   F6_3_8 (0)
 1^   F6_3_8 (1)
 2^   F6_3_8 (2)
 3^   F6_3_8 (3)
 4^   F6_3_8 (4)
 5^   F6_3_8 (5)
 8^   F6_3_8 (8)
 10^  F6_3_8 (10)
 15^  F6_3_8 (15)
 20^  F6_3_8 (20)
 25^  F6_3_8 (25)
 30^  F6_3_8 (30)
 35^  F6_3_8 (35)
 40^  F6_3_8 (40)
 50^  F6_3_8 (50)
 70^  F6_3_8 (70)
 75^  F6_3_8 (75)
 100^ F6_3_8 (100)
TF6_6_8_1^220
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Oral Systemics (e.g., cyclosporine, methotrexate)
 Total^TN^1
 0^  F6_6_8 (0)
 1^  F6_6_8 (1)
 2^  F6_6_8 (2)
 5^  F6_6_8 (5)
 8^  F6_6_8 (8)
 9^  F6_6_8 (9)
 10^ F6_6_8 (10)
 12^ F6_6_8 (12)
 15^ F6_6_8 (15)
 18^ F6_6_8 (18)
 20^ F6_6_8 (20)
 25^ F6_6_8 (25)
 30^ F6_6_8 (30)
 50^ F6_6_8 (50)
TF6_7_8_1^221
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Prescription Topical Corticosteroids (TCS)
 Total^TN^1
 0^   F6_7_8 (0)
 5^   F6_7_8 (5)
 7^   F6_7_8 (7)
 8^   F6_7_8 (8)
 10^  F6_7_8 (10)
 11^  F6_7_8 (11)
 20^  F6_7_8 (20)
 25^  F6_7_8 (25)
 30^  F6_7_8 (30)
 40^  F6_7_8 (40)
 50^  F6_7_8 (50)
 55^  F6_7_8 (55)
 65^  F6_7_8 (65)
 70^  F6_7_8 (70)
 75^  F6_7_8 (75)
 80^  F6_7_8 (80)
 85^  F6_7_8 (85)
 90^  F6_7_8 (90)
 95^  F6_7_8 (95)
 97^  F6_7_8 (97)
 100^ F6_7_8 (100)
TF6_8_8_1^222
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Prescription Topical Calcineurin Inhibitors (TCI)
 Total^TN^1
 0^   F6_8_8 (0)
 1^   F6_8_8 (1)
 5^   F6_8_8 (5)
 7^   F6_8_8 (7)
 10^  F6_8_8 (10)
 15^  F6_8_8 (15)
 20^  F6_8_8 (20)
 25^  F6_8_8 (25)
 30^  F6_8_8 (30)
 40^  F6_8_8 (40)
 45^  F6_8_8 (45)
 50^  F6_8_8 (50)
 60^  F6_8_8 (60)
 65^  F6_8_8 (65)
 70^  F6_8_8 (70)
 80^  F6_8_8 (80)
 100^ F6_8_8 (100)
TF6_9_8_1^223
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe ....  NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Other Prescription Topical Medications (e.g., Eucrisa® (crisaborole)) / Other Prescription Topical Medications
 Total^TN^1
 0^   F6_9_8 (0)
 1^   F6_9_8 (1)
 3^   F6_9_8 (3)
 4^   F6_9_8 (4)
 5^   F6_9_8 (5)
 10^  F6_9_8 (10)
 15^  F6_9_8 (15)
 20^  F6_9_8 (20)
 25^  F6_9_8 (25)
 40^  F6_9_8 (40)
 50^  F6_9_8 (50)
 100^ F6_9_8 (100)
TF6_10_8_1^224
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Oral Corticosteroids
 Total^TN^1
 0^  F6_10_8 (0)
 2^  F6_10_8 (2)
 3^  F6_10_8 (3)
 5^  F6_10_8 (5)
 10^ F6_10_8 (10)
 18^ F6_10_8 (18)
 20^ F6_10_8 (20)
 23^ F6_10_8 (23)
 25^ F6_10_8 (25)
 30^ F6_10_8 (30)
 50^ F6_10_8 (50)
TF6_12_8_1^225
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ C1_11_other ]
 Total^TN^1
 0^  F6_12_8 (0)
 25^ F6_12_8 (25)
TF6_15_8_1^226
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ C2_11_other ]
 Total^TN^1
 0^  F6_15_8 (0)
 5^  F6_15_8 (5)
 10^ F6_15_8 (10)
 15^ F6_15_8 (15)
 25^ F6_15_8 (25)
TF6_13_8_1^227
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ D1_11_other ]
 Total^TN^1
TF6_14_8_1^228
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) [ E1_11_other ]
 Total^TN^1
TF6_11_8_1^229
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Severe Atopic Dermatitis Patients Percent of Biologic / JAK-I-Experienced Patients NEXT 6 Months (With Product Z and JAK-Is and additional scenario) Other Prescription Therapies (Please specify)
 Total^TN^1
 0^ F6_11_8 (0)
TF6_11_oth_1^230
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F6 - Prescription Therapies Other Prescription Therapies (Please specify)
 Total^TN^1
TF7a_1_1^231
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F7a - Please indicate how important the below statement is to your clinical practice.
 Total^TN^1
 Not at all Important to My Clinical Practice 1^ F7A_1 (1)
 2^                                              F7A_1 (2)
 3^                                              F7A_1 (3)
 4^                                              F7A_1 (4)
 5^                                              F7A_1 (5)
 6^                                              F7A_1 (6)
 Extremely Important to My Clinical Practice 7^  F7A_1 (7)
TF8_1_1^232
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F8 - Part of an Accountable Care Organization (ACO)
 Total^TN^1
 Yes^          F8_1 (1)
 No^           F8_1 (2)
 I Don’t Know^ F8_1 (3)
TF8_2_1^233
 OR,OV,OI,O%,SF,RV,S1,P1,V1,SA,SP
 F8 - Part of an Integrated Health Organization
 Total^TN^1
 Yes^          F8_2 (1)
 No^           F8_2 (2)
 I Don’t Know^ F8_2 (3)
[BANNERS]
*US Speciality
 SW:1,10,1,10,1,10,1,10,1,10,1,10,1,10,1,10,1,10,1,10,1,10
 HP:1,1,1,1,1,1,1,1,1,1,1
 CP:0,-1
 SL:T,T1,A1,B1,C1,D1,T2,A2,B2,C2,D2
 ST:1,6/2,7/3,8/4,9/5,10/2,4,5/7,9,10^MW,034^PW,0348
 WT:
 OP:HD,W200
 BT:
 BF:
 PT:11,1
 ^W70
 SECTIONSDEORDERQUOTA(1)^W70
 USSPECIALITYHARDQUOTA (1) AND SECTIONSDEORDERQUOTA(1)^W70
 USSPECIALITYHARDQUOTA (1,3) AND SECTIONSDEORDERQUOTA(1)^W70
 USSPECIALITYHARDQUOTA (3) AND SECTIONSDEORDERQUOTA(1)^W100
 USSPECIALITYHARDQUOTA (2) AND SECTIONSDEORDERQUOTA(1)^W100
 SECTIONSDEORDERQUOTA(2)^W100
 USSPECIALITYHARDQUOTA (1) AND SECTIONSDEORDERQUOTA(2)^W100
 USSPECIALITYHARDQUOTA (1,3) AND SECTIONSDEORDERQUOTA(2)^W100
 USSPECIALITYHARDQUOTA (3) AND SECTIONSDEORDERQUOTA(2)^W100
 USSPECIALITYHARDQUOTA (2) AND SECTIONSDEORDERQUOTA(2)^W100
  .......... ...................................................... ......................................................
                                      DtoE                                                   EtoD                         
  .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... ..........
   Overall     Total      Derms      Derms      NPPAs    Allergists   Total      Derms      Derms      NPPAs    Allergists
    Total                            +NPPAs                                                 +NPPAs                        
*EU Banner
 SW:1,10,1,10,1,10,1,10,1,10,1,10,1,10,1,10,1,10
 HP:1,1,1,1,1,1,1,1,1
 CP:0,-1
 SL:T1,A1,B1,T2,A2,B2,T3,A3,B3
 ST:1,2/4,5/7,8^MW,034^PW,0348
 WT:
 OP:HD,W200
 BT:
 BF:
 PT:9,1
 COUNTRYHARDQUOTA (2)^W70
 COUNTRYHARDQUOTA (2) AND SECTIONSDEORDERQUOTA(1)^W70
 COUNTRYHARDQUOTA (2) AND SECTIONSDEORDERQUOTA(2)^W70
 COUNTRYHARDQUOTA (3)^W70
 COUNTRYHARDQUOTA (3) AND SECTIONSDEORDERQUOTA(1)^W100
 COUNTRYHARDQUOTA (3) AND SECTIONSDEORDERQUOTA(2)^W100
 COUNTRYHARDQUOTA (4)^W100
 COUNTRYHARDQUOTA (4) AND SECTIONSDEORDERQUOTA(1)^W100
 COUNTRYHARDQUOTA (4) AND SECTIONSDEORDERQUOTA(2)^W100
  ................................ ................................ ................................
              Germany                           France                             UK               
  .......... .......... .......... .......... .......... .......... .......... .......... ..........
    Total       EtoD       DtoE      Total       EtoD       DtoE      Total       EtoD       DtoE   
[TITLE]
 SRI MS Global Patient Segmentation 2019^TC
 Prepared by: Strategic Research Insights (SRI)|~DA^TL
